Pharmaceutical composition for prevention or treatment of nephropathy and / or diabetes mellitus, comprising enavogliflozin

MYPI2025002006A0Undetermined Publication Date: 2024-04-05DAEWOONG PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025002006
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-10-05
Filing Date
2023-10-05
Publication Date
2024-04-05

AI Technical Summary

Technical Problem

Current treatments for type 2 diabetes and renal impairment lack effective solutions, particularly for patients with renal impairment, as existing medications do not adequately address both conditions simultaneously.

Method used

A pharmaceutical composition containing inavogliflozin, an SGLT-2 inhibitor, is developed to prevent or treat diabetes and renal impairment by inhibiting the SGLT-2 transporter, thereby reducing blood sugar levels and excreting glucose through urine, which can be administered alone or in combination with other drugs for enhanced efficacy.

Benefits of technology

Inavogliflozin effectively lowers blood sugar levels, promotes weight loss, and shows therapeutic benefits for renal disorders such as diabetic nephropathy and chronic kidney disease, reducing the risk of cardiovascular and kidney-related deaths, with a synergistic effect when combined with other medications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025002006_DRAWING_001
    Figure PI2025002006_DRAWING_001
  • Figure PI2025002006_DRAWING_002
    Figure PI2025002006_DRAWING_002
  • Figure PI2025002006_DRAWING_003
    Figure PI2025002006_DRAWING_003
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition comprising enavogliflozin as an active ingredient for the prevention or treatment of diabetes and / or renal diseases in patients who have or are at risk of diabetes and / or renal diseases. FIGURE 1
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition for preventing or treating renal impairment and / or diabetes comprising inabogliflozin

[0001] The present invention relates to a pharmaceutical composition for preventing or treating diabetes and / or renal impairment in patients with or at risk of renal impairment and / or diabetes, comprising inabogliflozin as an active ingredient.

[0002] SGLT-2 (sodium glucose cotransporter 2) is a transporter that, along with SGLT-1 (sodium glucose cotransporter 1), is responsible for excessive blood sugar reabsorption in the kidneys, with SGLT-2 playing a major role. Therefore, when SGLT-2 inhibitors inhibit the SGLT-2 transporter, the amount of blood sugar excreted in the urine increases, which ultimately lowers blood sugar and further excretes the calories contained in blood sugar, resulting in weight loss.

[0003] One of the drugs developed as an SGLT-2 inhibitor that can be usefully used as a treatment for type 2 diabetes due to such effects is Enavogliflozin, represented by the structural formula (chemical formula 1) below, and disclosed in Korean Patent Publication No. 2014-0022086 (Patent Document 1).

[0004]

[0005] [Chemical Formula 1]

[0006]

[0007] Compound Name: (2S,3R,4R,5S,6R)-2-(7-chloro-6(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

[0008] Inavogliflozin (DWP16001) is a drug currently in phase 3 clinical trials, and the phase 2 clinical trial results confirmed a statistically significant blood sugar-lowering effect compared to the placebo in all dose groups of 0.1 mg, 0.3 mg, and 0.5 mg of Inavogliflozin.

[0009] It is evaluated that it showed excellent urinary glucose secretion (glucose excreted in urine) efficacy at a very low dose of 1 / 100th of the dose compared to drugs of the same class.

[0010] However, there have been no reports that inavogliflozin has therapeutic efficacy in renal impairment or is useful for treating diabetes in patients with or at risk for renal impairment.

[0011] The present inventors, in order to find a new treatment method for treating patients with or at risk of diabetes and / or kidney disease, administered inavogliflozin to the patients and confirmed that inavogliflozin can prevent or treat kidney disease, thereby completing the present invention.

[0012] Accordingly, the purpose of the present invention is to provide a pharmaceutical composition for preventing or treating renal impairment and / or diabetes in patients with or at risk of diabetes and / or renal impairment, comprising inabogliflozin as an active ingredient.

[0013] The present invention provides a pharmaceutical composition for preventing or treating renal impairment and / or diabetes in a patient with or at risk of diabetes and / or renal impairment, comprising inabogliflozin as an active ingredient.

[0014] Hereinafter, the present invention will be described in more detail.

[0015] The present invention provides a use of inavogliflozin for preventing or treating renal dysfunction, a pharmaceutical composition for preventing or treating renal dysfunction comprising inavogliflozin, and a method for preventing or treating renal dysfunction comprising administering an effective amount of inavogliflozin to a subject in need thereof.

[0016] In the present invention, renal impairment may include, but is not limited to, a disease selected from diabetic nephropathy, renal failure, chronic kidney disease, glomerulonephritis, and proteinuria.

[0017] In one specific embodiment of the present invention, the pharmaceutical composition may be used for reducing the risk of sustained decrease in estimated glomerular filtration rate (eGFR), reaching end-stage renal disease, death due to cardiovascular disease, and kidney-related death in patients with chronic kidney disease.

[0018] In another specific embodiment of the present invention, the renal disorder may be diabetic nephropathy.

[0019] In one specific example, the pharmaceutical composition may be administered to a patient with diabetes or a patient in the pre-diabetic stage.

[0020] A pharmaceutical composition containing inabogliflozin can be used in the form of single administration or combination administration.

[0021] Inavogliflozin alone is sufficient to prevent or treat diabetes and / or renal impairment. However, antidiabetic or antineoplastic agents are often administered in combination for various purposes, and since co-administration can produce complementary or synergistic effects, pharmaceutical compositions containing inavogliflozin can be administered in combination with other antidiabetic or antineoplastic agents.

[0022] In one specific example, the pharmaceutical composition comprising inabogliflozin may be for co-administration with metformin.

[0023] In another specific embodiment, the pharmaceutical composition comprising inabogliflozin may be for co-administration with a DPP4 inhibitor.

[0024] For example, but not limited to, the DPP4 inhibitor may be gemigliptin.

[0025] In another specific embodiment, the combination may be combination administration with two or more other drugs. For example, a pharmaceutical composition comprising inabogliflozin may be intended for combination administration with metformin and a DPP4 inhibitor.

[0026] Alternatively, the pharmaceutical composition comprising inabogliflozin may be co-administered with a sulfonylurea insulin secretagogue.

[0027] In another specific embodiment, a pharmaceutical composition comprising inabogliflozin may be co-administered with insulin.

[0028] The present invention also provides a use of inavogliflozin for preventing or treating diabetes in a patient with renal impairment, a pharmaceutical composition for preventing or treating diabetes in a patient with renal impairment comprising inavogliflozin, and a method for preventing or treating diabetes in a patient with renal impairment comprising administering an effective amount of inavogliflozin to a subject in need thereof.

[0029] In the present invention, renal impairment may include, but is not limited to, a disease selected from diabetic nephropathy, renal failure, chronic kidney disease, glomerulonephritis, and proteinuria.

[0030] In another specific embodiment of the present invention, the renal disorder may be diabetic nephropathy.

[0031] In one specific example, the pharmaceutical composition may be administered to a patient with diabetes or a patient in the pre-diabetic stage.

[0032] A pharmaceutical composition containing inabogliflozin can be used in the form of single administration or combination administration.

[0033] Inavogliflozin alone is sufficient to prevent or treat diabetes and / or renal impairment. However, antidiabetic or antineoplastic agents are often administered in combination for various purposes, and since co-administration can produce complementary or synergistic effects, pharmaceutical compositions containing inavogliflozin can be administered in combination with other antidiabetic or antineoplastic agents.

[0034] In one specific example, the pharmaceutical composition comprising inabogliflozin may be for co-administration with metformin.

[0035] In another specific embodiment, the pharmaceutical composition comprising inabogliflozin may be for co-administration with a DPP4 inhibitor.

[0036] For example, but not limited to, the DPP4 inhibitor may be gemigliptin.

[0037] In another specific embodiment, the combination may be combination administration with two or more other drugs. For example, a pharmaceutical composition comprising inabogliflozin may be intended for combination administration with metformin and a DPP4 inhibitor.

[0038] Alternatively, the pharmaceutical composition comprising inabogliflozin may be co-administered with a sulfonylurea insulin secretagogue.

[0039] In another specific embodiment, a pharmaceutical composition comprising inabogliflozin may be co-administered with insulin.

[0040] The term “prevention” as used herein means any act of inhibiting or delaying the onset of renal impairment and / or diabetes by administering a pharmaceutical composition according to the present invention.

[0041] Additionally, the term "treatment" as used herein means any action by which renal dysfunction and / or diabetes is improved or beneficially altered by administration of the pharmaceutical composition according to the present invention.

[0042] The dosage of inabogliflozin, which can be used for the prevention or treatment of diabetes and / or kidney disease in patients with or at risk of diabetes and / or kidney disease, is not particularly limited and can be appropriately adjusted depending on the severity of the patient's disease, weight, age, sex, presence or absence of other complications, etc.

[0043] The administration period of inavogliflozin can be appropriately adjusted by a clinician based on the preventive or therapeutic effect of inavogliflozin on diabetes and / or kidney disease in patients with or at risk of diabetes and / or kidney disease.

[0044] In one specific embodiment of the present invention, the treatment method may be a method of administering a pharmaceutical composition for preventing or treating diabetes and / or kidney disease in combination with metformin and / or gemigliptin.

[0045] Since the above method for treating diabetes and / or kidney disease uses a pharmaceutical composition for preventing or treating diabetes and / or kidney disease, any overlapping content between the two is omitted to avoid excessive description in the specification.

[0046] Inavogliflozin used as an active ingredient in the present invention can be synthesized through known prior literature. In the present invention, inavogliflozin can be crystalline or amorphous. For example, inavogliflozin can be inavogliflozin crystalline form A, crystalline form B, crystalline form C, crystalline form D, crystalline form E or inavogliflozin amorphous, which are reported to have the following X-ray diffraction spectra through Korean Patent Publication No. 2017-0142904 or Korean Patent Application No. 2022-0123673.

[0047] Crystalline Form A: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ] values ​​selected from 6.2°±0.2°, 7.2°±0.2°, 8.8°±0.2°, 17.6°±0.2°, 19.0°±0.2°, 22.5°±0.2°, and 25.1°±0.2°.

[0048] Crystalline Form B: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ] values ​​selected from 7.0°±0.2°, 14.9°±0.2°, 17.7°±0.2°, 18.8°±0.2°, 20.6°±0.2°, 21.8°±0.2°, and 23.5°±0.2°.

[0049] Crystalline Form C: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ] values ​​selected from 5.6°±0.2°, 7.3°±0.2°, 15.7°±0.2°, 17.2°±0.2°, 18.9°±0.2°, 21.2°±0.2°, and 21.9°±0.2°.

[0050] Crystalline Form D: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ] values ​​selected from 5.5°±0.2°, 7.2°±0.2°, 15.3°±0.2°, 17.2°±0.2°, 17.6°±0.2°, 18.9°±0.2°, and 21.1°±0.2°.

[0051] Crystalline Form E: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ] values ​​selected from 4.93°±0.2°, 6.12°±0.2°, 7.43°±0.2°, 8.89°±0.2°, 9.74°±0.2°, 14.79°±0.2°, 15.79°±0.2°, 16.11°±0.2°, 19.79°±0.2°, and 22.83°±0.2°

[0052]

[0053] The above crystal forms A, B, C, D and E can be characterized by X-ray diffraction spectra each having four or more peaks, for example, four, five, six, seven, eight or more, at the above-mentioned 2[θ] values.

[0054] Although not limited thereto, the pharmaceutical composition comprising inabogliflozin according to the present invention may have the composition of the pharmaceutical composition of PCT / KR2022 / 014640.

[0055] For example, the pharmaceutical composition of the present invention may be a pharmaceutical composition comprising a compound of formula 1 or a pharmaceutically acceptable salt thereof, an excipient, a disintegrant, and a binder as an active ingredient, and wherein the average particle size of the compound of formula 1 is 15 μm or less.

[0056] In a specific example of the present invention, the average particle size of inabogliflozin may be 15 um or less, preferably 10 um or less.

[0057] When the average particle size of inabogliflozin exceeds 15 μm, the 5-minute dissolution rate is very low, less than 40% of the total content of inabogliflozin, and the 30-minute dissolution rate is also less than 80%, so the final dissolution rate is found to be inadequate.

[0058] If micronization of drug particle size is required, the drug can be milled using a conventional mill capable of micronizing particles, such as a Z-mill, hammer mill, ball mill, or fluid energy mill. In addition, a size classification method, such as a sieving method using a sieve or air current classification, can be used to refine the drug particle size. Methods for controlling the desired particle size are well known in the art. For example, see the following literature: [Pharmaceutical dosage forms: volume 2, 2nd edition, Ed.: HALieberman, L. Lachman, J. B. Schwartz (Chapter 3: SIZE REDUCTION)].

[0059] In this specification, the particle size of a drug is expressed based on a particle size distribution such as D(X) = Y (where X and Y are positive numbers). D(X) = Y means that when the particle size distribution of a drug obtained by measuring the particle diameter of a certain drug in a formulation is expressed by a cumulative curve, the particle diameter at the point where the particle sizes accumulate from the smallest to the largest is X% (% is calculated based on number, volume, or weight), is Y. For example, D(10) represents the particle diameter at the point where the particle sizes of the drug accumulate from the smallest to the smallest, D(50) represents the particle diameter at the point where the particle sizes of the drug accumulate from the smallest to the smallest, and D(90) represents the particle diameter at the point where the particle sizes of the drug accumulate from the smallest to the smallest.

[0060] Whether the particle size distribution D(X) represents a percentage of the total cumulative particles by number, volume, or weight depends on the method used to measure the particle size distribution. Methods for measuring particle size distributions and the type of percentages associated with them are well known in the art. For example, when measuring particle size distributions by the well-known laser diffraction method, the X value in D(X) represents the percentage calculated by volume average. It is well known to those skilled in the art that particle size distribution measurement results obtained by a particular method can be correlated with those obtained by other techniques based on experience through routine experiments. For example, laser diffraction is sensitive to particle volume and provides a volume average particle size, which corresponds to a weight average particle size at constant density.

[0061] In the present invention, the particle size distribution of drug particles can be measured using a commercially available device based on laser diffraction and scattering method based on Mie theory. For example, measurement is performed using a commercially available device such as the Mastersizer laser diffraction device from Malvern Instruments. This device irradiates particles with a helium-neon laser beam and a blue light-emitting diode, causing scattering to occur, resulting in a light scattering pattern appearing on a detector. By interpreting this light scattering pattern according to Mie theory, the particle diameter distribution is obtained. The measurement method can be either a dry or wet method.

[0062] For reference, in the examples of the present invention, the particle size of the drug was measured by the volume average particle size using laser diffraction.

[0063] In a specific example of the present invention, the compound of Chemical Formula 1 may be included in an amount of less than 1 part by weight based on 100 parts by weight of the total pharmaceutical composition.

[0064] The appropriate daily dosage of inabogliflozin identified during clinical trials is 0.1 mg to 0.5 mg. When the pharmaceutical composition is formulated as a unit dosage form, the content of the active ingredient in the pharmaceutical composition may be 0.1 to 0.5 mg.

[0065] The pharmaceutical composition according to the present invention comprises pharmaceutically acceptable additives in addition to the compound of chemical formula 1, which is an active ingredient.

[0066] The pharmaceutical composition of the present invention includes excipients, disintegrants, and binders as additives.

[0067] Examples of excipients include lactose (including hydrate), dextrin, mannitol, sorbitol, starch, microcrystalline cellulose (e.g., Celphere™), silicified microcrystalline cellulose (e.g., Prosolv™), calcium phosphate hydrate, anhydrous calcium phosphate, calcium carbonate, sugars, or mixtures thereof. In embodiments of the present invention, a preferred excipient is microcrystalline cellulose.

[0068] Examples of disintegrants include crospovidone, croscarmellose sodium, sodium starch glycolate, and low-substituted hydroxypropyl cellulose. In a specific embodiment of the present invention, a preferred excipient is croscarmellose sodium.

[0069] Examples of binders include polyvinylpyrrolidone, povidone, gelatin, starch, sucrose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylalkylcellulose (e.g., hydroxypropylmethylcellulose), and mixtures thereof. In an embodiment of the invention, a preferred binder is hydroxypropylcellulose.

[0070] Examples of other additives include lubricants and colorants.

[0071] The above-mentioned lubricants include stearic acid, stearic acid salts (e.g., magnesium stearate), light anhydrous silicic acid, talc, corn starch, carnauba wax, magnesium silicate, synthetic aluminum silicate, hydrogenated oil, white lead, titanium dioxide, microcrystalline cellulose, macrogol 4000 and 6000, isopropyl myristate, calcium hydrogen phosphate, and mixtures thereof.

[0072] In a specific embodiment of the present invention, the excipient may be included in an amount of 80 to 95 parts by weight based on 100 parts by weight of the total pharmaceutical composition.

[0073] In a specific embodiment of the present invention, the disintegrant may be included in an amount of 2 to 8 parts by weight relative to 100 parts by weight of the total pharmaceutical composition. If the disintegrant is included in an amount of less than 2 parts by weight relative to 100 parts by weight of the total pharmaceutical composition, the initial disintegration power may be low, which may delay the dissolution rate, and this may affect the Cmax in the body. In addition, if the amount of the disintegrant is included in an amount of more than 8 parts by weight relative to 100 parts by weight of the total pharmaceutical composition, the amount of the disintegrant in the post-mixing portion may increase, which may reduce the overall flowability of the granules.

[0074] In a specific embodiment of the present invention, the binder may be included in an amount of 3 to 10 parts by weight relative to 100 parts by weight of the total pharmaceutical composition. If the binder is included in an amount of less than 3 parts by weight relative to 100 parts by weight of the total pharmaceutical composition, it may be difficult to form and maintain suitable dry granules, which may affect the maintenance of homogeneous dispersion of the main ingredient and the flowability of the granules due to the generation of fine particles. In addition, if the binder is included in an amount of more than 10 parts by weight relative to 100 parts by weight of the total pharmaceutical composition, granules having strong binding force are formed, which may affect the solubility of the granule particles that are initially disintegrated during dissolution, which may also affect the Cmax in the body.

[0075] The pharmaceutical composition according to the present invention may be an immediate-release formulation.

[0076] In one specific embodiment of the present invention, the pharmaceutical composition may have a dissolution rate of 50% or more, preferably 60% or more, of the total content of the active ingredient after 5 minutes.

[0077] In one specific embodiment of the present invention, the pharmaceutical composition may have a dissolution rate of 80% or more, preferably 80% or more, of the total content of the active ingredient after 15 minutes.

[0078] In one specific embodiment of the present invention, the pharmaceutical composition may have a dissolution rate of 85% or more, preferably 90% or more, of the total content of the active ingredient after 30 minutes.

[0079] The dissolution rate of the active ingredient in the pharmaceutical composition affects the peak blood concentration (Cmax) and the area under the blood concentration-time curve (AUC) when the drug is administered. Therefore, conversely, it is important to adjust the dissolution rate of the pharmaceutical composition to achieve appropriate Cmax and AUC. Since inavogliflozin has a Tmax of 1 to 2 hours, the drug absorption rate from above is considered important. The above dissolution rate was measured under the condition of a dissolution volume of 1.2 according to the dissolution test method 2 (paddle method) of the Korean Pharmacopoeia. For specific conditions, please refer to the experimental example below.

[0080] The present invention also

[0081] A pharmaceutical composition comprising a granule mixture comprising a premixed granule and a postmixed granule comprising a compound of formula 1 or a pharmaceutically acceptable salt thereof is provided.

[0082] During the study on formulation of the compound of chemical formula 1, the inventors of the present invention confirmed that preparing granules and formulating them into tablets, etc. is advantageous in terms of drug content uniformity and formulation uniformity.

[0083] In the above pharmaceutical composition, the granules are prepared by mixing pre-mixed granules and a post-mixed portion.

[0084] The above premixed granules may include a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof, an excipient, a binder, and a lubricant.

[0085] Additionally, the post-mixing portion may include excipients, disintegrants, and lubricants.

[0086] Descriptions of excipients, binders, disintegrants, lubricants, etc. are the same as those described above, so they are omitted to avoid duplicate description.

[0087] In a specific embodiment of the present invention, the pre-mixed granules and the post-mixed portion may each include an excipient. More specifically, the pre-mixed granules and the post-mixed portion may each include microcrystalline cellulose as an excipient.

[0088] According to the following examples, it was found that the microcrystalline cellulose included in the pre-mixed granules and post-mixed portion affects the uniformity of the drug content depending on its particle size and bulk density.

[0089] In a specific example of the present invention, the particle size of the microcrystalline cellulose in the pre-mixed granules may be 130 μm or less, preferably 60 to 130 μm. The bulk density of the microcrystalline cellulose in the pre-mixed granules may be 0.26 to 0.33. When the particle size and bulk density of the microcrystalline cellulose in the pre-mixed granules are as above, a formulation with a low deviation (SD) of content uniformity can be secured. When the particle size of the microcrystalline cellulose in the pre-mixed granules is 130 μm or less, the content uniformity of the pre-mixed granules, the content uniformity of the final granules, and the formulation all exhibited good levels, and the Carr's index value indicating the physical properties of the final granules was also good, so it was confirmed that the flowability of the formulation was also excellent. On the other hand, when the particle size of microcrystalline cellulose in the premixed granules exceeded 130 μm, both the content uniformity of the premixed granules and the content uniformity of the final granules showed a large deviation and were not suitable, and the formulation uniformity was also found to be poor.

[0090] Meanwhile, the particle size of the microcrystalline cellulose in the post-mixing unit may be 130 μm or more, preferably 130 to 250 μm. The bulk density of the excipient in the post-mixing unit may be 0.28 to 0.37. When the particle size of the microcrystalline cellulose in the post-mixing unit is less than 130 μm, it was confirmed that the Carr's index value, which indicates the physical properties of the final granules, was not appropriate and the granule flowability became poor.

[0091] When the microcrystalline cellulose in the pre-mixed granules is relatively compared to the microcrystalline cellulose in the post-mixed portion, it is found that, unlike the microcrystalline cellulose contained in the pre-mixed granules, it is desirable for the particle size of the microcrystalline cellulose in the post-mixed portion to be relatively large compared to the particle size of the microcrystalline cellulose contained in the pre-mixed granules.

[0092] According to the following examples, it was confirmed that not only the particle size of microcrystalline cellulose in the pre-mixed granules and the microcrystalline cellulose in the post-mixed portion, but also the weight ratio of the excipient in the pre-mixed granules and the excipient in the post-mixed portion affect the drug content uniformity.

[0093] In a specific example of the present invention, the weight ratio of the excipients in the pre-mixed granules and the excipients in the post-mixed portion may be 4:1 to 1:1. As the proportion of microcrystalline cellulose in the post-mixed portion increases, the flowability of the granules improves, but the content deviation increases, so it was determined that it is desirable to maintain the weight ratio within the above-described appropriate range.

[0094] Meanwhile, in the pharmaceutical composition according to the present invention, the binder may be at least one selected from the group consisting of hydroxypropylcellulose, povidone, copovidone, and hypromellose.

[0095] In one specific example of the present invention, the binder is hydroxypropyl cellulose and may have a weight average molecular weight of less than 200,000. If hydroxypropyl cellulose having a weight average molecular weight of 200,000 or more is used, both the 5-minute dissolution rate and the 30-minute dissolution rate are low, which is undesirable in terms of bioavailability.

[0096] Meanwhile, with respect to Carr's index, which is used as a measure of flowability in formulation, it is preferable that the Carr's index of the granules be 21 to 25.

[0097] Although not limited thereto, the granules in the pharmaceutical composition of the present invention may be dry granules. In another specific embodiment, the granules may be wet granules.

[0098] In the present invention, the pharmaceutical composition may have a dosage form for oral administration, such as a tablet or capsule. In one specific embodiment of the present invention, the pharmaceutical composition may have a dosage form of a tablet.

[0099] In a preferred embodiment, the pharmaceutical composition may contain the compound of formula 1 in a dosage of 0.3 mg to 0.5 mg.

[0100] The pharmaceutical composition according to the present invention may be administered orally once a day, but is not limited thereto.

[0101] The pharmaceutical composition comprising the inabogliflozin of the present invention as an active ingredient can be usefully used for the prevention or treatment of renal impairment, or the prevention or treatment of diabetes in patients with renal impairment.

[0102] Figure 1 shows the results of measuring HbA1c after 6, 12, 18, and 24 weeks of administration of inavogliflozin or inavogliflozin placebo alone for 24 weeks in patients with type 2 diabetes. The test group received inavogliflozin at a dose of 0.3 mg once daily for 24 weeks, and the control group received inavogliflozin placebo once daily for 24 weeks. The bar graph represents the mean of each variable, and the error bars represent the SD. A p value less than 0.05 was considered statistically significant.

[0103] Figure 2 shows the results of measuring HbA1c after 6, 12, 18, and 24 weeks of administration of inavogliflozin or dapagliflozin for 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. The test group was administered 0.3 mg of inavogliflozin or 10 mg of dapagliflozin placebo once daily for 24 weeks, and the control group was administered 0.3 mg of inavogliflozin placebo or 10 mg of dapagliflozin placebo once daily for 24 weeks. During this time, metformin was maintained at the same dose as before. The bar graph represents the mean of each variable, and the error bars represent SD. A p value less than 0.05 was considered statistically significant.

[0104] Figure 3 shows the results of measuring HbA1c after 6, 12, 18, and 24 weeks of administration of inavogliflozin or dapagliflozin for 24 weeks in patients with type 2 diabetes inadequately controlled with metformin and gemigliptin. The test group was administered 0.3 mg of inavogliflozin or 10 mg of dapagliflozin placebo once daily for 24 weeks, and the control group was administered 0.3 mg of inavogliflozin placebo or 10 mg of dapagliflozin placebo once daily for 24 weeks. During this time, metformin and gemigliptin were maintained at the same doses as before. The bar graph represents the mean of each variable, and the error bars represent SD. A p value less than 0.05 was considered statistically significant.

[0105] Figure 4 is a graph showing the change in UACR at 24 weeks according to administration of the test drug in a group of patients with proteinuria (baseline UACR of 30 to 3500 g / kg). Inavogliflozin monotherapy, inavogliflozin and metformin combination, and inavogliflozin, metformin, and gemigliptin combination all showed a significant decrease in the change in UACR at 24 weeks compared to the control group.

[0106] Figure 5 is a graph showing changes in urine glucose excretion following administration of 0.5 mg of inabogliflozin in patient groups with eGFR≥90, 60≤eGFR<90, 30≤eGFR<60, or 15≤eGFR<30.

[0107] Figure 6 is a graph showing the change in eGFR according to administration of 0.5 mg of inabogliflozin in patient groups with eGFR≥90, 60≤eGFR<90, 30≤eGFR<60, or 15≤eGFR<30.

[0108] Figure 7 is a graph showing the results of administering a test substance to SD rats treated with streptozotocin and measuring the urinary albumin concentration at 4, 8, and 12 weeks after administration.

[0109] Figure 8 is a graph showing the results of administering a test substance to SD rats treated with streptozotocin and measuring the GS score and TA score at the 12-week point of administration.

[0110] Hereinafter, one or more specific examples will be described in more detail through examples. However, these examples are provided for illustrative purposes only and the scope of the present invention is not limited to these examples.

[0111]

[0112] [Example]

[0113] Example 1: Inabogliflozin monotherapy in patients with type 2 diabetes

[0114] 1. Research process

[0115] If the subject voluntarily gave written consent to participate in this clinical trial, a screening test was conducted. Patients with type 2 diabetes who had inadequate glycemic control (7% ≤ HbA1c ≤ 10%) at Visit 1 (screening) were eligible to participate, and patients with type 2 diabetes who were taking hypoglycemic agents at the time of screening could participate in the trial after a washout period of at least 8 weeks (56 days) before screening. However, if the hypoglycemic agent was discontinued before Visit 1 (screening), the washout period was at least 8 weeks, including the discontinuation period, and a stable diet and exercise program was implemented during this period. Naive patients were screened without a separate washout period, and the criteria for naive patients were defined as patients who had not taken hypoglycemic agents within 24 weeks immediately prior to the date of obtaining written informed consent.

[0116] Selection / Exclusion Criteria [1] Subjects who met the criteria were administered placebo of the investigational drug in a single-blind (subject blinded) state during a 2-week run-in period. Subjects who had a placebo compliance rate of 70-130% during the run-in period and who met the final inclusion / exclusion criteria were centrally randomly assigned to either the test group (inavogliflozin 0.3 mg) or the control group (Placebo) in a 1:1 ratio at Visit 2 (randomization). At this time, subjects were stratified according to whether they had taken hypoglycemic agents within the 24 weeks immediately prior to the date of obtaining written informed consent (drug naive or previously administered hypoglycemic agents) and the HbA1c value (less than or equal to 8%) at Visit 1 (screening) measured in the central laboratory, and the subjects were administered the investigational drug in the assigned group for 24 weeks.

[0117] Randomized subjects were administered one tablet of the clinical trial drug corresponding to each treatment group once daily. Efficacy and safety were assessed at the institution at weeks 6, 12, 18, and 24 during the 24-week treatment period. Furthermore, subjects were instructed to maintain the regular exercise and dietary regimen they had begun eight weeks prior to screening without altering their daily routines throughout the trial period.

[0118] The results are shown in Tables 1 to 20 and Fig. 1.

[0119]

[0120] [1] [Selection Criteria]

[0121] Selection criteria at Pre-Visit (pre-screening) or Visit 1 (screening)

[0122] 1. Adults aged 19 to 80 as of the date of obtaining written consent

[0123] 2. Those with HbA1c* ≤ 7% ≤ 10% at Visit 1 (screening) and diagnosed with type 2 diabetes at least 8 weeks prior to Visit 1

[0124] (For subjects who were taking hypoglycemic agents within 8 weeks prior to Visit 1 (screening), the results of the test conducted at the institution at the time of Pre-Visit (pre-screening) must be 6.5% ≤ HbA1c ≤ 10%, and 7% ≤ HbA1c* ≤ 10% at Visit 1 (screening) after the drug-free period)

[0125] * Test results from the implementing agency or central laboratory are available. The final decision will be made based on the central laboratory results. However, if the testing results from the implementing agency are deemed appropriate before confirming the central laboratory results, a run-in can be initiated.

[0126] 3. Those with FPG < 270 mg / dL at Pre-visit (pre-screening) and Visit 1 (screening)

[0127] 4. Those with a BMI of 20-45 kg / m2 at Pre-visit (pre-screening) and Visit 1 (screening)

[0128] 5. Those who have followed a stable diet and exercise program for at least 8 weeks prior to Visit 1 (screening)

[0129] 6. Those who voluntarily decided to participate and gave written consent after hearing an explanation of the purpose, method, and effects of this clinical trial.

[0130] Selection criteria for Visit 2 (random assignment)

[0131] 1. Those whose HbA1c is 7% ≤ HbA1c ≤ 10% as tested at the central laboratory during Visit 1 (screening)

[0132] 2. Those with a placebo compliance rate of 70-130% during the run-in period confirmed at Visit 2 (randomization)

[0133]

[0134] [Exclusion criteria]

[0135] Exclusion criteria at Pre-Visit (pre-screening) or Visit 1 (screening)

[0136] 1. Those who have a history of hypersensitivity to the clinical trial drug or any drug or component of the same class (e.g., history of hypersensitivity to SGLT2 inhibitor drugs)

[0137] 2. Those with the following medical history or surgical / therapeutic history:

[0138] History of medically significant kidney disease: renal vascular occlusive disease, nephrectomy, kidney transplant, etc.

[0139] History of severe gastrointestinal surgery: total gastrectomy, total colectomy, small bowel resection, gastroenterostomy, gastrointestinal bypass, etc.

[0140] History of acute pancreatitis or pancreatic surgery

[0141] History of bariatric surgery within the past two years

[0142] Diabetic ketoacidosis, diabetic coma, or precoma within the past year

[0143] Urinary tract infection or genital infection within the past year

[0144] Alcohol or drug addiction within the past year

[0145] Occurrence of acute coronary syndrome, unstable angina, myocardial infarction requiring hospitalization, stroke, transient ischemic attack, or arrhythmia within the past 24 weeks

[0146] (However, those who have had the condition before 24 weeks and are currently cured or in a stable condition can register.)

[0147] Those who have had a history of major surgery that caused electrolyte imbalance within the past 12 weeks or are scheduled to have major surgery within 12 weeks after the end of the clinical trial

[0148] 3. Those with the following diseases or symptoms:

[0149] Any type of diabetes other than type 2 diabetes (type 1 diabetes, secondary diabetes, or congenital renal diabetes)

[0150] Symptoms of urinary incontinence, anuria, oliguria, and urinary retention that cannot be controlled with medication due to stress urinary incontinence, neurogenic bladder, and benign prostatic hyperplasia

[0151] Severe diabetic complications (proliferative diabetic retinopathy, nephropathy of stage 4 or higher, or severe diabetic neuropathy)

[0152] Chronic diseases requiring continuous use (oral, injected, or inhaled) of diuretics, systemic steroids, or immunosuppressants

[0153] Severe infection (e.g., severe infection requiring continued use of antibiotics or immunotherapy), clinically significant major trauma

[0154] unstable mental illness whose symptoms are not controlled by medication

[0155] Severe gastrointestinal disease: active ulcers, gastrointestinal / rectal bleeding, active inflammatory bowel syndrome, patients with biliary obstruction, active gastritis not controlled by medication, etc.

[0156] Uncontrolled hypertension (SBP > 180 mmHg or DBP > 110 mmHg)

[0157] Patients with moderate or severe renal impairment (eGFR < 60 mL / min / 1.73 m 2 )

[0158] Patients with severe liver impairment who fall under one of the following:

[0159] - AST or ALT > 3 times the upper limit of normal

[0160] - Total Bilirubin > 2 times the upper limit of normal

[0161] - Hepatitis or liver failure

[0162] Patients with severe hypertriglyceridemia (Triglyceride > 500 mg / dL)

[0163] Acquired immunodeficiency syndrome

[0164] Severe heart failure (NYHA class III~IV)

[0165] Those who require treatment for dehydration due to persistent diarrhea or vomiting, or are at risk of fluid volume depletion

[0166] 4. Patients who have used other clinical trial drugs / medical devices within the past 4 weeks (However, registration is possible in cases where the investigator determines that it will not affect the efficacy and safety of this study, such as observational studies or retrospective studies)

[0167] 5. Patients with a history of malignant tumor within the past 5 years

[0168] However, patients with appropriately controlled basal cell carcinoma, squamous cell carcinoma, or cervical intraepithelial carcinoma can participate.

[0169] However, participation is possible if there has been no recurrence for more than 5 years after a complete cure (complete removal of the tumor through surgery or completion of chemotherapy, etc.)

[0170] 6. Pregnant or lactating women or those who do not agree to use appropriate contraception during the clinical trial period.

[0171] *Appropriate contraception method for you or your partner: You must agree to one of the following:

[0172] ① If you have undergone one of the following: sterilization surgery (vasectomy, etc.) or intrauterine device (copper loop, hormone-containing intrauterine system).

[0173] ② Use of either non-oral hormonal contraceptives or spermicides in combination with the barrier method

[0174] ③ Use a cervical cap or diaphragm together with a male condom

[0175] 7. Those who are judged by the investigator to be ineligible for this clinical trial

[0176]

[0177] Exclusion criteria for Visit 1 (screening)

[0178] 1. Those who have a history of taking the following drugs or are expected to require continuous administration during the clinical trial period.

[0179] Systemic steroids (prednisolone >30 mg / day) within the past 2 weeks

[0180] Diabetes medications taken within the past 8 weeks

[0181] Those who have changed the dosage of thyroid dysfunction treatment within the past 6 weeks (if the treatment was administered stably before clinical trial registration, concurrent use is permitted during the trial period. If the stable condition is maintained, a dose reduction is permitted.)

[0182] Weight loss medications within the past 12 weeks

[0183]

[0184] 2. Experimental results

[0185] Description of the experimental results

[0186] 1) Change in HbA1c at 24 weeks after administration of clinical trial drug compared to Visit 2 (randomization)

[0187] The primary efficacy endpoint of this clinical trial was the 'change in HbA1c at 24 weeks after administration of the investigational drug compared to the baseline (Visit 2)'. An analysis of covariance (ANCOVA) was conducted with baseline and stratification factors (administration of hypoglycemic agents within 24 weeks prior to the date of obtaining written consent, HbA1c level (less than or equal to 8%) at Visit 1 (screening) as covariates. As a result, the least squares mean (LS Mean (SE)) of the change in HbA1c was -0.88 (0.10)%p for the test group and 0.11 (0.11)%p for the control group. The difference between the two groups (LS Mean Difference (95% CI)) was -0.99 (-1.24, -0.74)%p, which was a statistically significant difference, demonstrating the superiority of the test group over the control group (p<0.0001).

[0188] As a result of examining the change in HbA1c at each evaluation point after administration of the clinical trial drug, the test group showed a tendency to decrease over time, but the control group showed a tendency to increase after decreasing.

[0189] Change from baseline in HbA1c at week 24 - LOCF (Full Analysis Set) Inavogliflozin 0.3 mg (N=82) Placebo (N=79) Baseline n 82 79 Mean (SD) 7.64 (0.66) 7.72 (0.63) Median 7.50 7.60 Min, Max 6.67, 9.52 6.70, 9.68 Week 24 n 82 79 Mean (SD) 6.80 (0.59) 7.84 (1.15) Median 6.79 7.58 Min, Max 5.41, 8.59 5.76, 11.65 Change from baseline at week 24 n 82 79 Mean (SD) -0.84 (0.66) 0.12 (1.01) Median -0.78 0.06 Min, Max -2.72, 0.64 -1.83, 4.08 P-value [1]<0.0001 (t)0.4836 (w)ANCOVA ResultLS Mean(SE)-0.88(0.10)0.11(0.11)LS Mean Difference-0.9995% Confidence Interval for Difference[-1.24, -0.74]P-value [2]<0.0001

[0190]

[0191] 2) Changes in HbA1c at 6, 12, and 18 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0192] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference in HbA1c change between the two groups (LS Mean Difference (95% CI)) was -0.52 (-0.65, -0.39)%p at 6 weeks, -0.71 (-0.89, -0.54)%p at 12 weeks, and -0.79 (-1.00, -0.58)%p at 18 weeks, showing a statistically significant difference between the two groups at all time points (p<0.0001).

[0193] Change from baseline in HbA1c at week 6, 12 and 18 - LOCF (Full Analysis Set) 이나보글리플로진 0.3 mg(N=82)위약(N=79)Baselinen8279Mean(SD)7.64(0.66)7.72(0.63)Median7.507.60Min, Max6.67, 9.526.70, 9.68Week 6n8178Mean(SD)7.01(0.59)7.59(0.74)Median7.007.43Min, Max5.60, 8.746.07, 9.73Change from baseline at week 6n8178Mean(SD)-0.63(0.39)-0.12(0.51)Median-0.59-0.13Min, Max-1.86, 0.17-1.61, 1.59P-value [1]<0.0001 (t)0.0112 (w)ANCOVA ResultLS Mean(SE)-0.67(0.05)-0.16(0.05)LS Mean Difference-0.5295% Confidence Interval for Difference[-0.65, -0.39]P-value [2]<0.0001Week 12n8279Mean(SD)6.84(0.53)7.61(0.87)Median6.817.48Min, Max5.66, 8.866.03, 9.75Change from baseline at week 12n8279Mean(SD)-0.80(0.55)-0.11(0.67)Median-0.74-0.21Min, Max-2.47, 0.29-2.23, 2.51P-value [1]<0.0001 (w)0.0135 (w)ANCOVA ResultLS Mean(SE)-0.84(0.07)-0.13(0.07)LS Mean Difference-0.7195% Confidence Interval for Difference[-0.89, -0.54]P-value [2]<0.0001Week 18n8279Mean(SD)6.88(0.54)7.71(0.97)Median6.887.52Min, Max5.56, 8.786.02, 10.14Change from baseline at week 18n8279Mean(SD)-0.77(0.67)-0.01(0.80)Median-0.680.02Min, Max-2.92, 0.55-2.09, 2.51P-value [1]<0.0001 (w)0.8781 (t)ANCOVA ResultLS Mean(SE)-0.81(0.09)-0.02(0.09)LS Mean Difference-0.7995% Confidence Interval for Difference[-1.00, -0.58]P-value [2]<0.0001.

[0194] 3) Changes in FPG at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0195] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference in FPG change between the two groups (LS Mean Difference (95% CI)) was -26.91 (-33.19, -20.63) mg / dL at 6 weeks, -32.26 (-39.69, -24.82) mg / dL at 12 weeks, -33.40 (-41.59, -25.22) mg / dL at 18 weeks, and -40.08 (-49.39, -30.77) mg / dL at 24 weeks, showing a statistically significant difference between the two groups at all time points (p<0.0001).

[0196] Change from baseline in FPG at week 6, 12, 18 and 24 - LOCF (Full Analysis Set) 이나보글리플로진 0.3 mg(N=82)위약(N=79)Baselinen8279Mean(SD)141.00(24.10)141.47(23.51)Median137.50140.00Min, Max97.00, 220.0090.00, 214.00Week 6n8178Mean(SD)115.19(14.55)142.46(30.90)Median116.00139.00Min, Max78.00, 157.0095.00, 278.00Change from baseline at week 6n8178Mean(SD)-25.86(20.19)0.77(25.01)Median-22.00-1.00Min, Max-97.00, 50.00-74.00, 108.00P-value [1]<0.0001 (w)0.7975 (w)ANCOVA ResultLS Mean(SE)-27.78(2.47)-0.88(2.51)LS Mean Difference-26.9195% Confidence Interval for Difference[-33.19, -20.63]P-value [2]<0.0001Week 12n8279Mean(SD)111.66(13.55)144.18(36.21)Median112.00136.00Min, Max67.00, 151.0089.00, 304.00Change from baseline at week 12n8279Mean(SD)-29.34(20.90)2.71(30.34)Median-27.00-2.00Min, Max-96.00, 10.00-59.00, 136.00P-value [1]<0.0001 (w)0.8327 (w)ANCOVA ResultLS Mean(SE)-30.66(2.93)1.60(2.97)LS Mean Difference-32.2695% Confidence Interval for Difference[-39.69, -24.82]P-value [2]<0.0001Week 18n8279Mean(SD)110.48(14.49)144.04(37.52)Median112.50137.00Min, Max64.00, 159.0087.00, 304.00Change from baseline at week 18n8279Mean(SD)-30.52(22.34)2.57(34.84)Median-27.00-3.00Min, Max-106.00, 22.00-69.00, 151.00P-value [1]<0.0001 (w)0.3378 (w)ANCOVA ResultLS Mean(SE)-31.97(3.23)1.44(3.27)LS Mean Difference-33.4095% Confidence Interval for Difference[-41.59, -25.22]P-value [2]<0.0001Week 24n8279Mean(SD)111.00(14.56)151.34(44.39)Median110.50142.00Min, Max70.00, 150.0087.00, 322.00Change from baseline at week 24n8279Mean(SD)-30.00(20.73)9.87(39.42)Median-27.001.00Min, Max-100.00, 36.00-47.00, 201.00P-value [1]<0.0001 (w)0.1571 (w)ANCOVA ResultLS Mean(SE)-31.66(3.68)8.42(3.72)LS Mean Difference-40.0895% Confidence Interval for Difference[-49.39, -30.77]P-value [2]<0.0001.

[0197] 4) Proportion of subjects achieving HbA1c < 7% at each time point of 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0198] Logistic regression analysis adjusted for stratification factors showed that the odds ratio (95% CI) for achieving HbA1c < 7% in the test group compared to the control group was 6.55 (2.92, 14.70) at 6 weeks, 6.53 (3.11, 13.70) at 12 weeks, 4.85 (2.34, 10.07) at 18 weeks, and 9.08 (4.27, 19.31) at 24 weeks, showing a statistically significant difference between the two groups at all time points (p<0.0001).

[0199] Proportion of subjects achieving HbA1c target of < 7 % at week 6, 12, 18 and 24 - LOCF (Full Analysis Set) 이나보글리플로진 0.3 mg(N=82)위약(N=79)Proportion of subjects achieving HbA1c target of < 7 % at week 6, N8178Subjects with achieving HbA1c target of < 7 %, n(%)40(49.38)12(15.38)Logistic Regression ModelOdds Ratio6.5595% Confidence Interval[2.92, 14.70]P-value [1]<0.0001Proportion of subjects achieving HbA1c target of < 7 % at week 12, N8279Subjects with achieving HbA1c target of < 7 %, n(%)54(65.85)21(26.58)Logistic Regression ModelOdds Ratio6.5395% Confidence Interval[3.11, 13.70]P-value [1]<0.0001Proportion of subjects achieving HbA1c target of < 7 % at week 18, N8279Subjects with achieving HbA1c target of < 7 %, n(%)47(57.32)20(25.32)Logistic Regression ModelOdds Ratio4.8595% Confidence Interval[2.34, 10.07]P-value [1]<0.0001Proportion of subjects achieving HbA1c target of < 7 % at week 24, N8279Subjects with achieving HbA1c target of < 7 %, n(%)58(70.73)19(24.05)Logistic Regression ModelOdds Ratio9.0895% Confidence Interval[4.27, 19.31]P-value [1]<0.0001

[0200] 5) Proportion of subjects achieving HbA1c < 6.5% at each time point of 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0201] Logistic regression analysis adjusted for stratification factors showed that the odds ratio (95% CI) for achieving HbA1c < 6.5% in the test group compared to the control group was 3.29 (1.00, 10.83) at 6 weeks, 7.58 (2.43, 23.65) at 12 weeks, 5.58 (2.09, 14.90) at 18 weeks, and 12.10 (3.90, 37.53) at 24 weeks, showing statistically significant differences between the two groups at all time points (6 weeks p=0.0498, 12 weeks p=0.0005, 18 weeks p=0.0006, 24 weeks p<0.0001).

[0202] Proportion of subjects achieving HbA1c target of < 6.5 % at week 6, 12, 18 and 24 - LOCF (Full Analysis Set) 이나보글리플로진 0.3 mg(N=82)위약(N=79)Proportion of subjects achieving HbA1c target of < 6.5 % at week 6, N8178Subjects with achieving HbA1c target of < 6.5 %, n(%)12(14.81)4(5.13)Logistic Regression ModelOdds Ratio3.2995% Confidence Interval[1.00, 10.83]P-value [1]0.0498Proportion of subjects achieving HbA1c target of < 6.5 % at week 12, N8279Subjects with achieving HbA1c target of < 6.5 %, n(%)22(26.83)4(5.06)Logistic Regression ModelOdds Ratio7.5895% Confidence Interval[2.43, 23.65]P-value [1]0.0005Proportion of subjects achieving HbA1c target of < 6.5 % at week 18, N8279Subjects with achieving HbA1c target of < 6.5 %, n(%)24(29.27)6(7.59)Logistic Regression ModelOdds Ratio5.5895% Confidence Interval[2.09, 14.90]P-value [1]0.0006Proportion of subjects achieving HbA1c target of < 6.5 % at week 24, N8279Subjects with achieving HbA1c target of < 6.5 %, n(%)29(35.37)4(5.06)Logistic Regression ModelOdds Ratio12.1095% Confidence Interval[3.90, 37.53]P-value [1]<0.0001

[0203] 6) Proportion of subjects who achieved a therapeutic response (change in HbA1c at each evaluation time point (HbA1c at Visit 2 - HbA1c at each evaluation time point) > 0.5% or HbA1c < 7%) at each time point 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0204] Logistic regression analysis adjusted for stratification factors showed that the odds ratio (95% CI) for achieving a therapeutic response in the test group compared to the control group was 12.84 (5.76, 28.63) at 6 weeks, 14.77 (6.57, 33.17) at 12 weeks, 7.45 (3.48, 15.95) at 18 weeks, and 12.98 (5.78, 29.15) at 24 weeks, with statistically significant differences at all time points (p<0.0001).

[0205] Proportion of Subjects achieving a Therapeutic Glycemic Response at week 6, 12, 18 and 24 - LOCF (Full Analysis Set) 이나보글리플로진 0.3 mg(N=82)위약(N=79)Proportion of subjects achieving a therapeutic glycemic response at week 6, N8178Subjects with achieving a therapeutic glycemic response, n(%)61(75.31)18(23.08)Logistic Regression ModelOdds Ratio12.8495% Confidence Interval[5.76, 28.63]P-value [1]<0.0001Proportion of subjects achieving a therapeutic glycemic response at week 12, N8279Subjects with achieving a therapeutic glycemic response, n(%)70(85.37)24(30.38)Logistic Regression ModelOdds Ratio14.7795% Confidence Interval[6.57, 33.17]P-value [1]<0.0001Proportion of subjects achieving a therapeutic glycemic response at week 18, N8279Subjects with achieving a therapeutic glycemic response, n(%)60(73.17)26(32.91)Logistic Regression ModelOdds Ratio7.4595% Confidence Interval[3.48, 15.95]P-value [1]<0.0001Proportion of subjects achieving a therapeutic glycemic response at week 24, N8279Subjects with achieving a therapeutic glycemic response, n(%)68(82.93)25(31.65)Logistic Regression ModelOdds Ratio12.9895% Confidence Interval[5.78, 29.15]P-value [1]<0.0001.

[0206] 7) Changes in fasting C-peptide (FAS) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0207] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference (LS Mean Difference (95% CI)) between the two groups in the change in fasting C-peptide in the test group compared to the control group was -0.11 (-0.17, -0.06) ng / dL at 6 weeks, -0.12 (-0.18, -0.06) ng / dL at 12 weeks, -0.11 (-0.16, -0.05) ng / dL at 18 weeks, and -0.13 (-0.18, -0.07) ng / dL at 24 weeks, and there were statistically significant differences at all time points.

[0208] Change from baseline in fasting C-peptide at week 6, 12, 18 and 24 - LOCF (Full Analysis Set) 이나보글리플로진 0.3 mg(N=82)위약(N=79)Baselinen8279Mean(SD)0.75(0.30)0.76(0.30)Median0.710.70Min, Max0.30, 1.750.33, 1.62Week 6n8178Mean(SD)0.66(0.25)0.78(0.33)Median0.630.73Min, Max0.20, 1.390.30, 2.02Change from baseline at week 6n8178Mean(SD)-0.09(0.19)0.02(0.20)Median-0.100.03Min, Max-0.83, 0.63-0.63, 0.76P-value [1]<0.0001 (w)0.4517 (w)ANCOVA ResultLS Mean(SE)-0.10(0.02)0.01(0.02)LS Mean Difference-0.1195% Confidence Interval for Difference[-0.17, -0.06]P-value [2]0.0002Week 12n8279Mean(SD)0.64(0.26)0.77(0.32)Median0.600.70Min, Max0.30, 1.590.30, 1.82Change from baseline at week 12n8279Mean(SD)-0.11(0.17)0.01(0.22)Median-0.100.00Min, Max-0.79, 0.23-0.73, 0.89P-value [1]<0.0001 (w)0.9711 (w)ANCOVA ResultLS Mean(SE)-0.10(0.02)0.02(0.02)LS Mean Difference-0.1295% Confidence Interval for Difference[-0.18, -0.06]P-value [2]<0.0001Week 18n8279Mean(SD)0.65(0.29)0.77(0.30)Median0.560.70Min, Max0.26, 1.620.30, 1.56Change from baseline at week 18n8279Mean(SD)-0.10(0.16)0.01(0.21)Median-0.100.00Min, Max-0.50, 0.36-0.46, 0.96P-value [1]<0.0001 (t)0.9175 (w)ANCOVA ResultLS Mean(SE)-0.10(0.02)0.01(0.02)LS Mean Difference-0.1195% Confidence Interval for Difference[-0.16, -0.05]P-value [2]0.0001Week 24n8279Mean(SD)0.64(0.27)0.78(0.30)Median0.600.70Min, Max0.20, 1.560.30, 1.59Change from baseline at week 24n8279Mean(SD)-0.11(0.19)0.01(0.19)Median-0.100.00Min, Max-0.86, 0.33-0.46, 0.73P-value [1]<0.0001 (w)0.6740 (w)ANCOVA ResultLS Mean(SE)-0.10(0.02)0.02(0.02)LS Mean Difference-0.1395% Confidence Interval for Difference[-0.18, -0.07]P-value [2]<0.0001.

[0209] 8) Changes in body weight (FAS) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0210] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference in weight change between the two groups (LS Mean Difference (95% CI)) was -1.45 (-1.93, -0.97) kg at 6 weeks, -1.66 (-2.35, -0.96) kg at 12 weeks, -2.37 (-3.14, -1.60) kg at 18 weeks, and -2.47 (-3.30, -1.63) kg at 24 weeks, showing a statistically significant difference between the two groups at all time points.

[0211] Change from baseline in body weight at week 6, 12, 18 and 24 - LOCF (Full Analysis Set)이나보글리플로진 0.3 mg(N=82)위약(N=79)Baselinen8279Mean(SD)68.77(12.55)69.14(13.66)Median68.5068.20Min, Max42.00, 104.0048.00, 116.20Week 6n8178Mean(SD)66.81(11.92)68.48(13.73)Median67.0066.80Min, Max41.50, 95.0046.30, 116.40Change from baseline at week 6n8178Mean(SD)-2.05(1.80)-0.61(1.31)Median-1.90-0.45Min, Max-9.00, 1.40-4.80, 6.10P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-2.03(0.19)-0.58(0.19)LS Mean Difference-1.4595% Confidence Interval for Difference[-1.93, -0.97]P-value [2]<0.0001Week 12n8279Mean(SD)66.12(12.10)68.14(13.53)Median65.6067.00Min, Max42.80, 100.0047.10, 115.30Change from baseline at week 12n8279Mean(SD)-2.65(2.73)-1.00(1.65)Median-2.60-1.10Min, Max-12.80, 13.00-7.10, 4.70P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-2.59(0.27)-0.93(0.27)LS Mean Difference-1.6695% Confidence Interval for Difference[-2.35, -0.96]P-value [2]<0.0001Week 18n8279Mean(SD)65.32(11.77)68.04(13.90)Median64.8566.30Min, Max42.30, 99.4047.00, 115.60Change from baseline at week 18n8279Mean(SD)-3.44(2.76)-1.11(2.28)Median-3.05-1.20Min, Max-18.00, 1.00-6.10, 11.10P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-3.42(0.30)-1.05(0.30)LS Mean Difference-2.3795% Confidence Interval for Difference[-3.14, -1.60]P-value [2]<0.0001Week 24n8279Mean(SD)65.28(11.93)68.10(14.11)Median65.2566.00Min, Max42.70, 98.2048.10, 118.10Change from baseline at week 24n8279Mean(SD)-3.48(2.96)-1.04(2.42)Median-3.40-1.20Min, Max-20.80, 1.00-5.70, 10.00P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-3.47(0.33)-1.01(0.33)LS Mean Difference-2.4795% Confidence Interval for Difference[-3.30, -1.63]P-value [2]<0.0001.

[0212] 9) Changes in fasting lipid concentration (triglyceride) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0213] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference (LS Mean Difference (95% CI)) between the two groups in the amount of change in total cholesterol was 1.95 (-4.54, 8.43) mg / dL at 6 weeks, -4.04 (-11.86, 3.77) mg / dL at 12 weeks, -0.99 (-8.33, 6.34) mg / dL at 18 weeks, and -6.40 (-14.63, 1.83) mg / dL at 24 weeks, and there was no statistically significant difference at any time point.

[0214] Change from baseline in fasting lipid parameters at week 6, 12, 18 and 24 - LOCF (modified Full Analysis Set 1) [Total cholesterol] 이나보글리플로진 0.3 mg(N=77)위약(N=75)Baselinen7775Mean(SD)161.42(36.14)165.53(35.08)Median158.00170.00Min, Max101.00, 280.0082.00, 249.00Week 6n7674Mean(SD)166.11(39.22)168.09(36.93)Median159.00168.00Min, Max104.00, 313.0077.00, 263.00Change from baseline at week 6n7674Mean(SD)5.75(20.81)3.54(19.06)Median3.501.00Min, Max-39.00, 72.00-54.00, 68.00P-value [1]0.0185 (t)0.1145 (t)ANCOVA ResultLS Mean(SE)5.76(2.52)3.81(2.57)LS Mean Difference1.9595% Confidence Interval for Difference[-4.54, 8.43]P-value [2]0.5537Week 12n7775Mean(SD)167.40(37.13)174.99(40.86)Median157.00173.00Min, Max99.00, 310.0081.00, 277.00Change from baseline at week 12n7775Mean(SD)5.99(23.92)9.45(25.57)Median9.005.00Min, Max-45.00, 90.00-50.00, 100.00P-value [1]0.0311 (t)0.0036 (w)ANCOVA ResultLS Mean(SE)4.75(3.04)8.79(3.09)LS Mean Difference-4.0495% Confidence Interval for Difference[-11.86, 3.77]P-value [2]0.3083Week 18n7775Mean(SD)169.82(38.50)174.45(39.03)Median161.00173.00Min, Max107.00, 298.00104.00, 303.00Change from baseline at week 18n7775Mean(SD)8.40(23.74)8.92(22.79)Median5.006.00Min, Max-53.00, 71.00-42.00, 84.00P-value [1]0.0027 (t)0.0030 (w)ANCOVA ResultLS Mean(SE)6.45(2.86)7.44(2.90)LS Mean Difference-0.9995% Confidence Interval for Difference[-8.33, 6.34]P-value [2]0.7890Week 24n7775Mean(SD)168.00(36.92)177.92(42.51)Median159.00178.00Min, Max92.00, 289.0094.00, 273.00Change from baseline at week 24n7775Mean(SD)6.58(21.82)12.39(30.02)Median6.007.00Min, Max-61.00, 71.00-49.00, 126.00P-value [1]0.0098 (t)0.0017 (w)ANCOVA ResultLS Mean(SE)4.84(3.21)11.24(3.25)LS Mean Difference-6.4095% Confidence Interval for Difference[-14.63, 1.83]P-value [2]0.1267.

[0215] 10) Changes in fasting lipid concentration (LDL-C) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0216] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference in LDL-C change between the two groups (LS Mean Difference (95% CI)) was 0.64 (-5.12, 6.41) mg / dL at 6 weeks, -6.00 (-12.58, 0.57) mg / dL at 12 weeks, -2.35 (-8.59, 3.89) mg / dL at 18 weeks, and -6.91 (-13.54, -0.28) mg / dL at 24 weeks, and there was a statistically significant difference at 24 weeks.

[0217] Change from baseline in fasting lipid parameters at week 6, 12, 18 and 24 - LOCF (modified Full Analysis Set 1) [LDL-C]이나보글리플로진 0.3 mg(N=77)위약(N=75)Baselinen7775Mean(SD)95.47(33.86)99.01(33.01)Median88.0098.00Min, Max42.00, 204.0042.00, 181.00Week 6n7674Mean(SD)96.18(36.96)98.96(34.55)Median91.0094.00Min, Max45.00, 231.0025.00, 187.00Change from baseline at week 6n7674Mean(SD)1.55(18.30)0.74(17.15)Median0.00-0.50Min, Max-48.00, 46.00-51.00, 39.00P-value [1]0.4618 (t)0.7104 (t)ANCOVA ResultLS Mean(SE)1.23(2.24)0.59(2.29)LS Mean Difference0.6495% Confidence Interval for Difference[-5.12, 6.41]P-value [2]0.8264Week 12n7775Mean(SD)95.38(34.18)104.47(36.39)Median89.00101.00Min, Max42.00, 224.0023.00, 205.00Change from baseline at week 12n7775Mean(SD)-0.09(18.99)5.45(23.10)Median0.003.00Min, Max-54.00, 41.00-53.00, 97.00P-value [1]0.9666 (t)0.1281 (w)ANCOVA ResultLS Mean(SE)-2.31(2.56)3.70(2.60)LS Mean Difference-6.0095% Confidence Interval for Difference[-12.58, 0.57]P-value [2]0.0733Week 18n7775Mean(SD)97.16(34.89)102.68(35.85)Median92.00101.00Min, Max46.00, 213.0033.00, 227.00Change from baseline at week 18n7775Mean(SD)1.69(18.80)3.67(20.91)Median-3.00-1.00Min, Max-47.00, 64.00-43.00, 92.00P-value [1]0.8135 (w)0.3766 (w)ANCOVA ResultLS Mean(SE)-0.32(2.43)2.03(2.47)LS Mean Difference-2.3595% Confidence Interval for Difference[-8.59, 3.89]P-value [2]0.4581Week 24n7775Mean(SD)94.44(35.06)104.49(36.74)Median87.00101.00Min, Max39.00, 218.0033.00, 185.00Change from baseline at week 24n7775Mean(SD)-1.03(18.10)5.48(23.85)Median-1.003.00Min, Max-55.00, 64.00-43.00, 102.00P-value [1]0.6204 (t)0.1453 (w)ANCOVA ResultLS Mean(SE)-2.92(2.58)3.99(2.62)LS Mean Difference-6.9195% Confidence Interval for Difference[-13.54, -0.28]P-value [2]0.0412.

[0218] 11) Changes in fasting lipid concentration (HDL-C) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0219] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference in HDL-C change between the two groups (LS Mean Difference (95% CI)) was 1.89 (0.15, 3.64) mg / dL at 6 weeks, 2.36 (0.11, 4.62) mg / dL at 12 weeks, 2.69 (0.64, 4.74) mg / dL at 18 weeks, and 4.05 (1.71, 6.38) mg / dL at 24 weeks, showing a statistically significant difference between the two groups at all time points.

[0220] Change from baseline in fasting lipid parameters at week 6, 12, 18 and 24 - LOCF (modified Full Analysis Set 1) [HDL-C] 이나보글리플로진 0.3 mg(N=77)위약(N=75)Baselinen7775Mean(SD)51.92(10.64)49.20(11.90)Median50.0047.00Min, Max32.00, 84.0029.00, 91.00Week 6n7674Mean(SD)53.79(11.10)49.68(11.52)Median53.0047.50Min, Max31.00, 85.0028.00, 79.00Change from baseline at week 6n7674Mean(SD)2.07(5.44)0.43(5.56)Median2.000.00Min, Max-19.00, 16.00-17.00, 17.00P-value [1]0.0001 (w)0.5445 (w)ANCOVA ResultLS Mean(SE)2.40(0.67)0.50(0.69)LS Mean Difference1.8995% Confidence Interval for Difference[0.15, 3.64]P-value [2]0.0335Week 12n7775Mean(SD)54.14(12.02)49.41(12.03)Median54.0047.00Min, Max29.00, 100.0030.00, 82.00Change from baseline at week 12n7775Mean(SD)2.22(7.64)0.21(6.44)Median3.000.00Min, Max-19.00, 30.00-16.00, 24.00P-value [1]0.0032 (w)0.8457 (w)ANCOVA ResultLS Mean(SE)2.35(0.87)-0.01(0.89)LS Mean Difference2.3695% Confidence Interval for Difference[0.11, 4.62]P-value [2]0.0404Week 18n7775Mean(SD)55.55(10.83)50.68(11.07)Median55.0049.00Min, Max32.00, 82.0030.00, 83.00Change from baseline at week 18n7775Mean(SD)3.62(7.86)1.48(5.43)Median4.001.00Min, Max-19.00, 22.00-10.00, 16.00P-value [1]0.0001 (t)0.0209 (t)ANCOVA ResultLS Mean(SE)4.18(0.79)1.50(0.81)LS Mean Difference2.6995% Confidence Interval for Difference[0.64, 4.74]P-value [2]0.0106Week 24n7775Mean(SD)56.05(11.72)49.76(11.76)Median55.0047.00Min, Max38.00, 86.0029.00, 83.00Change from baseline at week 24n7775Mean(SD)4.13(8.36)0.56(6.35)Median4.001.00Min, Max-21.00, 36.00-19.00, 17.00P-value [1]<0.0001 (w)0.4476 (t)ANCOVA ResultLS Mean(SE)4.39(0.91)0.35(0.93)LS Mean Difference4.0595% Confidence Interval for Difference[1.71, 6.38]P-value [2]0.0008.

[0221] 12) Changes in fasting lipid concentration (triglyceride) at 6, 12, 18, and 24 weeks after administration of clinical trial drug compared to Visit 2 (randomization)

[0222] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference in triglyceride change between the two groups (LS Mean Difference (95% CI)) was -17.69 (-34.78, -0.60) mg / dL at 6 weeks, -10.37 (-28.69, 7.95) mg / dL at 12 weeks, -17.74 (-39.45, 3.98) mg / dL at 18 weeks, and -28.56 (-54.04, -3.07) mg / dL at 24 weeks, showing statistically significant differences at 6 and 24 weeks.

[0223] Change from baseline in fasting lipid parameters at week 6, 12, 18 and 24 - LOCF (modified Full Analysis Set 1) [Triglyceride]이나보글리플로진 0.3 mg(N=77)위약(N=75)Baselinen7775Mean(SD)117.44(49.60)137.88(75.62)Median109.00116.00Min, Max45.00, 262.0045.00, 390.00Week 6n7674Mean(SD)116.13(49.64)145.61(79.75)Median104.00120.50Min, Max53.00, 261.0041.00, 404.00Change from baseline at week 6n7674Mean(SD)-1.21(39.88)10.97(68.10)Median-1.0012.00Min, Max-133.00, 119.00-276.00, 229.00P-value [1]0.8044 (w)0.1447 (w)ANCOVA ResultLS Mean(SE)-5.05(6.60)12.64(6.74)LS Mean Difference-17.6995% Confidence Interval for Difference[-34.78, -0.60]P-value [2]0.0426Week 12n7775Mean(SD)120.34(74.85)149.63(91.82)Median96.00125.00Min, Max40.00, 553.0038.00, 642.00Change from baseline at week 12n7775Mean(SD)2.90(48.90)11.75(65.07)Median-5.003.00Min, Max-131.00, 291.00-203.00, 264.00P-value [1]0.8603 (w)0.2939 (w)ANCOVA ResultLS Mean(SE)6.37(7.08)16.74(7.20)LS Mean Difference-10.3795% Confidence Interval for Difference[-28.69, 7.95]P-value [2]0.2649Week 18n7775Mean(SD)113.30(52.73)146.80(106.25)Median108.00121.00Min, Max32.00, 321.0044.00, 675.00Change from baseline at week 18n7775Mean(SD)-4.14(39.69)8.92(88.46)Median-9.00-6.00Min, Max-138.00, 74.00-254.00, 571.00P-value [1]0.4143 (w)1.0000 (w)ANCOVA ResultLS Mean(SE)-8.82(8.40)8.92(8.54)LS Mean Difference-17.7495% Confidence Interval for Difference[-39.45, 3.98]P-value [2]0.1086Week 24n7775Mean(SD)119.39(62.72)166.87(124.09)Median101.00131.00Min, Max44.00, 353.0054.00, 741.00Change from baseline at week 24n7775Mean(SD)1.95(50.74)28.99(98.32)Median-1.008.00Min, Max-130.00, 221.00-232.00, 520.00P-value [1]0.7917 (w)0.0123 (w)ANCOVA ResultLS Mean(SE)-0.08(9.86)28.48(10.02)LS Mean Difference-28.5695% Confidence Interval for Difference[-54.04, -3.07]P-value [2]0.0284.

[0224] 13) Changes in blood pressure (systolic) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0225] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference in systolic blood pressure change between the two groups (LS Mean Difference (95% CI)) was -4.07 (-6.90, -1.23) mmHg at 6 weeks, -3.06 (-6.21, 0.09) mmHg at 12 weeks, -3.36 (-6.62, -0.10) mmHg at 18 weeks, and -5.75 (-9.39, -2.11) mmHg at 24 weeks, showing a statistically significant difference between the two groups at all time points except 12 weeks.

[0226] Change from baseline in blood pressures at week 6, 12, 18 and 24 - LOCF (modified Full Analysis Set 2) [Systolic Blood Pressure] 이나보글리플로진 0.3 mg(N=78)위약(N=74)Baselinen7874Mean(SD)127.85(13.39)129.47(12.31)Median128.50129.00Min, Max103.00, 168.00104.00, 165.00Week 6n7773Mean(SD)123.32(11.13)128.14(10.75)Median123.00129.00Min, Max94.00, 151.00107.00, 149.00Change from baseline at week 6n7773Mean(SD)-4.81(10.69)-1.41(10.63)Median-5.00-2.00Min, Max-32.00, 30.00-23.00, 28.00P-value [1]0.0002 (t)0.2606 (t)ANCOVA ResultLS Mean(SE)-5.38(1.10)-1.31(1.13)LS Mean Difference-4.0795% Confidence Interval for Difference[-6.90, -1.23]P-value [2]0.0053Week 12n7874Mean(SD)122.06(12.70)126.15(12.52)Median122.50125.00Min, Max94.00, 153.00105.00, 157.00Change from baseline at week 12n7874Mean(SD)-5.78(10.97)-3.32(10.70)Median-5.00-2.50Min, Max-39.00, 21.00-39.00, 18.00P-value [1]<0.0001 (t)0.0093 (t)ANCOVA ResultLS Mean(SE)-6.37(1.22)-3.31(1.25)LS Mean Difference-3.0695% Confidence Interval for Difference[-6.21, 0.09]P-value [2]0.0565Week 18n7874Mean(SD)121.63(12.18)126.00(13.40)Median121.00125.50Min, Max95.00, 147.00100.00, 155.00Change from baseline at week 18n7874Mean(SD)-6.22(11.60)-3.47(10.83)Median-6.50-2.50Min, Max-35.00, 23.00-30.00, 26.00P-value [1]<0.0001 (t)0.0073 (t)ANCOVA ResultLS Mean(SE)-6.56(1.27)-3.20(1.30)LS Mean Difference-3.3695% Confidence Interval for Difference[-6.62, -0.10]P-value [2]0.0435Week 24n7874Mean(SD)121.29(14.23)128.03(13.07)Median122.50127.50Min, Max90.00, 157.0098.00, 167.00Change from baseline at week 24n7874Mean(SD)-6.55(13.18)-1.45(11.37)Median-7.000.00Min, Max-35.00, 29.00-36.00, 22.00P-value [1]<0.0001 (t)0.2776 (t)ANCOVA ResultLS Mean(SE)-7.27(1.41)-1.52(1.45)LS Mean Difference-5.7595% Confidence Interval for Difference[-9.39, -2.11]P-value [2]0.0022.

[0227] 14) Changes in blood pressure (diastolic) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0228] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference in diastolic blood pressure change between the two groups (LS Mean Difference (95% CI)) was -2.43 (-4.65, -0.22) mmHg at 6 weeks, -2.33 (-4.53, -0.14) mmHg at 12 weeks, -1.90 (-3.98, 0.18) mmHg at 18 weeks, and -3.12 (-5.46, -0.77) mmHg at 24 weeks, showing a statistically significant difference between the two groups at all time points except 18 weeks.

[0229] Change from baseline in blood pressures at week 6, 12, 18 and 24 - LOCF (modified Full Analysis Set 2) [Diastolic Blood Pressure] 이나보글리플로진 0.3 mg(N=78)위약(N=74)Baselinen7874Mean(SD)76.23(8.12)76.80(8.61)Median76.0077.00Min, Max59.00, 98.0059.00, 97.00Week 6n7773Mean(SD)73.81(7.93)76.34(8.11)Median73.0076.00Min, Max48.00, 99.0062.00, 98.00Change from baseline at week 6n7773Mean(SD)-2.65(8.76)-0.29(6.90)Median-3.000.00Min, Max-20.00, 35.00-18.00, 16.00P-value [1]0.0008 (w)0.7226 (t)ANCOVA ResultLS Mean(SE)-2.99(0.86)-0.56(0.89)LS Mean Difference-2.4395% Confidence Interval for Difference[-4.65, -0.22]P-value [2]0.0316Week 12n7874Mean(SD)72.83(8.28)75.58(9.88)Median72.5077.00Min, Max49.00, 90.0055.00, 104.00Change from baseline at week 12n7874Mean(SD)-3.40(7.62)-1.22(6.76)Median-4.00-1.00Min, Max-20.00, 21.00-25.00, 12.00P-value [1]0.0002 (t)0.1262 (t)ANCOVA ResultLS Mean(SE)-3.82(0.86)-1.49(0.87)LS Mean Difference-2.3395% Confidence Interval for Difference[-4.53, -0.14]P-value [2]0.0376Week 18n7874Mean(SD)72.60(7.47)74.88(9.33)Median73.0076.00Min, Max56.00, 89.0057.00, 93.00Change from baseline at week 18n7874Mean(SD)-3.63(7.29)-1.92(6.91)Median-4.00-1.50Min, Max-22.00, 12.00-19.00, 10.00P-value [1]<0.0001 (t)0.0194 (t)ANCOVA ResultLS Mean(SE)-4.09(0.81)-2.19(0.83)LS Mean Difference-1.9095% Confidence Interval for Difference[-3.98, 0.18]P-value [2]0.0725Week 24n7874Mean(SD)72.68(8.44)76.16(9.59)Median74.0076.00Min, Max48.00, 92.0056.00, 101.00Change from baseline at week 24n7874Mean(SD)-3.55(8.02)-0.64(7.68)Median-4.000.50Min, Max-24.00, 29.00-19.00, 23.00P-value [1]<0.0001 (w)0.4791 (t)ANCOVA ResultLS Mean(SE)-3.92(0.91)-0.80(0.93)LS Mean Difference-3.1295% Confidence Interval for Difference[-5.46, -0.77]P-value [2]0.0096.

[0230] 15) Changes in beta-cell function measured by HOMA-beta at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0231] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference in HOMA-beta change between the two groups (LS Mean Difference (95% CI)) was 3.30 (-3.49, 10.09) at 6 weeks, 12.09 (-0.52, 24.70) at 12 weeks, 22.40 (-7.93, 52.73) at 18 weeks, and 5.88 (-2.31, 14.06) at 24 weeks, and there was no statistically significant difference between the two groups at any time point.

[0232] Change from baseline in beta-cell function at week 6, 12, 18 and 24 - LOCF (Full Analysis Set) [HOMA-beta] 이나보글리플로진 0.3 mg(N=82)위약(N=79)Baselinen8279Mean(SD)46.40(33.07)51.08(45.47)Median36.2537.90Min, Max4.40, 184.209.90, 269.00Week 6n8178Mean(SD)50.65(33.40)50.34(38.83)Median40.1039.30Min, Max9.60, 181.608.30, 231.80Change from baseline at week 6n8178Mean(SD)3.95(19.40)-0.33(28.22)Median3.100.85Min, Max-69.50, 54.50-181.80, 63.60P-value [1]0.0116 (w)0.5064 (w)ANCOVA ResultLS Mean(SE)3.20(2.65)-0.10(2.68)LS Mean Difference3.3095% Confidence Interval for Difference[-3.49, 10.09]P-value [2]0.3383Week 12n8279Mean(SD)58.83(60.44)50.84(39.63)Median42.3041.20Min, Max13.80, 477.007.30, 237.70Change from baseline at week 12n8279Mean(SD)12.44(50.57)-0.24(28.14)Median7.15-0.60Min, Max-49.20, 424.40-175.80, 83.60P-value [1]0.0002 (w)0.9383 (w)ANCOVA ResultLS Mean(SE)13.51(4.93)1.42(4.96)LS Mean Difference12.0995% Confidence Interval for Difference[-0.52, 24.70]P-value [2]0.0600Week 18n8279Mean(SD)70.05(138.49)53.01(46.64)Median43.8539.00Min, Max12.60, 1260.007.30, 237.70Change from baseline at week 18n8279Mean(SD)23.65(133.90)1.93(27.37)Median5.951.50Min, Max-44.10, 1207.40-64.00, 133.80P-value [1]0.0001 (w)0.5691 (w)ANCOVA ResultLS Mean(SE)28.64(11.87)6.24(11.93)LS Mean Difference22.4095% Confidence Interval for Difference[-7.93, 52.73]P-value [2]0.1465Week 24n8279Mean(SD)54.64(39.03)53.24(52.52)Median46.6537.00Min, Max14.40, 232.905.70, 248.20Change from baseline at week 24n8279Mean(SD)8.24(25.60)2.16(26.46)Median6.101.00Min, Max-52.90, 112.50-58.30, 132.30P-value [1]0.0026 (w)0.9575 (w)ANCOVA ResultLS Mean(SE)7.97(3.20)2.09(3.22)LS Mean Difference5.8895% Confidence Interval for Difference[-2.31, 14.06]P-value [2]0.1580.

[0233] 16) Changes in insulin resistance measured by HOMA-IR at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0234] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference in HOMA-IR change between the two groups (LS Mean Difference (95% CI)) was -1.81 (-2.73, -0.89) at 6 weeks, -1.72 (-2.32, -1.13) at 12 weeks, -1.49 (-2.01, -0.96) at 18 weeks, and -1.94 (-2.52, -1.37) at 24 weeks, showing a statistically significant difference between the two groups at all time points.

[0235] Change from baseline in insulin resistance at week 6, 12, 18 and 24 - LOCF (Full Analysis Set) [HOMA-IR] 이나보글리플로진 0.3 mg(N=82)위약(N=79)Baselinen8279Mean(SD)3.47(2.88)3.61(2.57)Median2.672.73Min, Max0.30, 15.900.84, 12.11Week 6n8178Mean(SD)1.96(1.17)3.84(4.61)Median1.622.50Min, Max0.22, 6.050.81, 36.65Change from baseline at week 6n8178Mean(SD)-1.53(2.21)0.23(3.90)Median-0.960.11Min, Max-9.85, 2.84-5.95, 28.25P-value [1]<0.0001 (w)0.8860 (w)ANCOVA ResultLS Mean(SE)-1.75(0.36)0.06(0.36)LS Mean Difference-1.8195% Confidence Interval for Difference[-2.73, -0.89]P-value [2]0.0002Week 12n8279Mean(SD)1.97(1.59)3.79(3.33)Median1.532.78Min, Max0.40, 11.140.77, 18.44Change from baseline at week 12n8279Mean(SD)-1.50(1.87)0.18(2.41)Median-1.090.01Min, Max-8.39, 1.11-6.09, 13.30P-value [1]<0.0001 (w)0.8884 (w)ANCOVA ResultLS Mean(SE)-1.60(0.23)0.12(0.24)LS Mean Difference-1.7295% Confidence Interval for Difference[-2.32, -1.13]P-value [2]<0.0001Week 18n8279Mean(SD)1.99(1.61)3.55(2.54)Median1.512.76Min, Max0.32, 10.100.80, 12.92Change from baseline at week 18n8279Mean(SD)-1.48(1.94)-0.06(2.43)Median-1.100.05Min, Max-8.60, 3.24-5.93, 10.61P-value [1]<0.0001 (w)0.8200 (w)ANCOVA ResultLS Mean(SE)-1.55(0.20)-0.06(0.21)LS Mean Difference-1.4995% Confidence Interval for Difference[-2.01, -0.96]P-value [2]<0.0001Week 24n8279Mean(SD)1.94(1.49)3.97(3.03)Median1.582.88Min, Max0.16, 8.260.79, 16.09Change from baseline at week 24n8279Mean(SD)-1.52(2.22)0.36(2.21)Median-0.990.19Min, Max-9.18, 5.11-4.62, 8.88P-value [1]<0.0001 (w)0.1820 (w)ANCOVA ResultLS Mean(SE)-1.57(0.23)0.38(0.23)LS Mean Difference-1.9495% Confidence Interval for Difference[-2.52, -1.37]P-value [2]<0.0001.

[0236] 17) Changes in renal function-related indicators measured by UACR at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0237] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference in UACR change between the two groups (LS Mean Difference (95% CI)) was 7.96 (-19.51, 35.43) g / kg at 6 weeks, -15.16 (-53.39, 23.06) g / kg at 12 weeks, -13.39 (-37.46, 10.68) g / kg at 18 weeks, and -13.92 (-41.03, 13.19) g / kg at 24 weeks. There was no statistically significant difference between the two groups at any time point.

[0238] Change from baseline in renal function parameters at week 6, 12, 18 and 24 - LOCF (Full Analysis Set) [UACR] 이나보글리플로진 0.3 mg(N=82)Placebo(N=79)Baselinen8279Mean(SD)28.20(68.67)53.92(190.18)Median10.5011.20Min, Max2.90, 472.803.00, 1274.70Week 6n8178Mean(SD)32.12(92.51)59.97(293.55)Median11.308.80Min, Max2.80, 764.001.40, 2456.40Change from baseline at week 6n8178Mean(SD)3.66(40.92)5.60(141.13)Median0.80-1.80Min, Max-98.50, 291.20-254.60, 1181.70P-value [1]0.3935 (w)0.0004 (w)ANCOVA ResultLS Mean(SE)1.45(10.64)-6.51(10.88)LS Mean Difference7.9695% Confidence Interval for Difference[-19.51, 35.43]P-value [2]0.5678Week 12n8279Mean(SD)20.43(36.73)74.59(355.48)Median11.159.90Min, Max2.00, 245.002.30, 3018.80Change from baseline at week 12n8279Mean(SD)-7.76(33.70)20.67(202.55)Median0.60-0.90Min, Max-227.80, 22.20-172.60, 1744.10P-value [1]0.8295 (w)0.0703 (w)ANCOVA ResultLS Mean(SE)-4.45(14.86)10.72(15.10)LS Mean Difference-15.1695% Confidence Interval for Difference[-53.39, 23.06]P-value [2]0.4345Week 18n8279Mean(SD)19.48(37.72)67.26(292.96)Median10.5010.20Min, Max2.20, 283.302.30, 2276.80Change from baseline at week 18n8279Mean(SD)-8.72(33.85)13.34(126.20)Median-0.75-1.00Min, Max-189.50, 27.40-216.60, 1002.10P-value [1]0.0897 (w)0.0293 (w)ANCOVA ResultLS Mean(SE)-5.53(9.36)7.86(9.51)LS Mean Difference-13.3995% Confidence Interval for Difference[-37.46, 10.68]P-value [2]0.2734Week 24n8279Mean(SD)21.44(47.37)67.74(281.42)Median9.0010.20Min, Max2.10, 384.802.30, 2288.80Change from baseline at week 24n8279Mean(SD)-6.75(42.08)13.82(127.61)Median-0.15-0.20Min, Max-306.20, 51.50-232.80, 1014.10P-value [1]0.3996 (w)0.7533 (w)ANCOVA ResultLS Mean(SE)-4.31(10.54)9.61(10.71)LS Mean Difference-13.9295% Confidence Interval for Difference[-41.03, 13.19]P-value [2]0.3120.

[0239] 18) Changes in renal function-related indicators measured by UGCR at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0240] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference in UGCR change between the two groups (LS Mean Difference (95% CI)) was 52.97 (46.70, 59.25) mg / mg at 6 weeks, 51.21 (45.41, 57.00) mg / mg at 12 weeks, 47.66 (42.32, 53.01) mg / mg at 18 weeks, and 47.36 (42.25, 52.48) mg / mg at 24 weeks, showing a statistically significant difference between the two groups at all time points.

[0241] Change from baseline in renal function parameters at week 6, 12, 18 and 24 - LOCF (Full Analysis Set) [UGCR] 이나보글리플로진 0.3 mg(N=82)위약(N=79)Baselinen8279Mean(SD)1.42(7.89)0.18(0.25)Median0.110.10Min, Max0.01, 70.440.01, 1.58Week 6n8178Mean(SD)54.67(29.72)0.22(0.51)Median51.060.10Min, Max0.03, 199.890.01, 4.10Change from baseline at week 6n8178Mean(SD)53.23(28.14)0.04(0.43)Median50.850.00Min, Max-0.03, 199.14-1.45, 3.14P-value [1]<0.0001 (w)0.3750 (w)ANCOVA ResultLS Mean(SE)55.38(2.44)2.40(2.47)LS Mean Difference52.9795% Confidence Interval for Difference[46.70, 59.25]P-value [2]<0.0001Week 12n8279Mean(SD)53.85(26.89)1.18(5.08)Median51.700.11Min, Max0.02, 159.790.01, 38.30Change from baseline at week 12n8279Mean(SD)52.43(25.29)1.00(5.08)Median51.210.00Min, Max-0.04, 159.73-0.32, 38.20P-value [1]<0.0001 (w)0.0817 (w)ANCOVA ResultLS Mean(SE)52.58(2.26)1.37(2.27)LS Mean Difference51.2195% Confidence Interval for Difference[45.41, 57.00]P-value [2]<0.0001Week 18n8279Mean(SD)52.38(25.25)2.71(11.15)Median54.510.10Min, Max0.03, 157.080.01, 78.29Change from baseline at week 18n8279Mean(SD)50.96(22.37)2.53(11.12)Median54.290.00Min, Max-0.04, 89.36-0.49, 77.75P-value [1]<0.0001 (w)0.4498 (w)ANCOVA ResultLS Mean(SE)51.70(2.08)4.04(2.09)LS Mean Difference47.6695% Confidence Interval for Difference[42.32, 53.01]P-value [2]<0.0001Week 24n8279Mean(SD)50.40(23.40)1.79(6.21)Median50.800.12Min, Max0.05, 117.440.01, 43.67Change from baseline at week 24n8279Mean(SD)48.97(21.97)1.61(6.20)Median50.090.02Min, Max-0.04, 105.40-1.35, 43.60P-value [1]<0.0001 (t)0.0035 (w)ANCOVA ResultLS Mean(SE)49.76(2.00)2.40(2.01)LS Mean Difference47.3695% Confidence Interval for Difference[42.25, 52.48]P-value [2]<0.0001.

[0242] 19) Changes in obesity-related indicators measured by adiponectin at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0243] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference in adiponectin change between the two groups (LS Mean Difference (95% CI)) was 0.26 (-0.72, 1.24) ㎍ / mL at 6 weeks, 0.67 (-0.50, 1.83) ㎍ / mL at 12 weeks, 1.04 (0.04, 2.05) ㎍ / mL at 18 weeks, and 0.98 (-0.05, 2.00) ㎍ / mL at 24 weeks, showing a statistically significant difference between the two groups at 18 weeks.

[0244] Change from baseline in obesity parameters at week 6, 12, 18 and 24 - LOCF (Full Analysis Set) [Adiponectin]이나보글리플로진 0.3 mg(N=82)위약(N=79)Baselinen8278Mean(SD)7.79(4.94)8.31(4.79)Median6.227.34Min, Max1.89, 23.951.59, 24.71Week 6n8178Mean(SD)7.91(4.42)8.06(4.08)Median6.677.29Min, Max2.17, 27.421.35, 20.20Change from baseline at week 6n8177Mean(SD)0.31(3.50)-0.23(3.63)Median0.48-0.03Min, Max-12.69, 11.26-12.97, 14.42P-value [1]0.1448 (w)0.8034 (w)ANCOVA ResultLS Mean(SE)0.22(0.38)-0.04(0.39)LS Mean Difference0.2695% Confidence Interval for Difference[-0.72, 1.24]P-value [2]0.6046Week 12n8279Mean(SD)8.57(5.06)8.25(5.28)Median6.597.29Min, Max2.14, 22.901.58, 35.29Change from baseline at week 12n8278Mean(SD)0.78(4.03)-0.01(3.80)Median0.650.02Min, Max-12.88, 12.32-8.98, 18.18P-value [1]0.0073 (w)0.9253 (w)ANCOVA ResultLS Mean(SE)0.94(0.46)0.28(0.46)LS Mean Difference0.6795% Confidence Interval for Difference[-0.50, 1.83]P-value [2]0.2620Week 18n8279Mean(SD)8.62(4.86)7.92(4.07)Median6.766.90Min, Max1.95, 24.631.43, 20.12Change from baseline at week 18n8278Mean(SD)0.83(4.07)-0.35(3.17)Median0.61-0.09Min, Max-10.98, 17.72-9.34, 9.51P-value [1]0.0045 (w)0.5192 (w)ANCOVA ResultLS Mean(SE)0.97(0.39)-0.08(0.39)LS Mean Difference1.0495% Confidence Interval for Difference[0.04, 2.05]P-value [2]0.0423Week 24n8279Mean(SD)9.07(5.17)8.45(4.66)Median7.576.80Min, Max2.47, 26.691.43, 26.74Change from baseline at week 24n8278Mean(SD)1.28(3.53)0.19(3.35)Median1.080.45Min, Max-12.64, 9.69-8.44, 11.42P-value [1]<0.0001 (w)0.2453 (w)ANCOVA ResultLS Mean(SE)1.25(0.40)0.27(0.40)LS Mean Difference0.9895% Confidence Interval for Difference[-0.05, 2.00]P-value [2]0.0610.

[0245] 20) Changes in obesity-related indicators measured by leptin at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0246] As a result of conducting an analysis of covariance with baseline and stratification factors as covariates, the difference in leptin change between the two groups (LS Mean Difference (95% CI)) was -2.89 (-4.30, -1.47) ng / mL at 6 weeks, -3.17 (-4.66, -1.68) ng / mL at 12 weeks, -2.36 (-3.58, -1.14) ng / mL at 18 weeks, and -2.99 (-4.30, -1.68) ng / mL at 24 weeks, showing a statistically significant difference between the two groups at all time points.

[0247] Change from baseline in obesity parameters at week 6, 12, 18 and 24 - LOCF (Full Analysis Set) [Leptin] 이나보글리플로진 0.3 mg(N=82)위약(N=79)Baselinen8278Mean(SD)11.16(11.33)13.23(10.53)Median6.9410.31Min, Max0.96, 62.351.85, 58.91Week 6n8178Mean(SD)8.61(8.62)13.08(10.44)Median5.7510.59Min, Max0.80, 44.181.75, 57.69Change from baseline at week 6n8177Mean(SD)-2.48(4.74)-0.09(5.48)Median-1.130.13Min, Max-20.68, 9.27-17.24, 14.95P-value [1]<0.0001 (w)0.7437 (w)ANCOVA ResultLS Mean(SE)-2.82(0.55)0.07(0.56)LS Mean Difference-2.8995% Confidence Interval for Difference[-4.30, -1.47]P-value [2]<0.0001Week 12n8279Mean(SD)8.78(9.16)13.68(11.82)Median6.2611.00Min, Max0.65, 51.852.07, 66.21Change from baseline at week 12n8278Mean(SD)-2.38(4.83)0.52(5.03)Median-1.15-0.10Min, Max-23.85, 9.64-15.51, 25.24P-value [1]<0.0001 (w)0.6533 (w)ANCOVA ResultLS Mean(SE)-2.35(0.58)0.82(0.58)LS Mean Difference-3.1795% Confidence Interval for Difference[-4.66, -1.68]P-value [2]<0.0001Week 18n8279Mean(SD)8.96(9.20)12.81(9.27)Median6.0511.40Min, Max0.24, 60.492.41, 57.25Change from baseline at week 18n8278Mean(SD)-2.20(4.87)-0.36(4.36)Median-1.210.28Min, Max-18.55, 12.75-15.51, 9.72P-value [1]<0.0001 (w)0.8378 (w)ANCOVA ResultLS Mean(SE)-2.70(0.48)-0.34(0.48)LS Mean Difference-2.3695% Confidence Interval for Difference[-3.58, -1.14]P-value [2]0.0002Week 24n8279Mean(SD)9.09(8.95)13.70(10.82)Median6.8910.71Min, Max0.61, 56.422.10, 57.25Change from baseline at week 24n8278Mean(SD)-2.07(4.73)0.53(4.40)Median-0.840.54Min, Max-20.86, 3.70-15.51, 12.34P-value [1]0.0005 (w)0.0596 (w)ANCOVA ResultLS Mean(SE)-2.36(0.51)0.63(0.51)LS Mean Difference-2.9995% Confidence Interval for Difference[-4.30, -1.68]P-value [2]<0.0001.

[0248] 1. 결론

[0249] The efficacy evaluation results demonstrated that the test group was superior to the control group in the change in HbA1c at 24 weeks after administration of the investigational drug compared to the baseline (Visit 2), which was the primary efficacy endpoint. In addition, the items that showed statistically significant differences between the test group and the control group at all time points after administration of the investigational drug compared to the baseline were all items of the secondary endpoints and the change in fasting C-peptide, change in body weight, change in fasting HDL-C, change in HOMA-IR, change in UGCR, and change in leptin among the exploratory endpoints. In addition, among the exploratory endpoints, the change in LDL-C (at 24 weeks), change in triglyceride (at 6 and 12 weeks), change in systolic blood pressure (at 6, 18, and 24 weeks), change in diastolic blood pressure (at 6, 12, and 24 weeks), and change in adiponectin (at 18 weeks) showed statistically significant differences between the test group and the control group at some time points.

[0250] In summary, the above efficacy evaluation results confirmed that inavogliflozin was effective in controlling blood sugar levels through HbA1c and FPG evaluations after administration, and the proportion of subjects who achieved the treatment goals of HbA1c < 7% or HbA1c < 6.5% recommended by diabetes treatment guidelines was also statistically significant, showing that inavogliflozin has the potential to be an effective diabetes treatment agent as a monotherapy. In addition, some items evaluated exploratoryly showed statistical significance, suggesting that it may have an indirect improvement effect on insulin resistance and obesity-related indicators.

[0251] The results of the safety evaluation showed that there was no statistically significant difference compared to the control group in the incidence of adverse reactions and adverse drug reactions, serious adverse reactions and serious adverse drug reactions, and adverse reactions that should be carefully checked. No adverse reactions or adverse drug reactions that led to discontinuation of administration of the investigational drug, or adverse reactions or adverse drug reactions that led to death occurred. All adverse drug reactions (PT) that occurred in this clinical trial, except for 'Periodontitis', 'Myelosuppression', and 'Skin ulcer', were adverse reactions included in the adverse reactions previously reported for the test drug, Inavogliflozin, and similar drugs. Among them, 'Pyelonephritis' and 'Skin ulcer' were adverse reactions that occurred in the control group, not the test group.

[0252] Based on the above, the efficacy and safety of inavogliflozin as a monotherapy in patients with type 2 diabetes were confirmed, and inavogliflozin is judged to be an effective diabetes treatment when used as a monotherapy.

[0253]

[0254] Example 2: Co-administration of inavogliflozin and metformin in patients with type 2 diabetes

[0255] 1. Research process

[0256] Inadequate glycemic control (7% at screening) despite receiving metformin at a constant dose (≥1,000 mg / day) for at least 8 weeks prior to Visit 1 (screening) <HbA1c≤10.5%)을 보이는 제 2형 당뇨병 환자는 참여가 가능하였으며, 스크리닝 시 메트포르민과 다른 혈당강하제를 같이 투여하고 있던 제 2형 당뇨병 환자는 메트포르민 이외 다른 혈당강하제의 휴약기간을 중단기간 포함하여 최소 8주(56일) 이상 거친 후 시험에 참여할 수 있었다.

[0257] Subjects who met the inclusion / exclusion criteria were administered a placebo of the investigational drug in a single-blind (subject-blinded) manner during a 2-week run-in period while continuing to administer metformin. Subjects who had a compliance rate of 70-130% for both the placebo and metformin during the run-in period and who finally met the inclusion / exclusion criteria were centrally randomly assigned to either the experimental group (inavogliflozin 0.3 mg) or the control group (dapagliflozin 10 mg) in a 1:1 ratio at Visit 2 (randomization). Randomized subjects were administered two tablets of the investigational drug corresponding to each administration group once daily, and visited the institution at weeks 6, 12, 18, and 24 during the 24-week administration period to undergo efficacy and safety evaluations.

[0258]

[0259] [Selection Criteria]

[0260] Selection criteria at Pre-Visit (pre-screening) or Visit 1 (screening)

[0261] 1. Patients with type 2 diabetes aged 19 to 80 years as of the date of obtaining written consent

[0262] 2. Those who received fixed dose metformin (≥1,000 mg / day) as monotherapy for at least 8 weeks prior to Visit 1 (screening) and had HbA1c* ≤ 7% ≤ 10.5% at Visit 1 (screening).

[0263] (For subjects who were taking a fixed dose of metformin (≥1,000 mg / day) and other hypoglycemic agents, the HbA1c must be 6.5% ≤ ≤ 10% at Pre-Visit (pre-screening), and 7% ≤ HbA1c* ≤ 10.5% at Visit 1 (screening) after the drug-free period.)

[0264] (* Results from the implementing agency or central laboratory are available. Final decision is made based on the results from the central laboratory. However, if the results from the implementing agency are suitable before confirming the results from the central laboratory, Run-in can be conducted.)

[0265] 3. Those with FPG < 270 mg / dL at Pre-visit (pre-screening) and Visit 1 (screening)

[0266] 4. Those with a BMI of 20-45 kg / m2 at Pre-visit (pre-screening) and Visit 1 (screening)

[0267] 5. Those who voluntarily decided to participate and gave written consent after hearing an explanation of the purpose, method, and effects of this clinical trial.

[0268]

[0269] Selection criteria for Visit 2 (random assignment)

[0270] 1. Those whose HbA1c is 7% ≤ HbA1c ≤ 10.5% as tested at the central laboratory during Visit 1 (screening)

[0271] 2. Those with a placebo and metformin medication compliance rate of 70-130% during the run-in period confirmed at Visit 2 (randomization)

[0272]

[0273] [Exclusion criteria]

[0274] Exclusion criteria at Pre-Visit (pre-screening) or Visit 1 (screening)

[0275] 1. Those who have a history of hypersensitivity to the clinical trial drug of this study, metformin, or any drug or component thereof (e.g., history of hypersensitivity to biguanide and SGLT2 inhibitor drugs, etc.)

[0276] 2. Those with the following medical history or surgical / therapeutic history:

[0277] History of medically significant kidney disease: renal vascular occlusive disease, nephrectomy, kidney transplant, etc.

[0278] History of severe gastrointestinal surgery: total gastrectomy, total colectomy, small bowel resection, gastroenterostomy, gastrointestinal bypass, etc.

[0279] History of acute pancreatitis or pancreatic surgery

[0280] History of bariatric surgery within the past two years

[0281] Diabetic ketoacidosis, diabetic coma, or precoma within the past year

[0282] Urinary tract infection or genital infection within the past year

[0283] Alcohol or drug addiction within the past year

[0284] Occurrence of acute coronary syndrome, unstable angina, myocardial infarction requiring hospitalization, stroke, transient ischemic attack, or arrhythmia within the past 24 weeks

[0285] (However, those who have had the condition before 24 weeks and are currently cured or in a stable condition can register.)

[0286] Those who have had a history of major surgery that caused electrolyte imbalance within the past 12 weeks or are scheduled to have major surgery within 12 weeks after the end of the clinical trial

[0287] Those with lactic acidosis or a history of lactic acidosis

[0288] 3. Those with the following diseases or symptoms:

[0289] Any type of diabetes other than type 2 diabetes (type 1 diabetes, secondary diabetes, or congenital renal diabetes)

[0290] Symptoms of urinary incontinence, anuria, oliguria, and urinary retention that cannot be controlled with medication due to stress urinary incontinence, neurogenic bladder, and benign prostatic hyperplasia

[0291] Severe diabetic complications (proliferative diabetic retinopathy, nephropathy of stage 4 or higher, or severe diabetic neuropathy)

[0292] Chronic diseases requiring continuous use (oral, injected, or inhaled) of diuretics, systemic steroids, or immunosuppressants

[0293] Pituitary insufficiency or adrenal insufficiency

[0294] Severe infection (e.g., severe infection requiring continued use of antibiotics or immunotherapy), clinically significant major trauma

[0295] unstable mental illness whose symptoms are not controlled by medication

[0296] Severe gastrointestinal disease: active ulcers, gastrointestinal / rectal bleeding, active inflammatory bowel syndrome, patients with biliary obstruction, active gastritis not controlled by medication, etc.

[0297] Uncontrolled hypertension (SBP > 180 mmHg or DBP > 110 mmHg)

[0298] Patients with moderate or severe renal impairment (eGFR < 60 mL / min / 1.73 m2)

[0299] Patients with severe liver impairment who fall under one of the following:

[0300] - AST or ALT > 3 times the upper limit of normal

[0301] - Total Bilirubin > 2 times the upper limit of normal

[0302] - Hepatitis or liver failure

[0303] Patients with severe hypertriglyceridemia (Triglyceride > 500 mg / dL)

[0304] Acquired immunodeficiency syndrome

[0305] Severe heart failure (NYHA class III / IV)

[0306] Patients with pulmonary infarction, severe pulmonary dysfunction, and other conditions prone to hypoxemia

[0307] Those who require treatment for dehydration due to persistent diarrhea or vomiting, or are at risk of fluid volume depletion

[0308] Those with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption

[0309] 4. Patients who have used other clinical trial drugs / medical devices within the past 4 weeks (However, registration is possible in cases where the investigator determines that it will not affect the efficacy and safety of this study, such as observational studies or retrospective studies)

[0310] 5. Patients with a history of malignant tumor within the past 5 years

[0311] - However, patients with appropriately controlled basal cell carcinoma, squamous cell carcinoma, or cervical intraepithelial carcinoma can participate.

[0312] - However, participation is possible if there has been no recurrence for more than 5 years after a complete cure (complete removal of the tumor through surgery or completion of anticancer treatment, etc.)

[0313] 6. Pregnant or lactating women or those who do not agree to use appropriate contraception during the clinical trial period.

[0314] You or your partner must agree to one of the following:

[0315] ① If you have undergone one of the following: sterilization surgery (vasectomy, etc.) or intrauterine device (copper loop, hormone-containing intrauterine system).

[0316] ② Use of either non-oral hormonal contraceptives or spermicides in combination with the barrier method

[0317] ③ Use a cervical cap or diaphragm together with a male condom

[0318] 7. Those who are judged by the investigator to be ineligible for this clinical trial

[0319]

[0320] Exclusion criteria for Visit 1 (screening)

[0321] 1. Those who have a history of taking the following drugs or are expected to require continuous administration during the clinical trial period.

[0322] Systemic steroids (prednisolone >30 mg / day) within the past 2 weeks

[0323] Those who have changed the dosage of thyroid dysfunction treatment within the past 6 weeks (concurrent use is permitted if the treatment was administered stably before clinical trial registration. A dose reduction is permitted if the stable condition is maintained.)

[0324] Diabetic medications other than metformin within the past 8 weeks

[0325] Weight loss medications within the past 12 weeks

[0326]

[0327] Validity assessment variables

[0328] [Primary efficacy endpoint]

[0329] 1. Change in HbA1c at 24 weeks after administration of clinical trial drug compared to Visit 2 (randomization)

[0330]

[0331] [Secondary efficacy endpoint]

[0332] 1. Changes in HbA1c at 6, 12, and 18 weeks after administration of clinical trial drug compared to Visit 2 (randomization)

[0333] 2. Changes in FPG at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0334] 3. Proportion of subjects achieving HbA1c < 7% at each time point of 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0335] 4. Proportion of subjects achieving HbA1c < 6.5% at each time point of 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0336] 5. Proportion of subjects who achieved a therapeutic response (change in HbA1c at each evaluation time point (HbA1c at Visit 2 - HbA1c at each evaluation time point) > 0.5% or HbA1c < 7%) at each time point 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0337]

[0338] [Exploratory Evaluation Variables]

[0339] 1. Changes in fasting c-peptide at 6, 12, 18, and 24 weeks after administration of clinical trial drug compared to Visit 2 (randomization)

[0340] 2. Changes in body weight at 6, 12, 18, and 24 weeks after administration of clinical trial drug compared to Visit 2 (randomization)

[0341] 3. Changes in fasting lipid levels (total cholesterol, LDL-C, HDL-C, triglyceride) at 6, 12, 18, and 24 weeks after administration of clinical trial drugs compared to Visit 2 (randomization)

[0342] 4. Changes in blood pressure (systolic, diastolic) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0343] 5. Changes in beta-cell function and insulin resistance measured by HOMA-beta and HOMA-IR at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0344] 6. Changes in renal function-related indicators (UACR, UGCR) at 6, 12, 18, and 24 weeks after administration of clinical trial drugs compared to Visit 2 (randomization)

[0345] Changes in obesity-related markers (adiponectin, leptin) at 6, 12, 18, and 24 weeks after administration of clinical trial drugs compared to Visit 2 (randomization)

[0346]

[0347] 1. Experimental results

[0348] 1.1.1.1. Primary efficacy endpoint

[0349] 1) Change in HbA1c at 24 weeks after administration of clinical trial drug compared to Visit 2 (randomization)

[0350] The results summarized for the PPS regarding the change in HbA1c at 24 weeks after administration of the investigational drug, which was the primary efficacy endpoint of this clinical trial, are presented in Table 21.

[0351] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written informed consent (before discontinuation of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in HbA1c at 24 weeks after administration of the investigational drug compared to the baseline was -0.80 (0.06)%p for the test group (inavogliflozin 0.3 mg) and -0.75 (0.06)%p for the control group (dapagliflozin 10 mg). The difference (LS Mean Difference (95% CI)) between the two groups was -0.04 (-0.21, 0.12)%p. The upper limit of the 95% confidence interval for [test group-control group] was 0.12%p, which was smaller than the non-inferiority margin of 0.35, proving that the test group was non-inferior to the control group.

[0352] The change (SD) in HbA1c by administration group was -0.78 (0.73)%p in the test group and -0.71 (0.76)%p in the control group, and there was a statistically significant difference within the groups in both groups (p<0.0001).

[0353] Change from baseline in HbA1c at week 24 (Per-Protocol Set) Inabogliflozin 0.3 mg (N=95) Dapagliflozin 10 mg (N=90) Baseline N9590 Mean (SD) 7.75 (0.82) 7.68 (0.73) Median 7.49 7.49 Min, Max 6.67, 10.2 16.69, 10.83 Week 24 N9590 Mean (SD) 6.98 (0.61) 6.97 (0.72) Median 6.88 6.84 Min, Max 5.78, 9.2 65.85, 9.85 Change from baseline at week 24 N9590 Mean (SD) -0.78 (0.73) -0.71 (0.76) Median -0.65 - 0.74 Min, Max -2.83, 1.01 - 2.85 0.97P-value [1]<0.0001 (w)<0.0001 (t)ANCOVA Result [2]LS Mean(SE)-0.80(0.06)-0.75(0.06)LS Mean Difference-0.0495% Confidence Interval for Difference[-0.21, 0.12]Non-inferiority (UCI < 0.35%)Yes

[0354] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error, UCI = upper limit confidence interval.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0355] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0356] Note: Baseline is Visit 2 (randomization).

[0357] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0358]

[0359] As a result of examining the change in HbA1c at each evaluation time point after administration of the clinical trial drug compared to the baseline (Visit 2) in PPS, both groups showed a tendency to decrease or maintain over time.

[0360]

[0361] Secondary efficacy endpoints

[0362] 1) Changes in HbA1c at 6, 12, and 18 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0363] The results of the summary of changes in HbA1c at 6, 12, and 18 weeks after administration of the clinical trial drug compared to baseline for PPS are presented in Table 22.

[0364] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in HbA1c at each time point after administration of the investigational drug compared to the baseline was -0.68 (0.04)%p for the 6-week test group (inavogliflozin 0.3 mg), -0.63 (0.04)%p for the control group (dapagliflozin 10 mg), -0.83 (0.06)%p for the 12-week test group, -0.79 (0.05)%p for the control group, -0.74 (0.06)%p for the 18-week test group, and the control group. -0.70(0.06)%p. The difference between the two groups (LS Mean Difference / test group-control group (hereinafter referred to as 'time-time') (95% CI)) was -0.05(-0.16, 0.06)%p at 6 weeks, -0.03(-0.17, 0.11)%p at 12 weeks, and -0.05(-0.21, 0.11)%p at 18 weeks, and there was no statistically significant difference between the two groups at any time point (6 weeks p=0.3806, 12 weeks p=0.6604, 18 weeks p=0.5606).

[0365] The change (SD) in HbA1c by time point was -0.62 (0.39)%p for the 6-week test group, -0.58 (0.51)%p for the control group, -0.77 (0.55)%p for the 12-week test group, -0.74 (0.69)%p for the control group, -0.71 (0.67)%p for the 18-week test group, -0.66 (0.76)%p for the control group, and there was a statistically significant difference within the group in all time points and administration groups (p<0.0001).

[0366] Change from baseline in HbA1c at week 6, 12 and 18 (Per-Protocol Set) 이나보글리플로진 0.3 mg(N=95)다파글리플로진 10 mg(N=90)BaselineN9590Mean(SD)7.75(0.82)7.68(0.73)Median7.497.49Min, Max6.67, 10.216.69, 10.83Week 6N9589Mean(SD)7.13(0.75)7.10(0.70)Median6.986.98Min, Max6.09, 9.676.08, 10.06Change from baseline at week 6N9589Mean(SD)-0.62(0.39)-0.58(0.51)Median-0.57-0.59Min, Max-1.79, 0.24-2.10, 2.04P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-0.68(0.04)-0.63(0.04)LS Mean Difference-0.0595% Confidence Interval for Difference[-0.16, 0.06]P-value [2]0.3806Week 12N9488Mean(SD)6.97(0.65)6.94(0.66)Median6.836.83Min, Max5.74, 9.245.74, 9.73Change from baseline at week 12N9488Mean(SD)-0.77(0.55)-0.74(0.69)Median-0.65-0.66Min, Max-2.33, 0.47-2.89, 1.71P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-0.83(0.06)-0.79(0.05)LS Mean Difference-0.0395% Confidence Interval for Difference[-0.17, 0.11]P-value [2]0.6604Week 18N9187Mean(SD)7.02(0.55)7.02(0.73)Median6.896.90Min, Max5.74, 8.805.79, 9.78Change from baseline at week 18N9187Mean(SD)-0.71(0.67)-0.66(0.76)Median-0.56-0.61Min, Max-2.72, 0.64-2.99, 1.67P-value [1]<0.0001 (w)<0.0001 (t)ANCOVA ResultLS Mean(SE)-0.74(0.06)-0.70(0.06)LS Mean Difference-0.0595% Confidence Interval for Difference[-0.21, 0.11]P-value [2]0.5606.

[0367] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0368] [2] Testing for difference between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0369] Note: Baseline is Visit 2 (randomization).

[0370] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0371]

[0372] 2) Changes in FPG at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0373] The results of the summary of changes in FPG at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for the PPS are presented in Table 23.

[0374] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in FPG at each time point after administration of the investigational drug compared to the baseline was -28.07 (2.14) mg / dL in the 6-week test group (inavogliflozin 0.3 mg), -23.81 (2.23) mg / dL in the control group (dapagliflozin 10 mg), -29.70 (1.96) mg / dL in the 12-week test group, -30.11 (2.03) mg / dL in the control group, and -18-week test group. -33.44 (1.60) mg / dL, control group -31.13 (1.63) mg / dL, 24-week test group -32.53 (1.76) mg / dL, control group -29.14 (1.82) mg / dL. The differences between the two groups (LS Mean Difference / Time-to-Time (95% CI)) were -4.27 (-10.08, 1.55) mg / dL at 6 weeks, 0.42 (-4.90, 5.74) mg / dL at 12 weeks, -2.31 (-6.62, 2.00) mg / dL at 18 weeks, and -3.38 (-8.15, 1.39) mg / dL at 24 weeks. There was no statistically significant difference between the two groups at any time point (6 weeks p=0.1491, 12 weeks p=0.8765, 18 weeks p=0.2911, 24 weeks p=0.1633).

[0375] The change in FPG by time point (SD) was -26.91 (22.00) mg / dL in the 6-week test group, -24.90 (28.02) mg / dL in the control group, -27.74 (24.23) mg / dL in the 12-week test group, -31.89 (31.22) mg / dL in the control group, -31.78 (23.46) mg / dL in the 18-week test group, -32.55 (26.20) mg / dL in the control group, and -31.77 (23.03) mg / dL in the 24-week test group, -31.42 (30.03) mg / dL in the control group. There was a statistically significant difference within the group at all time points and administration groups (p<0.0001).

[0376] Change from baseline in FPG at week 6, 12, 18 and 24 (Per-Protocol Set) 이나보글리플로진 0.3 mg(N=95)다파글리플로진 10 mg(N=90)BaselineN9590Mean(SD)145.35(26.60)149.33(31.85)Median147.00142.00Min, Max70.00, 235.0098.00, 240.00Week 6N9589Mean(SD)118.44(22.53)124.37(26.88)Median115.00122.00Min, Max77.00, 217.0060.00, 271.00Change from baseline at week 6N9589Mean(SD)-26.91(22.00)-24.90(28.02)Median-27.00-24.00Min, Max-112.00, 36.00-137.00, 42.00P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-28.07(2.14)-23.81(2.23)LS Mean Difference-4.2795% Confidence Interval for Difference[-10.08, 1.55]P-value [2]0.1491Week 12N9488Mean(SD)117.00(20.52)117.78(19.08)Median115.50116.50Min, Max76.00, 207.0070.00, 185.00Change from baseline at week 12N9488Mean(SD)-27.74(24.23)-31.89(31.22)Median-26.00-23.50Min, Max-113.00, 73.00-170.00, 25.00P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-29.70(1.96)-30.11(2.03)LS Mean Difference0.4295% Confidence Interval for Difference[-4.90, 5.74]P-value [2]0.8765Week 18N9187Mean(SD)112.95(15.78)116.53(17.58)Median113.00115.00Min, Max75.00, 150.0072.00, 182.00Change from baseline at week 18N9187Mean(SD)-31.78(23.46)-32.55(26.20)Median-31.00-26.00Min, Max-126.00, 21.00-114.00, 5.00P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-33.44(1.60)-31.13(1.63)LS Mean Difference-2.3195% Confidence Interval for Difference[-6.62, 2.00]P-value [2]0.2911Week 24N9590Mean(SD)113.58(17.21)117.91(19.38)Median113.00116.50Min, Max73.00, 179.0073.00, 176.00Change from baseline at week 24N9590Mean(SD)-31.77(23.03)-31.42(30.03)Median-31.00-24.00Min, Max-127.00, 14.00-160.00, 15.00P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-32.53(1.76)-29.14(1.82)LS Mean Difference-3.3895% Confidence Interval for Difference[-8.15, 1.39]P-value [2]0.1633.

[0377] FPG = fasting plasma glucose, SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0378] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0379] Note: Baseline is Visit 2 (randomization).

[0380] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0381]

[0382] 3) Proportion of subjects achieving HbA1c < 7% at each time point of 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0383] The results of the summary of the proportion of subjects achieving HbA1c < 7% at 6, 12, 18, and 24 weeks after administration of the clinical trial drug for PPS are presented in Table 24.

[0384] In the PPS, the results of logistic regression analysis adjusted for stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) showed that the odds ratio (95% CI) for achieving HbA1c < 7% at each time point in the test group (inavogliflozin 0.3 mg) compared to the control group (dapagliflozin 10 mg) was 1.06 (0.54, 2.09) at 6 weeks, 1.21 (0.63, 2.34) at 12 weeks, 1.29 (0.67, 2.46) at 18 weeks, and 0.97 (0.52, 1.83) at 24 weeks, and there was no statistically significant difference between the two groups at any time point (6 weeks). p=0.8592, 12 weeks p=0.5678, 18 weeks p=0.4413, 24 weeks p=0.9366).

[0385] The proportion of subjects who achieved HbA1c < 7% at each time point was 53.68% (51 / 95) in the 6-week test group, 51.69% (46 / 89) in the control group, 68.09% (64 / 94) in the 12-week test group, 63.64% (56 / 88) in the control group, 62.64% (57 / 91) in the 18-week test group, 57.47% (50 / 87) in the control group, 61.05% (58 / 95) in the 24-week test group, and 62.22% (56 / 90) in the control group.

[0386] Proportion of subjects achieving HbA1c target of < 7 % at week 6, 12, 18 and 24 (Per-Protocol Set)이나보글리플로진 0.3 mg(N=95)다파글리플로진 10 mg(N=90)Proportion of subjects achieving HbA1c target of< 7 % at week 6, N9589Subjects with achieving HbA1c target of< 7 %, n(%)51(53.68)46(51.69)Logistic Regression ModelOdds Ratio1.0695% Confidence Interval[0.54, 2.09]P-value [1]0.8592Proportion of subjects achieving HbA1c target of< 7 % at week 12, N9488Subjects with achieving HbA1c target of< 7 %, n(%)64(68.09)56(63.64)Logistic Regression ModelOdds Ratio1.2195% Confidence Interval[0.63, 2.34]P-value [1]0.5678Proportion of subjects achieving HbA1c target of< 7 % at week 18, N9187Subjects with achieving HbA1c target of< 7 %, n(%)57(62.64)50(57.47)Logistic Regression ModelOdds Ratio1.2995% Confidence Interval[0.67, 2.46]P-value [1]0.4413Proportion of subjects achieving HbA1c target of< 7 % at week 24, N9590Subjects with achieving HbA1c target of< 7 %, n(%)58(61.05)56(62.22)Logistic Regression ModelOdds Ratio0.9795% Confidence Interval[0.52, 1.83]P-value [1]0.9366.

[0387] Proportion = The number of subjects with HbA1c less than 7 % at week n / the number of subjects with available data at week n in the efficacy analysis set * 100, n = 6, 12, 18, 24.[1] Testing for differences between DWP16001 and Dapagliflozin (Logistic regression model with treatment group as a factor and stratification factors (regimen [monotherapy or combination] and HbA1c level at Visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0388] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0389]

[0390] 4) Proportion of subjects achieving HbA1c < 6.5% at each time point of 6, 12, 18, and 24 weeks after administration of clinical trial drugs

[0391] The results of the summary of the proportion of subjects achieving HbA1c < 6.5% at 6, 12, 18, and 24 weeks after administration of the clinical trial drug for PPS are presented in Table 25.

[0392] As a result of logistic regression analysis adjusted for stratification factors in PPS (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)), the odds ratio (95% CI) for achieving HbA1c < 6.5% at each time point in the test group (inavogliflozin 0.3 mg) compared to the control group (dapagliflozin 10 mg) was 0.83 (0.35, 1.97) at 6 weeks, 0.51 (0.24, 1.09) at 12 weeks, 0.31 (0.13, 0.72) at 18 weeks, and 0.40 (0.19, 0.86) at 24 weeks, there was no difference between the two groups at 18 and 24 weeks. There was a statistically significant difference (6 weeks p=0.6733, 12 weeks p=0.0819, 18 weeks p=0.0068, 24 weeks p=0.0188).

[0393] The proportion of subjects who achieved HbA1c < 6.5% at each time point was 12.63% (12 / 95 subjects) in the 6-week test group, 14.61% (13 / 89 subjects) in the control group, 15.96% (15 / 94 subjects) in the 12-week test group, 26.14% (23 / 88 subjects) in the control group, 9.89% (9 / 91 subjects) in the 18-week test group, 25.29% (22 / 87 subjects) in the control group, 13.68% (13 / 95 subjects) in the 24-week test group, and 27.78% (25 / 90 subjects) in the control group.

[0394] Proportion of subjects achieving HbA1c target of < 6.5 % at week 6, 12, 18 and 24 (Per-Protocol Set) 이나보글리플로진 0.3 mg(N=95)다파글리플로진 10 mg(N=90)Proportion of subjects achieving HbA1c target of< 6.5 % at week 6, N9589Subjects with achieving HbA1c target of< 6.5 %, n(%)12(12.63)13(14.61)Logistic Regression ModelOdds Ratio0.8395% Confidence Interval[0.35, 1.97]P-value [1]0.6733Proportion of subjects achieving HbA1c target of< 6.5 % at week 12, N9488Subjects with achieving HbA1c target of< 6.5 %, n(%)15(15.96)23(26.14)Logistic Regression ModelOdds Ratio0.5195% Confidence Interval[0.24, 1.09]P-value [1]0.0819Proportion of subjects achieving HbA1c target of< 6.5 % at week 18, N9187Subjects with achieving HbA1c target of< 6.5 %, n(%)9(9.89)22(25.29)Logistic Regression ModelOdds Ratio0.3195% Confidence Interval[0.13, 0.72]P-value [1]0.0068Proportion of subjects achieving HbA1c target of< 6.5 % at week 24, N9590Subjects with achieving HbA1c target of< 6.5 %, n(%)13(13.68)25(27.78)Logistic Regression ModelOdds Ratio0.4095% Confidence Interval[0.19, 0.86]P-value [1]0.0188

[0395] Proportion = The number of subjects with HbA1c less than 7 % at week n / the number of subjects with available data at week n in the efficacy analysis set * 100, n = 6, 12, 18, 24.[1] Testing for differences between DWP16001 and Dapagliflozin (Logistic regression model with treatment group as a factor and stratification factors (regimen [monotherapy or combination] and HbA1c level at Visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0396] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0397]

[0398] 5) Proportion of subjects who achieved a therapeutic response (change in HbA1c at each evaluation time point (HbA1c at Visit 2 - HbA1c at each evaluation time point) > 0.5% or HbA1c < 7%) at each time point 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0399] The results of the summary of the PPS regarding the proportion of subjects who achieved a therapeutic response at 6, 12, 18, and 24 weeks after administration of the clinical trial drug are presented in Table 26.

[0400] As a result of logistic regression analysis adjusted for stratification factors in PPS (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)), the odds ratio (95% CI) for achieving a therapeutic response at each time point in the test group (inavogliflozin 0.3 mg) compared to the control group (dapagliflozin 10 mg) was 0.98 (0.47, 2.02) at 6 weeks, 2.04 (0.89, 4.66) at 12 weeks, 1.58 (0.76, 3.28) at 18 weeks, and 1.30 (0.63, 2.68) at 24 weeks, and there was no statistically significant difference between the two groups at any time point (6 weeks). p=0.9484, 12 weeks p=0.0917, 18 weeks p=0.2197, 24 weeks p=0.4776).

[0401] The proportion of subjects who achieved a therapeutic response at each time point was 78.95% (75 / 95) in the 6-week test group, 79.78% (71 / 89) in the control group, 88.30% (83 / 94) in the 12-week test group, 79.55% (70 / 88) in the control group, 80.22% (73 / 91) in the 18-week test group, 73.56% (64 / 87) in the control group, 78.95% (75 / 95) in the 24-week test group, and 75.56% (68 / 90) in the control group.

[0402] Proportion of Subjects achieving a Therapeutic Glycemic Response at week 6, 12, 18 and 24 (Per-Protocol Set)이나보글리플로진 0.3 mg(N=95)다파글리플로진 10 mg(N=90)Proportion of subjects achieving a therapeutic glycemic response at week 6, N9589Subjects with achieving a therapeutic glycemic response, n(%)75(78.95)71(79.78)Logistic Regression ModelOdds Ratio0.9895% Confidence Interval[0.47, 2.02]P-value [1]0.9484Proportion of subjects achieving a therapeutic glycemic response at week 12, N9488Subjects with achieving a therapeutic glycemic response, n(%)83(88.30)70(79.55)Logistic Regression ModelOdds Ratio2.0495% Confidence Interval[0.89, 4.66]P-value [1]0.0917Proportion of subjects achieving a therapeutic glycemic response at week 18, N9187Subjects with achieving a therapeutic glycemic response, n(%)73(80.22)64(73.56)Logistic Regression ModelOdds Ratio1.5895% Confidence Interval[0.76, 3.28]P-value [1]0.2197Proportion of subjects achieving a therapeutic glycemic response at week 24, N9590Subjects with achieving a therapeutic glycemic response, n(%)75(78.95)68(75.56)Logistic Regression ModelOdds Ratio1.3095% Confidence Interval[0.63, 2.68]P-value [1]0.4776.

[0403] Proportion = The number of subjects achieving a therapeutic glycemic response at week n / the number of subjects with available data at week n in the efficacy analysis set * 100, n = 6, 12, 18, 24.[1] Testing for difference between DWP16001 and Dapagliflozin (Logistic regression model with treatment group as a factor and stratification factors (regimen [monotherapy or combination] and HbA1c level at Visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0404] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0405]

[0406] 탐색적 평가변수

[0407] 1)Visit 2(무작위배정) 대비 임상시험용의약품 투여 후 6주, 12주, 18주, 24주 각 시점의 공복 c-peptide 변화량

[0408] The results of the summary of changes in fasting c-peptide at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for PPS are presented in Table 27.

[0409] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in fasting c-peptide at each time point after administration of the investigational drug compared to the baseline was -0.07 (0.02) ng / mL in the 6-week test group (inavogliflozin 0.3 mg), -0.07 (0.02) ng / mL in the control group (dapagliflozin 10 mg), -0.08 (0.02) ng / mL in the 12-week test group, -0.09 (0.02) ng / mL in the control group, and -0.09 (0.02) ng / mL in the 18-week test group. -0.07 (0.18) ng / mL, control group -0.06 (0.19) ng / mL, 24-week test group -0.10 (0.16) ng / mL, control group -0.04 (0.26) ng / mL. The difference between the two groups (LS Mean Difference / Time-to-Time (95% CI)) was 0.00 (-0.05, 0.04) ng / mL at 6 weeks, 0.01 (-0.05, 0.06) ng / mL at 12 weeks, -0.02 (-0.07, 0.03) ng / mL at 18 weeks, and -0.06 (-0.12, 0.00) ng / mL at 24 weeks. There was a statistically significant difference between the two groups only at 24 weeks (6 weeks p=0.9601, 12 weeks p=0.8086, 18 weeks p=0.3689, 24 weeks p=0.0355).

[0410] The change (SD) in fasting c-peptide by time point was -0.06 (0.19) ng / mL in the 6-week test group, -0.07 (0.18) ng / mL in the control group, -0.07 (0.21) ng / mL in the 12-week test group, -0.08 (0.18) ng / mL in the control group, -0.07 (0.18) ng / mL in the 18-week test group, -0.07 (0.18) ng / mL in the control group, -0.06 (0.19) ng / mL in the 24-week test group, -0.10 (0.16) ng / mL in the control group, -0.04 (0.26) ng / mL. There was a statistically significant difference within the group at all time points and administration groups (6-week test group and control group p=0.0001, 12-week test group and control group p<0.0001, 18-week test group p=0.0002, control group p=0.0003, 24-week trial group p<0.0001, control group p=0.0016).

[0411] Change from baseline in fasting c-peptide at week 6, 12, 18 and 24 (Per-Protocol Set) 이나보글리플로진 0.3 mg(N=95)다파글리플로진 10 mg(N=90)Baselinen9590Mean(SD)0.72(0.29)0.74(0.23)Median0.660.71Min, Max0.30, 1.790.33, 1.39Week 6n9589Mean(SD)0.66(0.24)0.66(0.20)Median0.600.63Min, Max0.23, 1.460.26, 1.09Change from baseline at week 6n9589Mean(SD)-0.06(0.19)-0.07(0.18)Median-0.03-0.07Min, Max-0.86, 0.60-0.53, 0.46P-value [1]0.0001 (w)0.0001 (w)ANCOVA ResultLS Mean(SE)-0.07(0.02)-0.07(0.02)LS Mean Difference0.0095% Confidence Interval for Difference[-0.05, 0.04]P-value [2]0.9601Week 12n9488Mean(SD)0.65(0.28)0.66(0.23)Median0.610.65Min, Max0.23, 1.920.07, 1.49Change from baseline at week 12n9488Mean(SD)-0.07(0.21)-0.08(0.18)Median-0.07-0.10Min, Max-0.89, 0.93-0.50, 0.53P-value [1]<0.0001 (w)<0.0001 (t)ANCOVA ResultLS Mean(SE)-0.08(0.02)-0.09(0.02)LS Mean Difference0.0195% Confidence Interval for Difference[-0.05, 0.06]P-value [2]0.8086Week 18n9087Mean(SD)0.65(0.24)0.69(0.24)Median0.610.66Min, Max0.26, 1.420.13, 1.46Change from baseline at week 18n9087Mean(SD)-0.07(0.18)-0.06(0.19)Median-0.07-0.03Min, Max-0.73, 0.33-0.56, 0.83P-value [1]0.0002 (w)0.0003 (w)ANCOVA ResultLS Mean(SE)-0.08(0.02)-0.06(0.02)LS Mean Difference-0.0295% Confidence Interval for Difference[-0.07, 0.03]P-value [2]0.3689Week 24n9590Mean(SD)0.62(0.22)0.70(0.30)Median0.560.66Min, Max0.26, 1.260.13, 2.09Change from baseline at week 24n9590Mean(SD)-0.10(0.16)-0.04(0.26)Median-0.07-0.07Min, Max-0.66, 0.17-0.63, 1.26P-value [1]<0.0001 (w)0.0016 (w)ANCOVA ResultLS Mean(SE)-0.10(0.02)-0.04(0.02)LS Mean Difference-0.0695% Confidence Interval for Difference[-0.12, 0.00]P-value [2]0.0355.

[0412] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0413] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0414] Note: Baseline is Visit 2 (randomization).

[0415] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0416]

[0417] 2) Changes in body weight at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (random assignment)

[0418] The results of the summary of the PPS regarding the change in body weight at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to the baseline are presented in Table 28.

[0419] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in body weight at each time point after administration of the investigational drug compared to the baseline was -1.56 (0.20) kg in the 6-week test group (inavogliflozin 0.3 mg), -1.61 (0.21) kg in the control group (dapagliflozin 10 mg), -2.81 (0.23) kg in the 12-week test group, -2.63 (0.23) kg in the control group, and -3.14 (0.26) kg in the 18-week test group, and the control group. -3.16(0.26) kg in the 24-week experimental group, -3.77(0.33) kg in the 24-week experimental group, and -3.58(0.34) kg in the control group. The differences between the two groups (LS Mean Difference / time-to-time (95% CI)) were 0.04(-0.51, 0.59) kg at 6 weeks, -0.19(-0.81, 0.44) kg at 12 weeks, 0.02(-0.68, 0.71) kg at 18 weeks, and -0.18(-1.08, 0.71) kg at 24 weeks. There was no statistically significant difference between the two groups at any time point (6 weeks p=0.8846, 12 weeks p=0.5548, 18 weeks p=0.9590, 24 weeks p=0.6840).

[0420] The change in body weight (SD) by time point was -1.56 (2.30) kg for the 6-week test group, -1.60 (1.25) kg for the control group, -2.78 (2.48) kg for the 12-week test group, -2.61 (1.66) kg for the control group, -3.17 (2.68) kg for the 18-week test group, -3.19 (1.93) kg for the control group, and -3.78 (3.77) kg for the 24-week test group, -3.60 (2.14) kg for the control group. There was a statistically significant difference within the group at all time points and administration groups (p<0.0001).

[0421] Change from baseline in body weight at week 6, 12, 18 and 24 (Per-Protocol Set) 이나보글리플로진 0.3 mg(N=95)다파글리플로진 10 mg(N=90)BaselineN9590Mean(SD)70.17(11.06)70.52(11.81)Median67.4069.70Min, Max49.00, 97.0044.60, 105.00Week 6N9589Mean(SD)68.61(11.27)68.88(11.86)Median67.3066.90Min, Max45.00, 95.0042.90, 103.00Change from baseline at week 6N9589Mean(SD)-1.56(2.30)-1.60(1.25)Median-1.70-1.50Min, Max-5.10, 16.20-6.40, 2.10P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-1.56(0.20)-1.61(0.21)LS Mean Difference0.0495% Confidence Interval for Difference[-0.51, 0.59]P-value [2]0.8846Week 12N9488Mean(SD)67.44(11.05)68.19(11.65)Median65.7066.90Min, Max44.60, 93.0042.80, 100.20Change from baseline at week 12N9488Mean(SD)-2.78(2.48)-2.61(1.66)Median-2.75-2.55Min, Max-9.20, 15.20-10.00, 0.70P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-2.81(0.23)-2.63(0.23)LS Mean Difference-0.1995% Confidence Interval for Difference[-0.81, 0.44]P-value [2]0.5548Week 18N9287Mean(SD)66.72(11.26)67.54(11.96)Median64.3067.00Min, Max44.60, 95.0041.10, 98.00Change from baseline at week 18N9287Mean(SD)-3.17(2.68)-3.19(1.93)Median-3.20-3.00Min, Max-12.00, 15.20-12.20, 1.00P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-3.14(0.26)-3.16(0.26)LS Mean Difference0.0295% Confidence Interval for Difference[-0.68, 0.71]P-value [2]0.9590Week 24N9590Mean(SD)66.39(10.90)66.92(11.89)Median64.4066.05Min, Max44.80, 94.0041.20, 99.80Change from baseline at week 24N9590Mean(SD)-3.78(3.77)-3.60(2.14)Median-3.60-3.40Min, Max-27.00, 15.20-16.00, 1.10P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-3.77(0.33)-3.58(0.34)LS Mean Difference-0.1895% Confidence Interval for Difference[-1.08, 0.71]P-value [2]0.6840.

[0422] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0423] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0424] Note: Baseline is Visit 2 (randomization).

[0425] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0426]

[0427] 3) Changes in fasting lipid levels (total cholesterol, LDL-C, HDL-C, triglyceride) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0428] ①Total cholesterol

[0429] The results of the summary of the change in total cholesterol at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to the baseline using mPPS1 (modified Per-Protocol Set 1) are presented in Table 29.

[0430] In mPPS1, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written informed consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in total cholesterol at each time point after administration of the investigational drug compared to the baseline was 4.77 (2.19) mg / dL in the 6-week test group (inavogliflozin 0.3 mg), 6.87 (2.27) mg / dL in the control group (dapagliflozin 10 mg), 7.26 (1.98) mg / dL in the 12-week test group, 4.25 (2.04) mg / dL in the control group, and 18-week test group. The control group was 7.80 (2.16) mg / dL, the 24-week test group was 9.57 (2.20) mg / dL, and the control group was 6.74 (2.30) mg / dL. The differences between the two groups (LS Mean Difference / Time-to-Time (95% CI)) were -2.10 (-8.16, 3.95) mg / dL at 6 weeks, 3.01 (-2.45, 8.46) mg / dL at 12 weeks, -1.77 (-7.69, 4.15) mg / dL at 18 weeks, and 2.40 (-3.74, 8.53) mg / dL at 24 weeks. There was no statistically significant difference between the two groups at any time point (6 weeks p=0.4940, 12 weeks p=0.2784, 18 weeks p=0.5560, 24 weeks p=0.4422).

[0431] The change (SD) in total cholesterol by time point was 4.34 (17.75) mg / dL in the 6-week test group, 7.71 (22.44) mg / dL in the control group, 5.74 (18.70) mg / dL in the 12-week test group, 5.47 (18.88) mg / dL in the control group, 6.23 (16.54) mg / dL in the 18-week test group, 10.18 (22.74) mg / dL in the control group, 7.99 (20.78) mg / dL in the 24-week test group, 9.15 (22.59) mg / dL in the control group, and there was a statistically significant difference within the group at all time points and administration groups (6-week test group p=0.0371, control group p=0.0027, 12-week test group p=0.0010, control group p=0.0003, 18-week Test group p=0.0007, control group p<0.0001, 24-week test group and control group p<0.0001).

[0432] Change from baseline in fasting lipid parameters at week 6, 12, 18 and 24 (modified Per-Protocol Set 1) [Total cholesterol] 이나보글리플로진 0.3 mg(N=93)다파글리플로진 10 mg(N=87)Baselinen9387Mean(SD)151.43(32.91)137.87(26.64)Median150.00139.00Min, Max98.00, 244.0089.00, 212.00Week 6n9386Mean(SD)155.77(35.37)145.62(31.91)Median147.00145.50Min, Max93.00, 255.0065.00, 221.00Change from baseline at week 6n9386Mean(SD)4.34(17.75)7.71(22.44)Median3.007.00Min, Max-43.00, 66.00-35.00, 118.00P-value [1]0.0371 (w)0.0027 (w)ANCOVA ResultLS Mean(SE)4.77(2.19)6.87(2.27)LS Mean Difference-2.1095% Confidence Interval for Difference[-8.16, 3.95]P-value [2]0.4940Week 12n9285Mean(SD)157.39(31.50)143.19(28.59)Median150.00138.00Min, Max101.00, 257.0084.00, 208.00Change from baseline at week 12n9285Mean(SD)5.74(18.70)5.47(18.88)Median6.005.00Min, Max-56.00, 78.00-86.00, 38.00P-value [1]0.0010 (w)0.0003 (w)ANCOVA ResultLS Mean(SE)7.26(1.98)4.25(2.04)LS Mean Difference3.0195% Confidence Interval for Difference[-2.45, 8.46]P-value [2]0.2784Week 18n8884Mean(SD)156.99(32.54)148.48(30.10)Median149.00151.50Min, Max101.00, 250.0085.00, 225.00Change from baseline at week 18n8884Mean(SD)6.23(16.54)10.18(22.74)Median6.009.00Min, Max-28.00, 64.00-79.00, 88.00P-value [1]0.0007 (t)<0.0001 (w)ANCOVA ResultLS Mean(SE)7.80(2.16)9.57(2.20)LS Mean Difference-1.7795% Confidence Interval for Difference[-7.69, 4.15]P-value [2]0.5560Week 24n9387Mean(SD)159.42(32.17)147.02(27.55)Median157.00145.00Min, Max109.00, 267.0084.00, 221.00Change from baseline at week 24n9387Mean(SD)7.99(20.78)9.15(22.59)Median11.0010.00Min, Max-91.00, 67.00-78.00, 118.00P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)9.13(2.22)6.74(2.30)LS Mean Difference2.4095% Confidence Interval for Difference[-3.74, 8.53]P-value [2]0.4422.

[0433] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0434] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0435] Note: Baseline is Visit 2 (randomization).

[0436] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0437]

[0438] ②LDL-C

[0439] The results summarizing the changes in LDL-C at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for mPPS1 are presented in Table 30.

[0440] In mPPS1, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written informed consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in LDL-C at each time point after administration of the investigational drug compared to the baseline was -0.09 (1.89) mg / dL in the 6-week test group (inavogliflozin 0.3 mg), 4.20 (1.95) mg / dL in the control group (dapagliflozin 10 mg), 1.86 (1.68) mg / dL in the 12-week test group, 0.56 (1.73) mg / dL in the control group, and 18-week test group. The control group was 1.42 (1.86) mg / dL, the 24-week test group was 2.58 (1.89) mg / dL, the 24-week test group was 1.64 (1.92) mg / dL, and the control group was 0.93 (1.98) mg / dL. The differences between the two groups (LS Mean Difference / Time-to-Time (95% CI)) were -4.29 (-9.49, 0.90) mg / dL at 6 weeks, 1.30 (-3.31, 5.92) mg / dL at 12 weeks, -1.15 (-6.22, 3.91) mg / dL at 18 weeks, and 0.71 (-4.56, 5.99) mg / dL at 24 weeks. There was no statistically significant difference between the two groups at any time point (6 weeks p=0.1045, 12 weeks p=0.5783, 18 weeks p=0.6536, 24 weeks p=0.7898).

[0441] The change (SD) in LDL-C by time point was -0.67 (15.12) mg / dL in the 6-week test group, 4.87 (19.92) mg / dL in the control group, 0.78 (16.26) mg / dL in the 12-week test group, 1.33 (16.02) mg / dL in the control group, 0.50 (14.20) mg / dL in the 18-week test group, 3.27 (20.01) mg / dL in the control group, 0.88 (17.04) mg / dL in the 24-week test group, 2.68 (20.64) mg / dL in the control group, and there was a statistically significant difference within the group only in the control group at the 6-week time point (6-week test group p=0.3026, control group p=0.0469, 12-week test group p=0.5116, control group p=0.1260, 18-week trial group p=0.9665, control group p=0.0798, 24-week trial group p=0.2948, control group p=0.1171).

[0442] Change from baseline in fasting lipid parameters at week 6, 12, 18 and 24 (modified Per-Protocol Set 1) [LDL-C] 이나보글리플로진 0.3 mg(N=93)다파글리플로진 10 mg(N=87)Baselinen9387Mean(SD)86.52(30.53)76.16(26.27)Median83.0075.00Min, Max32.00, 182.0019.00, 157.00Week 6n9386Mean(SD)85.85(31.51)81.20(28.87)Median79.0076.50Min, Max28.00, 184.0023.00, 155.00Change from baseline at week 6n9386Mean(SD)-0.67(15.12)4.87(19.92)Median-2.003.00Min, Max-45.00, 55.00-37.00, 107.00P-value [1]0.3026 (w)0.0469 (w)ANCOVA ResultLS Mean(SE)-0.09(1.89)4.20(1.95)LS Mean Difference-4.2995% Confidence Interval for Difference[-9.49, 0.90]P-value [2]0.1045Week 12n9285Mean(SD)87.58(30.26)77.54(25.39)Median79.0077.00Min, Max38.00, 181.0032.00, 130.00Change from baseline at week 12n9285Mean(SD)0.78(16.26)1.33(16.02)Median1.002.00Min, Max-68.00, 58.00-97.00, 27.00P-value [1]0.5116 (w)0.1260 (w)ANCOVA ResultLS Mean(SE)1.86(1.68)0.56(1.73)LS Mean Difference1.3095% Confidence Interval for Difference[-3.31, 5.92]P-value [2]0.5783Week 18n8884Mean(SD)85.75(29.78)79.71(26.69)Median77.5080.00Min, Max37.00, 166.0030.00, 142.00Change from baseline at week 18n8884Mean(SD)0.50(14.20)3.27(20.01)Median-1.003.00Min, Max-26.00, 60.00-94.00, 74.00P-value [1]0.9665 (w)0.0798 (w)ANCOVA ResultLS Mean(SE)1.42(1.86)2.58(1.89)LS Mean Difference-1.1595% Confidence Interval for Difference[-6.22, 3.91]P-value [2]0.6536Week 24n9387Mean(SD)87.40(29.52)78.84(25.81)Median84.0076.00Min, Max40.00, 174.0032.00, 153.00Change from baseline at week 24n9387Mean(SD)0.88(17.04)2.68(20.64)Median3.002.00Min, Max-84.00, 58.00-93.00, 117.00P-value [1]0.2948 (w)0.1171 (w)ANCOVA ResultLS Mean(SE)1.64(1.92)0.93(1.98)LS Mean Difference0.7195% Confidence Interval for Difference[-4.56, 5.99]P-value [2]0.7898.

[0443] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0444] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0445] Note: Baseline is Visit 2 (randomization).

[0446] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0447]

[0448] ③HDL-C

[0449] The results summarizing the changes in HDL-C at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline, targeting mPPS1, are presented in Table 31.

[0450] In mPPS1, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written informed consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in HDL-C at each time point after administration of the investigational drug compared to the baseline was 1.11 (0.58) mg / dL in the 6-week test group (inavogliflozin 0.3 mg), 1.60 (0.61) mg / dL in the control group (dapagliflozin 10 mg), 2.31 (0.60) mg / dL in the 12-week test group, 2.25 (0.62) mg / dL in the control group, and 18-week test group. 2.46 (0.66) mg / dL, control group 3.08 (0.67) mg / dL, 24-week test group 3.06 (0.64) mg / dL, control group 3.19 (0.66) mg / dL. The differences between the two groups (LS Mean Difference / Time-to-Time (95% CI)) were -0.49 (-2.10, 1.12) mg / dL at 6 weeks, 0.06 (-1.59, 1.72) mg / dL at 12 weeks, -0.62 (-2.42, 1.19) mg / dL at 18 weeks, and -0.14 (-1.90, 1.63) mg / dL at 24 weeks. There was no statistically significant difference between the two groups at any time point (6 weeks p=0.5500, 12 weeks p=0.9405, 18 weeks p=0.4996, 24 weeks p=0.8788).

[0451] The change in HDL-C by time point was 1.18 (5.14) mg / dL in the 6-week test group, 1.94 (5.62) mg / dL in the control group, 2.08 (5.60) mg / dL in the 12-week test group, 2.65 (5.61) mg / dL in the control group, 1.89 (6.20) mg / dL in the 18-week test group, 3.17 (5.82) mg / dL in the control group, 2.75 (6.70) mg / dL in the 24-week test group, 3.55 (5.30) mg / dL in the control group, and there was a statistically significant difference within the group in all time points and administration groups (6-week test group p=0.0290, control group p=0.0037, 12-week test group p=0.0006, control group p<0.0001, 18-week test group p=0.0054, Control group p<0.0001, 24-week trial group p=0.0001, control group p<0.0001).

[0452] Change from baseline in fasting lipid parameters at week 6, 12, 18 and 24 (modified Per-Protocol Set 1) [HDL-C]이나보글리플로진 0.3 mg(N=93)다파글리플로진 10 mg(N=87)Baselinen9387Mean(SD)50.94(10.85)46.90(9.17)Median50.0046.00Min, Max28.00, 84.0026.00, 68.00Week 6n9386Mean(SD)52.12(11.10)48.83(10.55)Median51.0048.50Min, Max29.00, 85.0028.00, 81.00Change from baseline at week 6n9386Mean(SD)1.18(5.14)1.94(5.62)Median1.001.00Min, Max-11.00, 14.00-10.00, 21.00P-value [1]0.0290 (t)0.0037 (w)ANCOVA ResultLS Mean(SE)1.11(0.58)1.60(0.61)LS Mean Difference-0.4995% Confidence Interval for Difference[-2.10, 1.12]P-value [2]0.5500Week 12n9285Mean(SD)53.08(10.89)49.29(9.21)Median52.5049.00Min, Max29.00, 91.0029.00, 78.00Change from baseline at week 12n9285Mean(SD)2.08(5.60)2.65(5.61)Median2.002.00Min, Max-12.00, 16.00-10.00, 16.00P-value [1]0.0006 (t)<0.0001 (t)ANCOVA ResultLS Mean(SE)2.31(0.60)2.25(0.62)LS Mean Difference0.0695% Confidence Interval for Difference[-1.59, 1.72]P-value [2]0.9405Week 18n8884Mean(SD)53.49(11.50)49.93(9.16)Median52.5049.00Min, Max28.00, 95.0028.00, 70.00Change from baseline at week 18n8884Mean(SD)1.89(6.20)3.17(5.82)Median2.502.00Min, Max-10.00, 17.00-11.00, 24.00P-value [1]0.0054 (t)<0.0001 (w)ANCOVA ResultLS Mean(SE)2.46(0.66)3.08(0.67)LS Mean Difference-0.6295% Confidence Interval for Difference[-2.42, 1.19]P-value [2]0.4996Week 24n9387Mean(SD)53.69(10.72)50.45(9.72)Median53.0050.00Min, Max30.00, 95.0030.00, 77.00Change from baseline at week 24n9387Mean(SD)2.75(6.70)3.55(5.30)Median3.003.00Min, Max-15.00, 20.00-8.00, 19.00P-value [1]0.0001 (t)<0.0001 (t)ANCOVA ResultLS Mean(SE)3.06(0.64)3.19(0.66)LS Mean Difference-0.1495% Confidence Interval for Difference[-1.90, 1.63]P-value [2]0.8788.

[0453] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0454] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0455] Note: Baseline is Visit 2 (randomization).

[0456] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0457]

[0458] ④Triglyceride

[0459] The results summarizing the changes in triglyceride levels at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for mPPS1 are presented in Table 32.

[0460] In mPPS1, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in triglyceride at each time point after administration of the investigational drug compared to the baseline was 8.62 (6.88) mg / dL in the 6-week test group (inavogliflozin 0.3 mg), -10.14 (7.09) mg / dL in the control group (dapagliflozin 10 mg), -7.53 (4.80) mg / dL in the 12-week test group, -10.10 (4.92) mg / dL in the control group, and -18-week test group. -4.99 (5.99) mg / dL, control group 1.88 (6.04) mg / dL, 24-week test group -5.07 (5.14) mg / dL, control group -6.70 (5.28) mg / dL. The differences between the two groups (LS Mean Difference / Time-to-Time (95% CI)) were 18.76 (-0.01, 37.53) mg / dL at 6 weeks, 2.57 (-10.49, 15.62) mg / dL at 12 weeks, -6.87 (-23.09, 9.34) mg / dL at 18 weeks, and 1.63 (-12.36, 15.63) mg / dL at 24 weeks. There was no statistically significant difference between the two groups at any time point (6 weeks p=0.0501, 12 weeks p=0.6984, 18 weeks p=0.4038, 24 weeks p=0.8181).

[0461] The change in triglyceride (SD) by time point was 9.49 (73.63) mg / dL in the 6-week test group, -11.86 (54.93) mg / dL in the control group, -5.00 (57.85) mg / dL in the 12-week test group, -14.35 (70.12) mg / dL in the control group, -2.70 (78.86) mg / dL in the 18-week test group, -4.10 (62.62) mg / dL in the control group, -2.47 (76.88) mg / dL in the 24-week test group, -10.64 (52.51) mg / dL in the control group, and there was no statistically significant difference within the group at any time point or administration group (6-week test group p=0.8181, control group p=0.1343, 12-week test group p=0.7179, control group p=0.0965, 18-week trial group p=0.9181, control group p=0.3730, 24-week trial group p=0.7295, control group p=0.0749).

[0462] Change from baseline in fasting lipid parameters at week 6, 12, 18 and 24 (modified Per-Protocol Set 1) [Triglyceride]이나보글리플로진 0.3 mg(N=93)다파글리플로진 10 mg(N=87)Baselinen9387Mean(SD)122.10(85.91)132.92(75.63)Median101.00115.00Min, Max53.00, 742.0047.00, 580.00Week 6n9386Mean(SD)131.59(114.93)120.41(53.12)Median97.00104.50Min, Max39.00, 799.0052.00, 364.00Change from baseline at week 6n9386Mean(SD)9.49(73.63)-11.86(54.93)Median-3.00-2.00Min, Max-101.00, 547.00-310.00, 135.00P-value [1]0.8181 (w)0.1343 (w)ANCOVA ResultLS Mean(SE)8.62(6.88)-10.14(7.09)LS Mean Difference18.7695% Confidence Interval for Difference[-0.01, 37.53]P-value [2]0.0501Week 12n9285Mean(SD)116.23(59.46)119.06(50.67)Median100.00104.00Min, Max47.00, 429.0046.00, 269.00Change from baseline at week 12n9285Mean(SD)-5.00(57.85)-14.35(70.12)Median3.00-6.00Min, Max-313.00, 116.00-477.00, 124.00P-value [1]0.7179 (w)0.0965 (w)ANCOVA ResultLS Mean(SE)-7.53(4.80)-10.10(4.92)LS Mean Difference2.5795% Confidence Interval for Difference[-10.49, 15.62]P-value [2]0.6984Week 18n8884Mean(SD)118.10(55.93)130.88(70.92)Median108.00110.00Min, Max49.00, 402.0047.00, 408.00Change from baseline at week 18n8884Mean(SD)-2.70(78.86)-4.10(62.62)Median-2.501.00Min, Max-485.00, 334.00-277.00, 232.00P-value [1]0.9181 (w)0.3730 (w)ANCOVA ResultLS Mean(SE)-4.99(5.99)1.88(6.04)LS Mean Difference-6.8795% Confidence Interval for Difference[-23.09, 9.34]P-value [2]0.4038Week 24n9387Mean(SD)119.62(58.93)122.28(58.14)Median104.00110.00Min, Max54.00, 404.0046.00, 351.00Change from baseline at week 24n9387Mean(SD)-2.47(76.88)-10.64(52.51)Median0.00-7.00Min, Max-509.00, 196.00-312.00, 111.00P-value [1]0.7295 (w)0.0749 (w)ANCOVA ResultLS Mean(SE)-5.07(5.14)-6.70(5.28)LS Mean Difference1.6395% Confidence Interval for Difference[-12.36, 15.63]P-value [2]0.8181.

[0463] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0464] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0465] Note: Baseline is Visit 2 (randomization).

[0466] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0467]

[0468] 4) Changes in systolic and diastolic blood pressure at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0469] ①Systolic blood pressure (SBP)

[0470] The results of the summary of the change in systolic blood pressure at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to the baseline using mPPS2 (modified Per-Protocol Set 2) are presented in Table 33.

[0471] In mPPS2, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written informed consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in systolic blood pressure at each time point after administration of the investigational drug compared to the baseline was -3.29 (1.02) mmHg in the 6-week test group (inavogliflozin 0.3 mg), -2.71 (1.06) mmHg in the control group (dapagliflozin 10 mg), -5.86 (1.04) mmHg in the 12-week test group, -6.12 (1.07) mmHg in the control group, and -6.69 (1.12) in the 18-week test group. mmHg, control group -5.97 (1.15) mmHg, 24-week test group -5.93 (1.01) mmHg, control group -6.57 (1.04) mmHg. The differences between the two groups (LS Mean Difference / Time-to-Time (95% CI)) were -0.58 (-3.40, 2.23) mmHg at 6 weeks, 0.26 (-2.59, 3.10) mmHg at 12 weeks, -0.72 (-3.78, 2.34) mmHg at 18 weeks, and 0.63 (-2.13, 3.39) mmHg at 24 weeks, and there was no statistically significant difference between the two groups at any time point (6 weeks p=0.6824, 12 weeks p=0.8582, 18 weeks p=0.6433, 24 weeks p=0.6512).

[0472] The change in systolic blood pressure (SD) by time point was -3.28 (9.34) mmHg in the 6-week test group, -1.98 (11.14) mmHg in the control group, -6.42 (9.73) mmHg in the 12-week test group, -5.86 (11.46) mmHg in the control group, -7.04 (10.51) mmHg in the 18-week test group, -5.43 (12.97) mmHg in the control group, -6.34 (9.75) mmHg in the 24-week test group, -6.03 (12.13) mmHg in the control group. There was a statistically significant difference within the group in all time points and administration groups except for the control group at the 6-week time point (6-week test group p = 0.0010, control group p = 0.1035, 12-week test group and control group p < 0.0001, 18-week test group p < 0.0001, Control group p=0.0002, 24-week trial group and control group p<0.0001).

[0473] Change from baseline in blood pressures at week 6, 12, 18 and 24 (modified Per-Protocol Set 2) [Systolic Blood Pressure] 이나보글리플로진 0.3 mg(N=93)다파글리플로진 10 mg(N=87)Baselinen9387Mean(SD)129.72(13.64)127.44(14.12)Median130.00127.00Min, Max91.00, 168.0087.00, 168.00Week 6n9386Mean(SD)126.44(14.45)125.24(13.01)Median128.00126.00Min, Max83.00, 169.0089.00, 157.00Change from baseline at week 6n9386Mean(SD)-3.28(9.34)-1.98(11.14)Median-4.00-1.50Min, Max-24.00, 25.00-34.00, 27.00P-value [1]0.0010 (t)0.1035 (t)ANCOVA ResultLS Mean(SE)-3.29(1.02)-2.71(1.06)LS Mean Difference-0.5895% Confidence Interval for Difference[-3.40, 2.23]P-value [2]0.6824Week 12n9285Mean(SD)123.29(13.73)121.46(12.64)Median123.00123.00Min, Max87.00, 153.0084.00, 152.00Change from baseline at week 12n9285Mean(SD)-6.42(9.73)-5.86(11.46)Median-6.00-6.00Min, Max-30.00, 18.00-42.00, 19.00P-value [1]<0.0001 (t)<0.0001 (t)ANCOVA ResultLS Mean(SE)-5.86(1.04)-6.12(1.07)LS Mean Difference0.2695% Confidence Interval for Difference[-2.59, 3.10]P-value [2]0.8582Week 18n9184Mean(SD)122.70(12.89)122.27(12.91)Median122.00122.00Min, Max81.00, 162.0091.00, 154.00Change from baseline at week 18n9184Mean(SD)-7.04(10.51)-5.43(12.97)Median-9.00-5.00Min, Max-26.00, 26.00-44.00, 18.00P-value [1]<0.0001 (w)0.0002 (t)ANCOVA ResultLS Mean(SE)-6.69(1.12)-5.97(1.15)LS Mean Difference-0.7295% Confidence Interval for Difference[-3.78, 2.34]P-value [2]0.6433Week 24n9387Mean(SD)123.38(12.55)121.40(11.90)Median122.00122.00Min, Max101.00, 159.0086.00, 153.00Change from baseline at week 24n9387Mean(SD)-6.34(9.75)-6.03(12.13)Median-5.00-7.00Min, Max-27.00, 13.00-34.00, 25.00P-value [1]<0.0001 (t)<0.0001 (t)ANCOVA ResultLS Mean(SE)-5.93(1.01)-6.57(1.04)LS Mean Difference0.6395% Confidence Interval for Difference[-2.13, 3.39]P-value [2]0.6512.

[0474] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0475] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0476] Note: Baseline is Visit 2 (randomization).

[0477] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0478]

[0479] ② Diastolic blood pressure (DBP)

[0480] The results of the summary of the change in diastolic blood pressure at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline, targeting mPPS2, are presented in Table 34.

[0481] In mPPS2, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written informed consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in diastolic blood pressure at each time point after administration of the investigational drug compared to the baseline was -2.75 (0.69) mmHg in the 6-week test group (inavogliflozin 0.3 mg), -1.47 (0.72) mmHg in the control group (dapagliflozin 10 mg), -4.19 (0.79) mmHg in the 12-week test group, -4.35 (0.81) mmHg in the control group, and -4.80 (0.78) in the 18-week test group. mmHg, control group -4.10 (0.81) mmHg, 24-week test group -5.41 (0.65) mmHg, control group -4.26 (0.67) mmHg. The differences between the two groups (LS Mean Difference / Time-to-Time (95% CI)) were -1.28 (-3.18, 0.63) mmHg at 6 weeks, 0.16 (-2.00, 2.32) mmHg at 12 weeks, -0.70 (-2.85, 1.45) mmHg at 18 weeks, and -1.15 (-2.94, 0.63) mmHg at 24 weeks, and there was no statistically significant difference between the two groups at any time point (6 weeks p=0.1879, 12 weeks p=0.8819, 18 weeks p=0.5201, 24 weeks p=0.2044).

[0482] The diastolic blood pressure change (SD) by time point was -2.80 (6.99) mmHg for the 6-week test group, -1.10 (7.02) mmHg for the control group, -4.33 (7.69) mmHg for the 12-week test group, -4.06 (8.78) mmHg for the control group, -5.05 (6.71) mmHg for the 18-week test group, -3.94 (9.82) mmHg for the control group, -5.40 (5.94) mmHg for the 24-week test group, -3.87 (7.93) mmHg for the control group. Except for the control group at the 6-week time point, there was a statistically significant difference within the group in all time points and administration groups (6-week test group p = 0.0002, control group p = 0.2694, 12-week test group and control group p < 0.0001, 18-week test group p < 0.0001, control group p=0.0004, 24-week test group and control group p<0.0001).

[0483] Change from baseline in blood pressures at week 6, 12, 18 and 24 (modified Per-Protocol Set 2) [Diastolic Blood Pressure] 이나보글리플로진 0.3 mg(N=93)다파글리플로진 10 mg(N=87)Baselinen9387Mean(SD)77.04(9.72)75.92(10.50)Median77.0075.00Min, Max55.00, 103.0049.00, 107.00Week 6n9386Mean(SD)74.25(10.12)74.57(9.02)Median74.0075.00Min, Max36.00, 104.0050.00, 102.00Change from baseline at week 6n9386Mean(SD)-2.80(6.99)-1.10(7.02)Median-3.000.00Min, Max-19.00, 10.00-26.00, 14.00P-value [1]0.0002 (t)0.2694 (w)ANCOVA ResultLS Mean(SE)-2.75(0.69)-1.47(0.72)LS Mean Difference-1.2895% Confidence Interval for Difference[-3.18, 0.63]P-value [2]0.1879Week 12n9285Mean(SD)72.66(10.22)71.86(8.61)Median72.0072.00Min, Max48.00, 96.0050.00, 95.00Change from baseline at week 12n9285Mean(SD)-4.33(7.69)-4.06(8.78)Median-4.00-3.00Min, Max-23.00, 15.00-26.00, 19.00P-value [1]<0.0001 (t)<0.0001 (w)ANCOVA ResultLS Mean(SE)-4.19(0.79)-4.35(0.81)LS Mean Difference0.1695% Confidence Interval for Difference[-2.00, 2.32]P-value [2]0.8819Week 18n9184Mean(SD)71.85(9.37)72.08(9.06)Median71.0071.00Min, Max44.00, 98.0045.00, 94.00Change from baseline at week 18n9184Mean(SD)-5.05(6.71)-3.94(9.82)Median-5.00-2.50Min, Max-19.00, 15.00-34.00, 14.00P-value [1]<0.0001 (t)0.0004 (t)ANCOVA ResultLS Mean(SE)-4.80(0.78)-4.10(0.81)LS Mean Difference-0.7095% Confidence Interval for Difference[-2.85, 1.45]P-value [2]0.5201Week 24n9387Mean(SD)71.65(9.39)72.05(8.44)Median71.0071.00Min, Max55.00, 101.0045.00, 89.00Change from baseline at week 24n9387Mean(SD)-5.40(5.94)-3.87(7.93)Median-6.00-4.00Min, Max-18.00, 11.00-22.00, 14.00P-value [1]<0.0001 (t)<0.0001 (t)ANCOVA ResultLS Mean(SE)-5.41(0.65)-4.26(0.67)LS Mean Difference-1.1595% Confidence Interval for Difference[-2.94, 0.63]P-value [2]0.2044.

[0484] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0485] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0486] Note: Baseline is Visit 2 (randomization).

[0487] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0488]

[0489] 5) Changes in beta-cell function and insulin resistance measured by HOMA-beta and HOMA-IR at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0490] ① Beta cell function measured by HOMA-beta

[0491] The results of a summary of the changes in HOMA-beta at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline, using PPS, are presented in Table 35.

[0492] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in HOMA-beta at each time point after administration of the investigational drug compared to the baseline was 7.22 (5.44) in the 6-week test group (inavogliflozin 0.3 mg), -1.79 (5.59) in the control group (dapagliflozin 10 mg), 5.57 (3.08) in the 12-week test group, 8.75 (3.15) in the control group, 10.97 (3.06) in the 18-week test group, and 13.49 (3.08) in the control group. The 24-week experimental group was 6.94 (3.17), and the control group was 11.93 (3.25). The difference between the two groups (LS Mean Difference / time-to-time (95% CI)) was 9.01 (-5.78, 23.80) at 6 weeks, -3.17 (-11.52, 5.17) at 12 weeks, -2.53 (-10.76, 5.71) at 18 weeks, and -4.99 (-13.60, 3.62) at 24 weeks. There was no statistically significant difference between the two groups at any time point (6 weeks p=0.2307, 12 weeks p=0.4542, 18 weeks p=0.5459, 24 weeks p=0.2545).

[0493] The change (SD) in HOMA-beta by time point was 5.87 (22.04) in the 6-week test group, -2.83 (69.39) in the control group, 5.59 (26.08) in the 12-week test group, 8.97 (32.68) in the control group, 10.63 (28.28) in the 18-week test group, 13.46 (27.25) in the control group, 6.80 (28.34) in the 24-week test group, 12.23 (31.72) in the control group, and there was a statistically significant difference within the group in all time points and administration groups except for the control group at the 6-week time point (6-week test group p<0.0001, control group p=0.1818, 12-week test group p=0.0003, control group p=0.0027, 18-week test group and control group p<0.0001, 24-week test group p=0.0069, control group p=0.0002).

[0494] Change from baseline in beta-cell function at week 6, 12, 18 and 24 (Per-Protocol Set) [HOMA-beta] 이나보글리플로진 0.3 mg(N=95)다파글리플로진 10 mg(N=90)Baselinen9590Mean(SD)45.53(36.34)44.44(25.03)Median35.0038.75Min, Max7.70, 210.9013.70, 178.60Week 6n9589Mean(SD)51.39(36.66)41.10(71.67)Median43.0042.20Min, Max12.30, 236.60-576.00, 154.10Change from baseline at week 6n9589Mean(SD)5.87(22.04)-2.83(69.39)Median8.101.10Min, Max-72.30, 71.80-627.00, 74.70P-value [1]<0.0001 (w)0.1818 (w)ANCOVA ResultLS Mean(SE)7.22(5.44)-1.79(5.59)LS Mean Difference9.0195% Confidence Interval for Difference[-5.78, 23.80]P-value [2]0.2307Week 12n9488Mean(SD)51.45(35.30)53.77(37.80)Median41.6045.50Min, Max7.10, 192.3012.20, 288.00Change from baseline at week 12n9488Mean(SD)5.59(26.08)8.97(32.68)Median5.104.55Min, Max-97.10, 95.10-41.10, 252.00P-value [1]0.0003 (w)0.0027 (w)ANCOVA ResultLS Mean(SE)5.57(3.08)8.75(3.15)LS Mean Difference-3.1795% Confidence Interval for Difference[-11.52, 5.17]P-value [2]0.4542Week 18n9087Mean(SD)56.39(44.68)58.55(35.39)Median40.4551.80Min, Max9.80, 223.4010.00, 168.50Change from baseline at week 18n9087Mean(SD)10.63(28.28)13.46(27.25)Median5.759.80Min, Max-83.70, 102.10-53.10, 128.90P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)10.97(3.06)13.49(3.08)LS Mean Difference-2.5395% Confidence Interval for Difference[-10.76, 5.71]P-value [2]0.5459Week 24n9590Mean(SD)52.32(40.75)56.67(38.17)Median42.0046.75Min, Max9.90, 189.0014.00, 228.30Change from baseline at week 24n9590Mean(SD)6.80(28.34)12.23(31.72)Median4.005.30Min, Max-79.80, 127.90-50.50, 148.70P-value [1]0.0069 (w)0.0002 (w)ANCOVA ResultLS Mean(SE)6.94(3.17)11.93(3.25)LS Mean Difference-4.9995% Confidence Interval for Difference[-13.60, 3.62]P-value [2]0.2545.

[0495] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0496] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0497] Note: Baseline is Visit 2 (randomization).

[0498] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0499]

[0500] ②Insulin resistance confirmed by HOMA-IR

[0501] The results of the summary of changes in HOMA-IR at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for PPS are presented in Table 36.

[0502] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in HOMA-IR at each time point after administration of the investigational drug compared to the baseline was -1.47 (0.14) in the 6-week test group (inavogliflozin 0.3 mg), -1.31 (0.15) in the control group (dapagliflozin 10 mg), -1.58 (0.17) in the 12-week test group, -1.60 (0.17) in the control group, -1.79 (0.11) in the 18-week test group, -1.47 (0.12) in the control group, and -1.47 (0.12) in the 24-week test group. The experimental group was -1.85 (0.13), and the control group was -1.31 (0.14). The difference between the two groups (LS Mean Difference / time-to-time (95% CI)) was -0.16 (-0.55, 0.22) at 6 weeks, 0.02 (-0.43, 0.47) at 12 weeks, -0.32 (-0.63, -0.01) at 18 weeks, and -0.53 (-0.90, -0.17) at 24 weeks, and there was a statistically significant difference between the two groups only at 18 and 24 weeks (6 weeks p=0.4053, 12 weeks p=0.9442, 18 weeks p=0.0420, 24 weeks p=0.0041).

[0503] The change (SD) in HOMA-IR by time point was -1.35 (3.16) for the 6-week test group and -1.46 (1.88) for the control group, -1.36 (3.30) for the 12-week test group and -1.74 (2.16) for the control group, -1.58 (3.10) for the 18-week test group and -1.61 (2.09) for the control group, and -1.69 (2.98) for the 24-week test group and -1.47 (2.30) for the control group. There was a statistically significant difference within the group in all time points and administration groups (p<0.0001).

[0504]

[0505] Change from baseline in insulin resistance at week 6, 12, 18 and 24 (Per-Protocol Set) [HOMA-IR] 이나보글리플로진 0.3 mg(N=95)다파글리플로진 10 mg(N=90)Baselinen9590Mean(SD)3.45(3.42)3.85(2.49)Median2.673.05Min, Max0.38, 29.590.68, 11.24Week 6n9589Mean(SD)2.10(1.51)2.34(1.48)Median1.722.07Min, Max0.41, 8.550.55, 8.97Change from baseline at week 6n9589Mean(SD)-1.35(3.16)-1.46(1.88)Median-0.91-1.03Min, Max-26.74, 6.38-8.53, 3.61P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-1.47(0.14)-1.31(0.15)LS Mean Difference-0.1695% Confidence Interval for Difference[-0.55, 0.22]P-value [2]0.4053Week 12n9488Mean(SD)2.10(1.97)2.17(1.29)Median1.611.89Min, Max0.37, 15.900.47, 6.76Change from baseline at week 12n9488Mean(SD)-1.36(3.30)-1.74(2.16)Median-0.99-1.27Min, Max-24.47, 12.69-9.52, 2.06P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-1.58(0.17)-1.60(0.17)LS Mean Difference0.0295% Confidence Interval for Difference[-0.43, 0.47]P-value [2]0.9442Week 18n9087Mean(SD)1.86(1.15)2.28(1.28)Median1.512.07Min, Max0.39, 6.090.36, 6.47Change from baseline at week 18n9087Mean(SD)-1.58(3.10)-1.61(2.09)Median-0.94-1.07Min, Max-26.87, 1.34-8.17, 4.40P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-1.79(0.11)-1.47(0.12)LS Mean Difference-0.3295% Confidence Interval for Difference[-0.63, -0.01]P-value [2]0.0420Week 24n9590Mean(SD)1.76(1.07)2.39(1.67)Median1.481.82Min, Max0.48, 5.340.42, 9.95Change from baseline at week 24n9590Mean(SD)-1.69(2.98)-1.47(2.30)Median-1.06-1.17Min, Max-26.66, 0.77-8.89, 6.19P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-1.85(0.13)-1.31(0.14)LS Mean Difference-0.5395% Confidence Interval for Difference[-0.90, -0.17]P-value [2]0.0041.

[0506] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0507] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0508] Note: Baseline is Visit 2 (randomization).

[0509] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0510]

[0511] 6) Changes in renal function-related indicators (UACR, UGCR) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0512] ①UACR

[0513] The results of a summary of the changes in UACR at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for the PPS are presented in Table 37.

[0514] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in UACR at each time point after administration of the investigational drug compared to the baseline was -12.75 (10.48) g / kg in the 6-week test group (inavogliflozin 0.3 mg), 8.13 (10.88) g / kg in the control group (dapagliflozin 10 mg), -21.65 (7.38) g / kg in the 12-week test group, -3.38 (7.57) g / kg in the control group, and -18-week test group. -23.05(5.06) g / kg, control group -12.95(5.11) g / kg, 24-week test group -24.29(3.38) g / kg, control group -17.37(3.48) g / kg. The differences between the two groups (LS Mean Difference / Time-to-Time (95% CI)) were -20.88 (-49.57, 7.82) at 6 weeks, -18.27 (-38.36, 1.82) at 12 weeks, -10.10 (-23.81, 3.61) at 18 weeks, and -6.93 (-16.14, 2.29) at 24 weeks, and there was no statistically significant difference between the two groups at any time point (6 weeks p=0.1528, 12 weeks p=0.0744, 18 weeks p=0.1479, 24 weeks p=0.1399).

[0515] The change in UACR by time point (SD) was -11.44 (123.47) g / kg for the 6-week test group, 4.49 (84.95) g / kg for the control group, -18.55 (130.70) g / kg for the 12-week test group, -8.38 (40.82) g / kg for the control group, -17.48 (143.19) g / kg for the 18-week test group, -20.54 (102.64) for the control group, -18.27 (144.42) g / kg for the 24-week test group, -25.76 (128.93) g / kg for the control group. There was a statistically significant difference within the group in all time points and administration groups except for the test and control groups at the 6-week time point and the test group at the 18-week time point (6-week test group p=0.7353, control group p=0.7282, 12-week test group p=0.0070, control group p=0.0090, 18-week trial group p=0.0656, control group p=0.0067, 24-week trial group p=0.0270, control group p=0.0013).

[0516] Change from baseline in renal function parameters at week 6, 12, 18 and 24 (Per-Protocol Set) [UACR] 이나보글리플로진 0.3 mg(N=95)다파글리플로진 10 mg(N=90)Baselinen9589Mean(SD)38.19(163.98)57.42(198.64)Median10.1015.50Min, Max2.80, 1600.002.10, 1474.70Week 6n9587Mean(SD)26.76(57.01)62.95(236.30)Median11.4013.90Min, Max3.70, 433.302.20, 1752.20Change from baseline at week 6n9587Mean(SD)-11.44(123.47)4.49(84.95)Median0.000.00Min, Max-1166.70, 221.90-375.80, 639.50P-value [1]0.7353 (w)0.7282 (w)ANCOVA ResultLS Mean(SE)-12.75(10.48)8.13(10.88)LS Mean Difference-20.8895% Confidence Interval for Difference[-49.57, 7.82]P-value [2]0.1528Week 12n9488Mean(SD)19.80(37.19)49.42(183.74)Median11.0511.95Min, Max1.90, 341.001.70, 1402.80Change from baseline at week 12n9487Mean(SD)-18.55(130.70)-8.38(40.82)Median-1.40-1.80Min, Max-1259.00, 74.90-311.30, 113.00P-value [1]0.0070 (w)0.0090 (w)ANCOVA ResultLS Mean(SE)-21.65(7.38)-3.38(7.57)LS Mean Difference-18.2795% Confidence Interval for Difference[-38.36, 1.82]P-value [2]0.0744Week 18n9087Mean(SD)20.32(34.13)37.26(113.12)Median9.8011.60Min, Max3.30, 260.901.40, 983.60Change from baseline at week 18n9086Mean(SD)-17.48(143.19)-20.54(102.64)Median-0.70-1.75Min, Max-1339.10, 129.10-775.20, 78.60P-value [1]0.0656 (w)0.0067 (w)ANCOVA ResultLS Mean(SE)-23.05(5.06)-12.95(5.11)LS Mean Difference-10.1095% Confidence Interval for Difference[-23.81, 3.61]P-value [2]0.1479Week 24n9590Mean(SD)19.93(29.10)31.37(76.71)Median10.2011.10Min, Max2.50, 207.403.20, 650.70Change from baseline at week 24n9589Mean(SD)-18.27(144.42)-25.76(128.93)Median-1.10-1.70Min, Max-1392.60, 131.90-850.60, 48.60P-value [1]0.0270 (w)0.0013 (w)ANCOVA ResultLS Mean(SE)-24.29(3.38)-17.37(3.48)LS Mean Difference-6.9395% Confidence Interval for Difference[-16.14, 2.29]P-value [2]0.1399.

[0517] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0518] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0519] Note: Baseline is Visit 2 (randomization).

[0520] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0521]

[0522] ②UGCR

[0523] The results of the summary of changes in UGCR at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for PPS are presented in Table 38.

[0524] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in UGCR at each time point after administration of the investigational drug compared to the baseline was 65.72 (2.70) mg / mg in the 6-week test group (DWP16001 0.3 mg), 50.10 (2.80) mg / mg in the control group (dapagliflozin 10 mg), 64.70 (2.58) mg / mg in the 12-week test group, 45.14 (2.66) mg / mg in the control group, and 18-week test group. The mean daily dose was 60.97 (2.13) mg / mg in the 6-week treatment group, 42.72 (2.15) mg / mg in the control group, and 60.48 (2.12) mg / mg in the 24-week treatment group and 44.94 (2.18) mg / mg in the control group. The difference between the two groups (LS Mean Difference / time-to-time (95% CI)) was 15.62 (8.25, 23.00) mg / mg at week 6, 19.57 (12.55, 26.58) mg / mg at week 12, 18.25 (12.50, 24.00) mg / mg at week 18, and 15.54 (9.77, 21.31) mg / mg at week 24. There was a statistically significant difference between the two groups at all time points (p<0.0001).

[0525] The change in UGCR by time point (SD) was 63.13 (24.93) mg / mg in the 6-week test group and 47.54 (26.73) mg / mg in the control group, 63.04 (24.63) mg / mg in the 12-week test group and 43.59 (23.33) mg / mg in the control group, 59.41 (19.10) mg / mg in the 18-week test group and 41.06 (21.79) mg / mg in the control group, and 58.90 (20.59) mg / mg in the 24-week test group and 43.01 (20.50) mg / mg in the control group. There was a statistically significant difference within the group in all time points and administration groups (p<0.0001).

[0526] Change from baseline in renal function parameters at week 6, 12, 18 and 24 (Per-Protocol Set) [UGCR]이나보글리플로진 0.3 mg(N=95)다파글리플로진 10 mg(N=90)Baselinen9589Mean(SD)1.54(8.70)1.83(7.49)Median0.140.15Min, Max0.02, 82.790.01, 66.03Week 6n9587Mean(SD)64.66(25.06)48.64(27.88)Median58.4543.08Min, Max23.06, 152.750.04, 177.89Change from baseline at week 6n9587Mean(SD)63.13(24.93)47.54(26.73)Median57.9142.30Min, Max10.38, 149.85-0.06, 164.09P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)65.72(2.70)50.10(2.80)LS Mean Difference15.6295% Confidence Interval for Difference[8.25, 23.00]P-value [2]<0.0001Week 12n9488Mean(SD)64.53(24.11)45.57(27.08)Median62.3040.89Min, Max4.01, 131.800.03, 186.83Change from baseline at week 12n9487Mean(SD)63.04(24.63)43.59(23.33)Median58.9140.62Min, Max3.37, 131.66-1.61, 120.80P-value [1]<0.0001 (t)<0.0001 (t)ANCOVA ResultLS Mean(SE)64.70(2.58)45.14(2.66)LS Mean Difference19.5795% Confidence Interval for Difference[12.55, 26.58]P-value [2]<0.0001Week 18n9087Mean(SD)60.98(18.79)43.00(20.49)Median58.4240.86Min, Max20.09, 105.730.02, 101.64Change from baseline at week 18n9086Mean(SD)59.41(19.10)41.06(21.79)Median57.5440.72Min, Max13.05, 105.51-38.93, 95.28P-value [1]<0.0001 (t)<0.0001 (t)ANCOVA ResultLS Mean(SE)60.97(2.13)42.72(2.15)LS Mean Difference18.2595% Confidence Interval for Difference[12.50, 24.00]P-value [2]<0.0001Week 24n9590Mean(SD)60.43(20.76)45.27(20.91)Median57.8843.81Min, Max23.67, 118.490.05, 103.17Change from baseline at week 24n9589Mean(SD)58.90(20.59)43.01(20.50)Median56.4342.01Min, Max14.79, 118.34-0.05, 103.03P-value [1]<0.0001 (t)<0.0001 (t)ANCOVA ResultLS Mean(SE)60.48(2.12)44.94(2.18)LS Mean Difference15.5495% Confidence Interval for Difference[9.77, 21.31]P-value [2]<0.0001.

[0527] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0528] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0529] Note: Baseline is Visit 2 (randomization).

[0530] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0531]

[0532] 7) Changes in obesity-related indicators (adiponectin, leptin) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (random assignment)

[0533] ①Adiponectin

[0534] The results of the summary of changes in adiponectin at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for PPS are presented in Table 39.

[0535] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in adiponectin at each time point after administration of the investigational drug compared to the baseline was 0.92 (0.28) ng / mL in the 6-week test group (inavogliflozin 0.3 mg), 0.80 (0.29) ng / mL in the control group (dapagliflozin 10 mg), 0.84 (0.27) ng / mL in the 12-week test group, 1.02 (0.27) ng / mL in the control group, and 18-week test group. The control group was 1.33 (0.28) ng / mL, the 24-week test group was 1.29 (0.29) ng / mL, and the control group was 1.67 (0.31) ng / mL. The differences between the two groups (LS Mean Difference / Time-to-Time (95% CI)) were 0.13 (-0.65, 0.90) ng / mL at 6 weeks, -0.19 (-0.91, 0.54) ng / mL at 12 weeks, 0.04 (-0.74, 0.81) ng / mL at 18 weeks, and -0.02 (-0.87, 0.84) ng / mL at 24 weeks, with no statistically significant differences between the two groups at any time point (6 weeks p=0.7474, 12 weeks p=0.6107, 18 weeks p=0.9266, 24 weeks p=0.9688).

[0536] Adiponectin change (SD) by time point was 0.84 (3.17) ng / mL in the 6-week test group, 0.77 (2.20) ng / mL in the control group, 0.90 (2.61) ng / mL in the 12-week test group, 1.08 (2.33) ng / mL in the control group, 1.26 (2.49) ng / mL in the 18-week test group, 1.28 (2.77) ng / mL in the control group, and 1.72 (3.03) ng / mL in the 24-week test group, 1.72 (2.78) ng / mL in the control group. There was a statistically significant difference within the group in all time points and administration groups (6-week test group p=0.0010, control group p=0.0007, 12-, 18-, and 24-week test groups and control group p<0.0001).

[0537] Change from baseline in obesity parameters at week 6, 12, 18 and 24 (Per-Protocol Set) [Adiponectin] 이나보글리플로진 0.3 mg(N=95)다파글리플로진 10 mg(N=90)Baselinen9589Mean(SD)6.96(4.84)6.60(4.23)Median5.995.94Min, Max2.14, 42.191.06, 27.09Week 6n9589Mean(SD)7.80(4.79)7.40(4.41)Median6.876.36Min, Max2.32, 38.801.43, 26.28Change from baseline at week 6n9588Mean(SD)0.84(3.17)0.77(2.20)Median0.580.51Min, Max-11.28, 12.35-4.43, 10.81P-value [1]0.0010 (w)0.0007 (w)ANCOVA ResultLS Mean(SE)0.92(0.28)0.80(0.29)LS Mean Difference0.1395% Confidence Interval for Difference[-0.65, 0.90]P-value [2]0.7474Week 12n9488Mean(SD)7.87(5.03)7.76(5.01)Median6.916.53Min, Max2.38, 45.251.45, 33.98Change from baseline at week 12n9487Mean(SD)0.90(2.61)1.08(2.33)Median0.680.83Min, Max-10.52, 8.35-3.53, 10.38P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)0.84(0.27)1.02(0.27)LS Mean Difference-0.1995% Confidence Interval for Difference[-0.91, 0.54]P-value [2]0.6107Week 18n9087Mean(SD)8.30(4.95)7.98(4.70)Median7.337.08Min, Max2.70, 40.681.33, 27.32Change from baseline at week 18n9086Mean(SD)1.26(2.49)1.28(2.77)Median1.140.73Min, Max-6.25, 8.37-4.73, 17.48P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)1.33(0.28)1.29(0.29)LS Mean Difference0.0495% Confidence Interval for Difference[-0.74, 0.81]P-value [2]0.9266Week 24n9590Mean(SD)8.68(5.52)8.35(5.52)Median7.647.19Min, Max2.83, 45.181.76, 39.40Change from baseline at week 24n9589Mean(SD)1.72(3.03)1.72(2.78)Median1.211.06Min, Max-7.29, 11.46-5.08, 12.31P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)1.67(0.31)1.69(0.32)LS Mean Difference-0.0295% Confidence Interval for Difference[-0.87, 0.84]P-value [2]0.9688.

[0538] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0539] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0540] Note: Baseline is Visit 2 (randomization).

[0541] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0542]

[0543] ②Leptin

[0544] The results of the summary of changes in leptin at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline, targeting PPS, are presented in Table 40.

[0545] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (alone or in combination) within 24 weeks prior to the date of obtaining written consent (before withdrawal of hypoglycemic agents other than metformin), HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in leptin at each time point after administration of the investigational drug compared to the baseline was -2.43 (0.46) ng / mL in the 6-week test group (inavogliflozin 0.3 mg), -1.62 (0.47) ng / mL in the control group (dapagliflozin 10 mg), -2.64 (0.49) ng / mL in the 12-week test group, -2.70 (0.51) ng / mL in the control group, and -2.70 (0.51) ng / mL in the 18-week test group. -2.49(0.52) ng / mL, control group -1.23(0.53) ng / mL, 24-week test group -2.40(0.51) ng / mL, control group -1.28(0.53) ng / mL. The differences between the two groups (LS Mean Difference / Time-to-Time (95% CI)) were -0.81 (-2.05, 0.44) ng / mL at 6 weeks, 0.07 (-1.28, 1.41) ng / mL at 12 weeks, -1.26 (-2.68, 0.16) ng / mL at 18 weeks, and -1.12 (-2.51, 0.27) ng / mL at 24 weeks, with no statistically significant differences between the two groups at any time point (6 weeks p=0.2035, 12 weeks p=0.9233, 18 weeks p=0.0825, 24 weeks p=0.1151).

[0546] The change in leptin (SD) by time point was -2.54 (4.67) ng / mL for the 6-week test group, -1.61 (4.75) ng / mL for the control group, -2.73 (4.67) ng / mL for the 12-week test group, -2.70 (5.87) ng / mL for the control group, -2.50 (4.99) ng / mL for the 18-week test group, -1.20 (5.47) ng / mL for the control group, and -2.53 (4.17) ng / mL for the 24-week test group, -1.31 (6.08) ng / mL for the control group. There was a statistically significant difference within the group in all time points and administration groups (p<0.0001).

[0547] Change from baseline in obesity parameters at week 6, 12, 18 and 24 (Per-Protocol Set) [Leptin] 이나보글리플로진 0.3 mg(N=95)다파글리플로진 10 mg(N=90)Baselinen9589Mean(SD)12.21(11.08)11.76(10.51)Median8.008.32Min, Max0.74, 46.070.32, 62.65Week 6n9589Mean(SD)9.66(8.89)9.85(10.35)Median5.995.51Min, Max0.41, 34.040.54, 55.17Change from baseline at week 6n9588Mean(SD)-2.54(4.67)-1.61(4.75)Median-1.36-1.46Min, Max-18.64, 16.55-20.22, 16.61P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-2.43(0.46)-1.62(0.47)LS Mean Difference-0.8195% Confidence Interval for Difference[-2.05, 0.44]P-value [2]0.2035Week 12n9488Mean(SD)9.56(8.48)9.07(10.18)Median6.606.05Min, Max0.53, 41.850.35, 65.39Change from baseline at week 12n9487Mean(SD)-2.73(4.67)-2.70(5.87)Median-1.45-1.94Min, Max-23.19, 6.88-27.30, 23.09P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-2.64(0.49)-2.70(0.51)LS Mean Difference0.0795% Confidence Interval for Difference[-1.28, 1.41]P-value [2]0.9233Week 18n9087Mean(SD)9.71(8.27)10.72(11.35)Median7.226.16Min, Max0.48, 38.620.20, 65.25Change from baseline at week 18n9086Mean(SD)-2.50(4.99)-1.20(5.47)Median-1.32-1.37Min, Max-20.85, 7.76-18.32, 22.95P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-2.49(0.52)-1.23(0.53)LS Mean Difference-1.2695% Confidence Interval for Difference[-2.68, 0.16]P-value [2]0.0825Week 24n9590Mean(SD)9.68(8.31)10.37(11.37)Median7.456.69Min, Max0.70, 36.170.54, 75.67Change from baseline at week 24n9589Mean(SD)-2.53(4.17)-1.31(6.08)Median-1.77-1.17Min, Max-16.62, 7.69-17.60, 33.37P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-2.40(0.51)-1.28(0.53)LS Mean Difference-1.1295% Confidence Interval for Difference[-2.51, 0.27]P-value [2]0.1151.

[0548] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0549] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen [monotherapy or combination] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %])) as covariates).

[0550] Note: Baseline is Visit 2 (randomization).

[0551] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0552]

[0553] 3. Conclusion

[0554] As a result of the efficacy evaluation, the upper limit of the 95% confidence interval for the difference between the two groups (LS Mean Difference / test group - control group) in the change in HbA1c at 24 weeks after administration of the investigational drug compared to the baseline, which was the primary efficacy endpoint, was 0.12%p, which was smaller than the non-inferiority margin of 0.35, demonstrating that the test group was non-inferior to the control group. In addition, most secondary and exploratory endpoints, including FPG, showed similar results between the test group and the control group.

[0555] The safety assessment results showed no significant difference in the incidence of adverse reactions and serious adverse reactions between the test group and the control group. There was a significant difference in the incidence of adverse drug reactions between the groups, but the incidence was higher in the control group (1 case in the test group, 7 cases in the control group). In addition, the incidence of serious adverse reactions and adverse reactions that should be carefully monitored (hypoglycemia, urinary tract infection, genital infection, polyuria, and frequency) showed a tendency to be lower in the test group than in the control group, although the difference was not significant. All of the adverse drug reactions that occurred were adverse reactions previously reported for SGLT2 inhibitor drugs. However, in this clinical trial, one adverse reaction (PT: Prostate cancer) that led to discontinuation of the investigational drug occurred in the control group, but it was confirmed that this was not related to the investigational drug. Other than this, no serious adverse drug reactions, adverse drug reactions that led to discontinuation of the investigational drug, adverse reactions that led to death, or adverse drug reactions occurred. In other safety evaluation items, there were no clinically significant findings except for one adverse reaction related to vital signs (PT name: Hypertension).

[0556] Based on the above, the efficacy and safety of inavogliflozin in combination therapy with metformin were confirmed in patients with type 2 diabetes whose blood sugar control was insufficient with metformin, and inavogliflozin is judged to be an effective diabetes treatment when used in combination therapy with metformin.

[0557]

[0558] Example 3: Combination administration of inabogliflozin, metformin, and gemigliptin to patients with type 2 diabetes

[0559] 1. Research process

[0560] 1) If metformin (≥1,000 mg / day) was administered at a constant dose for at least 8 weeks prior to Pre-Visit (pre-screening)

[0561] : Metformin (≥1,000 mg / day) and gemigliptin (50 mg / day) were co-administered during an 8-week stabilization period.

[0562] 2) If metformin (<1,000 mg / day) and oral hypoglycemic agents were used in combination at a fixed dose for at least 8 weeks prior to pre-visit (pre-screening)

[0563] : Metformin was increased to a minimum of 1,000 mg / day for a maximum of 4 weeks, followed by a stabilization period of 8 weeks with concurrent administration of metformin (≥1,000 mg / day) and gemigliptin (50 mg / day), with a washout period for other oral hypoglycemic agents.

[0564] 3) If metformin (≥1,000 mg / day) and oral hypoglycemic agents (excluding gemigliptin) were used concurrently at a fixed dose for at least 8 weeks prior to Pre-Visit (pre-screening).

[0565] : Metformin (≥1,000 mg / day) and gemigliptin (50 mg / day) were administered concurrently during an 8-week stabilization period, and other oral hypoglycemic agents that were being administered concurrently with metformin were withdrawn during a drug-free period.

[0566] 4) If metformin (≥1,000 mg / day) and gemigliptin (50 mg / day) were used concurrently at a fixed dose for at least 8 weeks prior to Pre-Visit (pre-screening)

[0567] : Without a separate stabilization period, Pre-Visit (pre-screening) was Visit 1 (screening).

[0568] In each case, patients with type 2 diabetes who showed inadequate glycemic control at Visit 1 (screening) after screening participated in this clinical trial.

[0569]

[0570] [Run-in period]

[0571] Subjects who met the inclusion / exclusion criteria continued to receive metformin and gemigliptin while receiving placebo for a 2-week run-in period in a single-blind (subject-blinded) manner. Subjects who achieved 70-130% compliance with placebo, metformin, and gemigliptin during the run-in period and who met the final inclusion / exclusion criteria were randomized to Visit 2 (randomization).

[0572] [Treatment period]

[0573] Subjects were randomly assigned to either the test group (inavogliflozin 0.3 mg) or the control group (dapagliflozin 10 mg) in a 1:1 ratio at Visit 2, and stratified according to the previous hypoglycemic agent administration regimen (2 or fewer drugs (monotherapy or 2 drugs) or 3 or more drugs in combination) within 24 weeks prior to obtaining written informed consent (before discontinuation of other hypoglycemic agents) and HbA1c (<8% or ≥8%) at Visit 1 (screening) measured at the central laboratory.

[0574] Randomized subjects received two tablets of the clinical trial drug corresponding to each treatment group once daily. Efficacy and safety were assessed at the study site at weeks 6, 12, 18, and 24 during the 24-week treatment period. Furthermore, subjects were instructed to maintain regular exercise and dietary control throughout the trial period without altering their daily routines.

[0575] [Selection Criteria]

[0576] Selection criteria at Pre-Visit (pre-screening) or Visit 1 (screening)

[0577] 1. Patients with type 2 diabetes aged 19 to 80 years as of the date of obtaining written consent

[0578] 2. Those whose HbA1c confirmed during Pre-Visit (pre-screening) corresponds to the following:

[0579] 1) If metformin (≥1,000 mg / day) was administered at a constant dose for at least 8 weeks immediately prior to Pre-Visit (pre-screening): 7.5% ≤ HbA1c ≤ 11%

[0580] 2) If metformin (<1,000 mg / day) and oral hypoglycemic agents were used at a constant dose for at least 8 weeks prior to Pre-Visit (pre-screening): 7.5% ≤ HbA1c ≤ 11%

[0581] 3) If metformin (≥1,000 mg / day) and oral hypoglycemic agents (excluding gemigliptin) were used at a constant dose for at least 8 weeks prior to Pre-Visit (pre-screening): 7% ≤ HbA1c ≤ 11%

[0582] 4) If metformin (≥1,000 mg / day) and gemigliptin (50 mg / day) were administered at a constant dose for at least 8 weeks prior to Pre-Visit (pre-screening): 7% ≤ HbA1c ≤ 11%

[0583] 3. At Visit 1 (screening), HbA1c is 7% ≤ HbA1c* ≤ 11%

[0584] (* Results from the implementing agency or central laboratory are available. Final decision is made based on the results from the central laboratory. However, if the results from the implementing agency are suitable before confirming the results from the central laboratory, Run-in can be conducted.)

[0585] 4. Those with FPG < 270 mg / dL at Pre-Visit (pre-screening) and Visit 1 (screening)

[0586] 5. Those with a BMI of 20-45 kg / m2 at Pre-Visit (pre-screening) and Visit 1 (screening)

[0587] 6. Those who voluntarily decided to participate and gave written consent after hearing an explanation of the purpose, method, and effects of this clinical trial.

[0588]

[0589] Selection criteria for Visit 2 (random assignment)

[0590] 1. Those whose HbA1c is 7% ≤ HbA1c ≤ 10.5% as tested at the central laboratory during Visit 1 (screening)

[0591] 2. Those who had a medication compliance rate of 70-130% for placebo, metformin, and gemigliptin during the run-in period confirmed at Visit 2 (randomization)

[0592]

[0593] [Exclusion criteria]

[0594] Exclusion criteria at Pre-Visit (pre-screening) or Visit 1 (screening)

[0595] 1. Those who have a history of hypersensitivity to the clinical trial drugs of this study, including metformin, gemigliptin, or similar drugs and components (e.g., history of hypersensitivity to biguanide, DPP-4 inhibitor, and SGLT2 inhibitor drugs)

[0596] 2. Those with the following medical history or surgical / therapeutic history:

[0597] History of medically significant kidney disease: renal vascular occlusive disease, nephrectomy, kidney transplant, etc.

[0598] History of severe gastrointestinal surgery: total gastrectomy, total colectomy, small bowel resection, gastroenterostomy, gastrointestinal bypass, etc.

[0599] History of acute pancreatitis or pancreatic surgery

[0600] History of bariatric surgery within the past two years

[0601] Diabetic ketoacidosis, diabetic coma, or precoma within the past year

[0602] Recurrent urinary tract infections or genital infections requiring treatment within the past year

[0603] Alcohol or drug addiction within the past year

[0604] Occurrence of acute coronary syndrome, unstable angina, myocardial infarction requiring hospitalization, stroke, transient ischemic attack, or arrhythmia within the past 24 weeks

[0605] (However, those who have had the condition before 24 weeks and are currently cured or in a stable condition can register.)

[0606] Those who have had a history of major surgery that caused electrolyte imbalance within the past 12 weeks or are scheduled to have major surgery within 12 weeks after the end of the clinical trial

[0607] Those with lactic acidosis or a history of lactic acidosis

[0608] People with a history of Stevens-Johnson syndrome

[0609] 3. Those with the following diseases or symptoms:

[0610] Any type of diabetes other than type 2 diabetes (type 1 diabetes, secondary diabetes, or congenital renal diabetes)

[0611] Symptoms of urinary incontinence, anuria, oliguria, and urinary retention that cannot be controlled with medication due to stress urinary incontinence, neurogenic bladder, and benign prostatic hyperplasia

[0612] Severe diabetic complications (proliferative diabetic retinopathy, nephropathy of stage 4 or higher, or severe diabetic neuropathy)

[0613] Chronic diseases requiring continuous use (oral, injected, or inhaled) of diuretics, systemic steroids, or immunosuppressants

[0614] Pituitary insufficiency or adrenal insufficiency

[0615] Severe infection (e.g., severe infection requiring continued use of antibiotics or immunotherapy), clinically significant major trauma

[0616] unstable mental illness whose symptoms are not controlled by medication

[0617] Severe gastrointestinal disease: active ulcers, gastrointestinal / rectal bleeding, active inflammatory bowel syndrome, patients with biliary obstruction, active gastritis not controlled by medication, etc.

[0618] Uncontrolled hypertension (SBP > 180 mmHg or DBP > 110 mmHg)

[0619] Patients with moderate or severe renal impairment (eGFR < 60 mL / min / 1.73 m2)

[0620] Patients with severe liver impairment who fall under one of the following:

[0621] - AST or ALT > 3 times the upper limit of normal

[0622] - Total Bilirubin > 2 times the upper limit of normal

[0623] - Hepatitis or liver failure

[0624] Patients with severe hypertriglyceridemia (Triglyceride > 500 mg / dL)

[0625] Acquired immunodeficiency syndrome

[0626] Severe heart failure (NYHA class II~IV)

[0627] Patients with pulmonary infarction, severe pulmonary dysfunction, and other conditions prone to hypoxemia

[0628] Those who require treatment for dehydration due to persistent diarrhea or vomiting, or are at risk of fluid volume depletion

[0629] Those with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption

[0630] 4. Patients who have used other clinical trial drugs / medical devices within the past 4 weeks (However, registration is possible in cases where the investigator determines that it will not affect the efficacy and safety of this study, such as observational studies or retrospective studies)

[0631] 5. Patients with a history of malignant tumor within the past 5 years

[0632] - However, patients with appropriately controlled basal cell carcinoma, squamous cell carcinoma, cervical intraepithelial carcinoma, or thyroid cancer can participate.

[0633] - However, participation is possible if there has been no recurrence for more than 5 years after a complete cure (complete removal of the tumor through surgery or completion of anticancer treatment, etc.)

[0634] 6. Pregnant or lactating women or those who do not agree to use appropriate contraception during the clinical trial period.

[0635] You or your partner must agree to one of the following:

[0636] ① If you have undergone one of the following: sterilization surgery (vasectomy, etc.) or intrauterine device (copper loop, hormone-containing intrauterine system).

[0637] ② Use of either non-oral hormonal contraceptives or spermicides in combination with the barrier method

[0638] ③ Use a cervical cap or diaphragm together with a male condom

[0639] 7. Those who are judged by the investigator to be ineligible for this clinical trial

[0640]

[0641] Exclusion criteria for Visit 1 (screening)

[0642] 1. Those who have a history of taking the following drugs or are expected to require continuous administration during the clinical trial period.

[0643] Systemic steroids (prednisolone >30 mg / day) within the past 2 weeks

[0644] Those who have changed the dosage of thyroid dysfunction treatment within the past 6 weeks (concurrent use is permitted if the treatment has been administered stably before clinical trial registration. A reduction in dosage is permitted if the stable condition is maintained.)

[0645] Diabetic medications other than metformin and gemigliptin within the past 8 weeks

[0646] Weight loss medications within the past 12 weeks

[0647] Those expected to require continuous administration of oral hypoglycemic agents, excluding clinical trial drugs, concomitant drugs (metformin, gemigliptin), and rescue drugs, during the clinical trial period.

[0648]

[0649] Primary efficacy endpoint

[0650] 1) Change in HbA1c at 24 weeks after administration of clinical trial drug compared to Visit 2 (randomization)

[0651]

[0652] Secondary efficacy endpoints

[0653] 1) Changes in HbA1c at 6, 12, and 18 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0654] 2) Changes in FPG at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0655] 3) Proportion of subjects achieving HbA1c < 7% at each time point of 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0656] 4) Proportion of subjects achieving HbA1c < 6.5% at each time point of 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0657] 5) Proportion of subjects who achieved a therapeutic response (change in HbA1c at each evaluation time point (HbA1c at Visit 2 - HbA1c at each evaluation time point) > 0.5% or HbA1c < 7%) at each time point 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0658] 6) Proportion of subjects who achieved a therapeutic response (change in HbA1c at each evaluation time point (HbA1c at Visit 2 - HbA1c at each evaluation time point) > 0.7% or HbA1c < 7%) at each time point 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0659] 7) Proportion of subjects who achieved a therapeutic response (change in HbA1c at each evaluation time point (HbA1c at Visit 2 - HbA1c at each evaluation time point) > 1% or HbA1c < 7%) at each time point 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0660]

[0661] Exploratory evaluation variables

[0662] 1) Changes in fasting C-peptide at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0663] 2) Changes in body weight at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (random assignment)

[0664] 3) Changes in fasting lipid levels (total cholesterol, LDL-C, HDL-C, triglyceride) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0665] 4) Changes in blood pressure (systolic, diastolic) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (random assignment)

[0666] 5) Changes in beta-cell function and insulin resistance measured by HOMA-beta and HOMA-IR at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0667] 6) Changes in renal function-related indicators (UACR, UGCR) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0668] 7) Changes in obesity-related indicators (adiponectin, leptin) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0669] 8) Proportion of subjects who received rescue medication at each time point of 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0670]

[0671] 2. Experimental Results

[0672] Primary efficacy endpoint

[0673] 1) Change in HbA1c at 24 weeks after administration of clinical trial drug compared to Visit 2 (randomization)

[0674] The results summarized for the PPS regarding the change in HbA1c at 24 weeks after administration of the investigational drug, which was the primary efficacy endpoint of this clinical trial, are presented in Table 41.

[0675] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (monotherapy or 2 drugs) or combination of 3 or more drugs) within 24 weeks prior to obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in HbA1c at 24 weeks after administration of the investigational drug compared to the baseline was -0.92 (0.05)%p for the test group (inavogliflozin 0.3 mg) and -0.86 (0.05)%p for the control group (dapagliflozin 10 mg). The difference (LS Mean Difference (95% CI)) between the two groups was -0.06 (-0.19, 0.06)%p. The upper limit of the 95% confidence interval for [test group-control group] was 0.06%p, which was smaller than the non-inferiority margin of 0.35, proving that the test group was non-inferior to the control group.

[0676] The change (SD) in HbA1c by administration group was -0.93 (0.70)%p in the test group and -0.89 (0.65)%p in the control group, and there was a statistically significant difference within the groups in both groups (p<0.0001).

[0677] Change from baseline in HbA1c at week 24 (Per-Protocol Set) 이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Baselinen119123Mean(SD)7.79(0.77)7.83(0.81)Median7.607.64Min, Max6.81, 10.546.73, 10.30Week 24n119123Mean(SD)6.86(0.54)6.94(0.64)Median6.766.81Min, Max5.44, 8.625.78, 9.87Change from baseline at week 24n119123Mean(SD)-0.93(0.70)-0.89(0.65)Median-0.83-0.86Min, Max-3.64, 0.95-3.05, 1.59P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA Result [2]LS Mean(SE)-0.92(0.05)-0.86(0.05)LS Mean Difference-0.0695% Confidence Interval for Difference[-0.19, 0.06]Non-inferiority (UCI < 0.35 %)Yes

[0678] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error, UCI = upper limit confidence interval.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0679] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0680] Note: Baseline is Visit 2 (randomization).

[0681] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0682]

[0683] Secondary efficacy endpoints

[0684] 1) Changes in HbA1c at 6, 12, and 18 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0685] The results of the summary of changes in HbA1c at 6, 12, and 18 weeks after administration of the clinical trial drug compared to baseline for PPS are presented in Table 42.

[0686] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double) or 3 or more combined) within 24 weeks prior to the date of obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) of the change in HbA1c at each time point after administration of the investigational drug compared to the baseline was -0.73 (0.03)%p in the 6-week test group (inavogliflozin 0.3 mg), -0.70 (0.03)%p in the control group (dapagliflozin 10 mg), -0.87 (0.04)%p in the 12-week test group, -0.83 (0.04)%p in the control group, and -0.83 (0.04)%p in the 18-week test group. -0.83(0.05)%p, control group -0.75(0.04)%p. The difference between the two groups (LS Mean Difference (95% CI)) was -0.03(-0.11, 0.06)%p at 6 weeks, -0.04(-0.15, 0.06)%p at 12 weeks, and -0.07(-0.19, 0.04)%p at 18 weeks, and there was no statistically significant difference between the two groups at any time point (6 weeks p=0.5606, 12 weeks p=0.4085, 18 weeks p=0.1951).

[0687] The change (SD) in HbA1c by time point was -0.74 (0.46)%p for the 6-week test group, -0.72 (0.41)%p for the control group, -0.89 (0.62)%p for the 12-week test group, -0.87 (0.57)%p for the control group, -0.84 (0.69)%p for the 18-week test group, -0.79 (0.61)%p for the control group, and there was a statistically significant difference within the group in all time points and administration groups.

[0688] Change from baseline in HbA1c at week 6, 12 and 18 (Per-Protocol Set) 이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Baselinen119123Mean(SD)7.79(0.77)7.83(0.81)Median7.607.64Min, Max6.81, 10.546.73, 10.30Week 6n116122Mean(SD)7.06(0.58)7.10(0.67)Median6.946.96Min, Max6.22, 9.385.90, 9.48Change from baseline at week 6n116122Mean(SD)-0.74(0.46)-0.72(0.41)Median-0.65-0.65Min, Max-3.06, -0.06-2.15, 0.19P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-0.73(0.03)-0.70(0.03)LS Mean Difference-0.0395% Confidence Interval for Difference[-0.11, 0.06]P-value [2]0.5606Week 12n117123Mean(SD)6.90(0.55)6.96(0.60)Median6.836.84Min, Max5.71, 8.865.93, 9.32Change from baseline at week 12n117123Mean(SD)-0.89(0.62)-0.87(0.57)Median-0.75-0.85Min, Max-3.66, 0.25-2.88, 0.30P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-0.87(0.04)-0.83(0.04)LS Mean Difference-0.0495% Confidence Interval for Difference[-0.15, 0.06]P-value [2]0.4085Week 18n117123Mean(SD)6.95(0.53)7.04(0.56)Median6.876.97Min, Max5.75, 8.496.03, 9.51Change from baseline at week 18n117123Mean(SD)-0.84(0.69)-0.79(0.61)Median-0.72-0.72Min, Max-3.61, 0.79-2.97, 0.99P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-0.83(0.05)-0.75(0.04)LS Mean Difference-0.0795% Confidence Interval for Difference[-0.19, 0.04]P-value [2]0.1951.

[0689] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0690] [2] Testing for difference between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0691] Note: Baseline is Visit 2 (randomization).

[0692] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0693]

[0694] 2) Changes in FPG at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0695] The results of the summary of changes in FPG at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for the PPS are presented in Table 43.

[0696] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double) or 3 or more combined) within 24 weeks prior to the date of obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in FPG at each time point after administration of the investigational drug compared to the baseline was -25.96 (1.42) mg / dL for the 6-week test group (inavogliflozin 0.3 mg), -22.71 (1.39) mg / dL for the control group (dapagliflozin 10 mg), -27.17 (1.54) mg / dL for the 12-week test group, -24.42 (1.50) mg / dL for the control group, and -24.42 (1.50) mg / dL for the 18-week test group. The test group was -27.77 (1.63) mg / dL, the control group was -23.55 (1.59) mg / dL, the 24-week test group was -27.21 (1.81) mg / dL, and the control group was -23.72 (1.78) mg / dL. The difference between the two groups (LS Mean Difference (95% CI)) was -3.24 (-6.84, 0.36) mg / dL at 6 weeks, -2.75 (-6.64, 1.14) mg / dL at 12 weeks, -4.22 (-8.33, -0.11) mg / dL at 18 weeks, and -3.49 (-8.08, 1.10) mg / dL at 24 weeks, indicating a statistically significant difference between the two groups at 18 weeks (6 weeks p=0.0773, 12 weeks p=0.1651, 18 weeks p=0.0444, 24 weeks p=0.1354).

[0697] The change in FPG by time point (SD) was -25.72 (21.79) mg / dL in the 6-week test group, -22.87 (23.96) in the control group, -27.47 (22.64) mg / dL in the 12-week test group, -25.28 (27.86) mg / dL in the control group, -28.00 (26.03) mg / dL in the 18-week test group, -24.80 (27.29) mg / dL in the control group, and -26.31 (25.46) mg / dL in the 24-week test group, -23.70 (29.86) mg / dL in the control group. There were statistically significant differences within the groups at all time points and administration groups.

[0698] Change from baseline in FPG at week 6, 12, 18 and 24 (Per-Protocol Set)이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Baselinen119123Mean(SD)139.34(27.95)140.52(29.73)Median135.00136.00Min, Max87.00, 240.0085.00, 265.00Week 6n116122Mean(SD)114.21(17.63)117.64(17.75)Median113.00116.50Min, Max65.00, 157.0058.00, 169.00Change from baseline at week 6n116122Mean(SD)-25.72(21.79)-22.87(23.96)Median-24.50-18.50Min, Max-87.00, 13.00-123.00, 41.00P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-25.96(1.42)-22.71(1.39)LS Mean Difference-3.2495% Confidence Interval for Difference[-6.84, 0.36]P-value [2]0.0773Week 12n117123Mean(SD)112.29(17.27)115.24(17.60)Median110.00112.00Min, Max72.00, 154.0070.00, 166.00Change from baseline at week 12n117123Mean(SD)-27.47(22.64)-25.28(27.86)Median-25.00-20.00Min, Max-94.00, 15.00-181.00, 21.00P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-27.17(1.54)-24.42(1.50)LS Mean Difference-2.7595% Confidence Interval for Difference[-6.64, 1.14]P-value [2]0.1651Week 18n117123Mean(SD)111.10(15.80)115.72(19.61)Median109.00114.00Min, Max81.00, 168.0048.00, 175.00Change from baseline at week 18n117123Mean(SD)-28.00(26.03)-24.80(27.29)Median-24.00-19.00Min, Max-119.00, 25.00-156.00, 23.00P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-27.77(1.63)-23.55(1.59)LS Mean Difference-4.2295% Confidence Interval for Difference[-8.33, -0.11]P-value [2]0.0444Week 24n119123Mean(SD)113.03(17.63)116.82(21.31)Median110.00114.00Min, Max60.00, 180.0066.00, 226.00Change from baseline at week 24n119123Mean(SD)-26.31(25.46)-23.70(29.86)Median-20.00-20.00Min, Max-102.00, 28.00-151.00, 79.00P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-27.21(1.81)-23.72(1.78)LS Mean Difference-3.4995% Confidence Interval for Difference[-8.08, 1.10]P-value [2]0.1354.

[0699] FPG = fasting plasma glucose, SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0700] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0701] Note: Baseline is Visit 2 (randomization).

[0702] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0703]

[0704] 3) Proportion of subjects achieving HbA1c < 7% at each time point of 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0705] The results of the summary of the proportion of subjects achieving HbA1c < 7% at 6, 12, 18, and 24 weeks after administration of the clinical trial drug for PPS are presented in Table 44.

[0706] In the PPS, the stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double) or 3 or more combined) within 24 weeks prior to the date of obtaining written consent, HbA1c level (less than or equal to 8%) at Visit 1 (screening)) were adjusted for logistic regression analysis. As a result, the odds ratio (95% CI) of achieving HbA1c < 7% at each time point in the test group (inavogliflozin 0.3 mg) compared to the control group (dapagliflozin 10 mg) was 1.22 (0.66, 2.25) at 6 weeks, 1.20 (0.66, 2.19) at 12 weeks, 1.36 (0.78, 2.38) at 18 weeks, and 1.17 (0.66, 2.09) at 24 weeks, were statistically different between the two groups at all time points. There was no significant difference (6 weeks p=0.5326, 12 weeks p=0.5560, 18 weeks p=0.2743, 24 weeks p=0.5862).

[0707] The proportion of subjects who achieved HbA1c < 7% at each time point was 56.03% (65 / 116 subjects) in the 6-week test group, 51.64% (63 / 122 subjects) in the control group, 67.52% (79 / 117 subjects) in the 12-week test group, 63.41% (78 / 123 subjects) in the control group, 63.25% (74 / 117 subjects) in the 18-week test group, 56.10% (69 / 123 subjects) in the control group, 66.39% (79 / 119 subjects) in the 24-week test group, and 62.60% (77 / 123 subjects) in the control group.

[0708] Proportion of subjects achieving HbA1c target of < 7 % at week 6, 12, 18 and 24 (Per-Protocol Set) 이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Proportion of subjects achieving HbA1c target of < 7 % at week 6, N116122Subjects with achieving HbA1c target of < 7 %, n(%)65(56.03)63(51.64)Logistic Regression ModelOdds Ratio1.2295% Confidence Interval[0.66, 2.25]P-value [1]0.5326Proportion of subjects achieving HbA1c target of < 7 % at week 12, N117123Subjects with achieving HbA1c target of < 7 %, n(%)79(67.52)78(63.41)Logistic Regression ModelOdds Ratio1.2095% Confidence Interval[0.66, 2.19]P-value [1]0.5560Proportion of subjects achieving HbA1c target of < 7 % at week 18, N117123Subjects with achieving HbA1c target of < 7 %, n(%)74(63.25)69(56.10)Logistic Regression ModelOdds Ratio1.3695% Confidence Interval[0.78, 2.38]P-value [1]0.2743Proportion of subjects achieving HbA1c target of < 7 % at week 24, N119123Subjects with achieving HbA1c target of < 7 %, n(%)79(66.39)77(62.60)Logistic Regression ModelOdds Ratio1.1795% Confidence Interval[0.66, 2.09]P-value [1]0.5862

[0709] Proportion = The number of subjects with HbA1c less than 7 % at week n / the number of subjects with available data at week n in the efficacy analysis set * 100, n = 6, 12, 18, 24.[1] Testing for differences between DWP16001 and Dapagliflozin (Logistic regression model with treatment group as a factor and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0710] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0711]

[0712] 4) Proportion of subjects achieving HbA1c < 6.5% at each time point of 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0713] The results of the summary of the proportion of subjects achieving HbA1c < 6.5% at 6, 12, 18, and 24 weeks after administration of the clinical trial drug, based on the PPS, are presented in Table 45.

[0714] In the PPS, the stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double agents) or 3 or more agents in combination) within 24 weeks prior to the date of obtaining written consent, HbA1c level (less than or equal to 8%) at Visit 1 (screening)) were adjusted for logistic regression analysis. As a result, the odds ratio (95% CI) of achieving HbA1c < 6.5% at each time point in the test group (inavogliflozin 0.3 mg) compared to the control group (dapagliflozin 10 mg) was 0.65 (0.30, 1.41) at 6 weeks, 1.44 (0.74, 2.80) at 12 weeks, 1.20 (0.56, 2.58) at 18 weeks, and 1.27 (0.66, 2.46) at 24 weeks, were two-fold at all time points. There was no statistically significant difference between the groups (6 weeks p=0.2729, 12 weeks p=0.2784, 18 weeks p=0.6372, 24 weeks p=0.4729).

[0715] The proportion of subjects who achieved HbA1c < 6.5% at each time point was 11.21% (13 / 116 subjects) in the 6-week test group, 15.57% (19 / 122 subjects) in the control group, 23.08% (27 / 117 subjects) in the 12-week test group, 17.07% (21 / 123 subjects) in the control group, 14.53% (17 / 117 subjects) in the 18-week test group, 12.20% (15 / 123 subjects) in the control group, 21.01% (25 / 119 subjects) in the 24-week test group, and 17.07% (21 / 123 subjects) in the control group.

[0716] Proportion of subjects achieving HbA1c target of < 6.5 % at week 6, 12, 18 and 24 (Per-Protocol Set) 이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Proportion of subjects achieving HbA1c target of < 6.5 % at week 6, N116122Subjects with achieving HbA1c target of < 6.5 %, n(%)13(11.21)19(15.57)Logistic Regression ModelOdds Ratio0.6595% Confidence Interval[0.30, 1.41]P-value [1]0.2729Proportion of subjects achieving HbA1c target of < 6.5 % at week 12, N117123Subjects with achieving HbA1c target of < 6.5 %, n(%)27(23.08)21(17.07)Logistic Regression ModelOdds Ratio1.4495% Confidence Interval[0.74, 2.80]P-value [1]0.2784Proportion of subjects achieving HbA1c target of < 6.5 % at week 18, N117123Subjects with achieving HbA1c target of < 6.5 %, n(%)17(14.53)15(12.20)Logistic Regression ModelOdds Ratio1.2095% Confidence Interval[0.56, 2.58]P-value [1]0.6372Proportion of subjects achieving HbA1c target of < 6.5 % at week 24, N119123Subjects with achieving HbA1c target of < 6.5 %, n(%)25(21.01)21(17.07)Logistic Regression ModelOdds Ratio1.2795% Confidence Interval[0.66, 2.46]P-value [1]0.4729

[0717] Proportion = The number of subjects with HbA1c less than 6.5 % at week n / the number of subjects with available data at week n in the efficacy analysis set * 100, n = 6, 12, 18, 24.[1] Testing for differences between DWP16001 and Dapagliflozin (Logistic regression model with treatment group as a factor and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥8 %]) as covariates).

[0718] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0719]

[0720] 5) Proportion of subjects who achieved a therapeutic response (change in HbA1c at each evaluation time point (HbA1c at Visit 2 - HbA1c at each evaluation time point) > 0.5% or HbA1c < 7%) at each time point 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0721] The results summarized for the PPS regarding the proportion of subjects who achieved a therapeutic response (change in HbA1c at each evaluation point (HbA1c at Visit 2 - HbA1c at each evaluation point) > 0.5% or HbA1c < 7%) at 6, 12, 18, and 24 weeks after administration of the investigational drug are presented in Table 46.

[0722] In the PPS, the stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double agents) or 3 or more agents in combination) within 24 weeks prior to the date of obtaining written consent, HbA1c level (less than or equal to 8%) at Visit 1 (screening)) were adjusted for logistic regression analysis. As a result, the odds ratio (95% CI) of achieving a therapeutic response at each time point in the test group (inavogliflozin 0.3 mg) compared to the control group (dapagliflozin 10 mg) was 1.52 (0.74, 3.13) at 6 weeks, 1.09 (0.47, 2.55) at 12 weeks, 1.02 (0.52, 2.02) at 18 weeks, and 1.15 (0.55, 2.40) at 24 weeks, and there was no statistically significant difference between the two groups at any time point (6 weeks). p=0.2571, 12 weeks p=0.8399, 18 weeks p=0.9545, 24 weeks p=0.7187).

[0723] The proportion of subjects who achieved a therapeutic response at each time point was 87.07% (101 / 116) in the 6-week test group and 81.97% (100 / 122) in the control group, 89.74% (105 / 117) in the 12-week test group and 89.43% (110 / 123) in the control group, 82.91% (97 / 117) in the 18-week test group and 82.93% (102 / 123) in the control group, and 86.55% (103 / 119) in the 24-week test group and 85.37% (105 / 123) in the control group.

[0724] Proportion of subjects achieving a therapeutic glycemic response 1 at week 6, 12, 18 and 24 (Per-Protocol Set)이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Proportion of subjects achieving a therapeutic glycemic response 1 at week 6, N116122Subjects with achieving a therapeutic glycemic response 1, n(%)101(87.07)100(81.97)Logistic Regression ModelOdds Ratio1.5295% Confidence Interval[0.74, 3.13]P-value [1]0.2571Proportion of subjects achieving a therapeutic glycemic response 1 at week 12, N117123Subjects with achieving a therapeutic glycemic response 1, n(%)105(89.74)110(89.43)Logistic Regression ModelOdds Ratio1.0995% Confidence Interval[0.47, 2.55]P-value [1]0.8399Proportion of subjects achieving a therapeutic glycemic response 1 at week 18, N117123Subjects with achieving a therapeutic glycemic response 1, n(%)97(82.91)102(82.93)Logistic Regression ModelOdds Ratio1.0295% Confidence Interval[0.52, 2.02]P-value [1]0.9545Proportion of subjects achieving a therapeutic glycemic response 1 at week 24, N119123Subjects with achieving a therapeutic glycemic response 1, n(%)103(86.55)105(85.37)Logistic Regression ModelOdds Ratio1.1595% Confidence Interval[0.55, 2.40]P-value [1]0.7187.

[0725] Proportion = The number of subjects achieving a therapeutic glycemic response 1 at week n / the number of subjects with available data at week n in the efficacy analysis set * 100, n = 6, 12, 18, 24.[1] Testing for difference between DWP16001 and Dapagliflozin (Logistic regression model with treatment group as a factor and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0726] Note: Therapeutic glycemic response 1 = Change from Visit 2 [randomization] in HbA1c [HbA1c at Visit 2 - HbA1c at each assessment time point] > 0.5 % at each assessment time point or HbA1c < 7 %.

[0727] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0728]

[0729] 6) Proportion of subjects who achieved a therapeutic response (change in HbA1c at each evaluation time point (HbA1c at Visit 2 - HbA1c at each evaluation time point) > 0.7% or HbA1c < 7%) at each time point 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0730] The results summarized for the PPS regarding the proportion of subjects who achieved a therapeutic response (change in HbA1c at each evaluation point (HbA1c at Visit 2 - HbA1c at each evaluation point) > 0.7% or HbA1c < 7%) at 6, 12, 18, and 24 weeks after administration of the investigational drug are presented in Table 47.

[0731] In the PPS, the stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double) or 3 or more combined) within 24 weeks prior to the date of obtaining written consent, HbA1c level (less than or equal to 8%) at Visit 1 (screening)) were adjusted for logistic regression analysis. As a result, the odds ratio (95% CI) of achieving a therapeutic response at each time point in the test group (inavogliflozin 0.3 mg) compared to the control group (dapagliflozin 10 mg) was 1.16 (0.62, 2.15) at 6 weeks, 1.30 (0.65, 2.60) at 12 weeks, 1.09 (0.60, 2.00) at 18 weeks, and 0.98 (0.51, 1.91) at 24 weeks, and there was no statistically significant difference between the two groups at any time point (6 weeks). p=0.6458, 12 weeks p=0.4581, 18 weeks p=0.7760, 24 weeks p=0.9633).

[0732] The proportion of subjects who achieved a therapeutic response at each time point was 78.45% (91 / 116 subjects) in the 6-week test group, 76.23% (93 / 122 subjects) in the control group, 85.47% (100 / 117 subjects) in the 12-week test group, 82.11% (101 / 123 subjects) in the control group, 77.78% (91 / 117 subjects) in the 18-week test group, 76.42% (94 / 123 subjects) in the control group, 81.51% (97 / 119 subjects) in the 24-week test group, and 82.11% (101 / 123 subjects) in the control group.

[0733] Proportion of subjects achieving a therapeutic glycemic response 2 at week 6, 12, 18 and 24 (Per-Protocol Set) 이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Proportion of subjects achieving a therapeutic glycemic response 2 at week 6, N116122Subjects with achieving a therapeutic glycemic response 2, n(%)91(78.45)93(76.23)Logistic Regression ModelOdds Ratio1.1695% Confidence Interval[0.62, 2.15]P-value [1]0.6458Proportion of subjects achieving a therapeutic glycemic response 2 at week 12, N117123Subjects with achieving a therapeutic glycemic response 2, n(%)100(85.47)101(82.11)Logistic Regression ModelOdds Ratio1.3095% Confidence Interval[0.65, 2.60]P-value [1]0.4581Proportion of subjects achieving a therapeutic glycemic response 2 at week 18, N117123Subjects with achieving a therapeutic glycemic response 2, n(%)91(77.78)94(76.42)Logistic Regression ModelOdds Ratio1.0995% Confidence Interval[0.60, 2.00]P-value [1]0.7760Proportion of subjects achieving a therapeutic glycemic response 2 at week 24, N119123Subjects with achieving a therapeutic glycemic response 2, n(%)97(81.51)101(82.11)Logistic Regression ModelOdds Ratio0.9895% Confidence Interval[0.51, 1.91]P-value [1]0.9633.

[0734] Proportion = The number of subjects achieving a therapeutic glycemic response 2 at week n / the number of subjects with available data at week n in the efficacy analysis set * 100, n = 6, 12, 18, 24.[1] Testing for difference between DWP16001 and Dapagliflozin (Logistic regression model with treatment group as a factor and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0735] Note: Therapeutic glycemic response 2 = Change from Visit 2 [randomization] in HbA1c [HbA1c at Visit 2 - HbA1c at each assessment time point] > 0.7 % at each assessment time point or HbA1c < 7 %.

[0736] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0737]

[0738] 7) Proportion of subjects who achieved a therapeutic response (change in HbA1c at each evaluation time point (HbA1c at Visit 2 - HbA1c at each evaluation time point) > 1% or HbA1c < 7%) at each time point of 6, 12, 18, and 24 weeks after administration of the clinical trial drug

[0739] The results summarized for the PPS regarding the proportion of subjects who achieved a therapeutic response (change in HbA1c at each evaluation point (HbA1c at Visit 2 - HbA1c at each evaluation point) > 1% or HbA1c < 7%) at 6, 12, 18, and 24 weeks after administration of the investigational drug are presented in Table 48.

[0740] In the PPS, the stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double) or 3 or more combined) within 24 weeks prior to the date of obtaining written consent, HbA1c level (less than or equal to 8%) at Visit 1 (screening)) were adjusted for logistic regression analysis. As a result, the odds ratio (95% CI) of achieving a therapeutic response at each time point in the test group (inavogliflozin 0.3 mg) compared to the control group (dapagliflozin 10 mg) was 1.38 (0.78, 2.43) at 6 weeks, 1.31 (0.71, 2.42) at 12 weeks, 1.22 (0.68, 2.17) at 18 weeks, and 1.22 (0.67, 2.25) at 24 weeks, and there was no statistically significant difference between the two groups at any time point (6 weeks). p=0.2640, 12 weeks p=0.3950, 18 weeks p=0.5063, 24 weeks p=0.5130).

[0741] The proportion of subjects who achieved a therapeutic response at each time point was 70.69% (82 / 116 subjects) in the 6-week test group, 63.93% (78 / 122 subjects) in the control group, 78.63% (92 / 117 subjects) in the 12-week test group, 73.98% (91 / 123 subjects) in the control group, 74.36% (87 / 117 subjects) in the 18-week test group, 70.73% (87 / 123 subjects) in the control group, 78.15% (93 / 119 subjects) in the 24-week test group, and 74.80% (92 / 123 subjects) in the control group.

[0742] Proportion of subjects achieving a therapeutic glycemic response 3 at week 6, 12, 18 and 24 (Per-Protocol Set) 이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Proportion of subjects achieving a therapeutic glycemic response 3 at week 6, N116122Subjects with achieving a therapeutic glycemic response 3, n(%)82(70.69)78(63.93)Logistic Regression ModelOdds Ratio1.3895% Confidence Interval[0.78, 2.43]P-value [1]0.2640Proportion of subjects achieving a therapeutic glycemic response 3 at week 12, N117123Subjects with achieving a therapeutic glycemic response 3, n(%)92(78.63)91(73.98)Logistic Regression ModelOdds Ratio1.3195% Confidence Interval[0.71, 2.42]P-value [1]0.3950Proportion of subjects achieving a therapeutic glycemic response 3 at week 18, N117123Subjects with achieving a therapeutic glycemic response 3, n(%)87(74.36)87(70.73)Logistic Regression ModelOdds Ratio1.2295% Confidence Interval[0.68, 2.17]P-value [1]0.5063Proportion of subjects achieving a therapeutic glycemic response 3 at week 24, N119123Subjects with achieving a therapeutic glycemic response 3, n(%)93(78.15)92(74.80)Logistic Regression ModelOdds Ratio1.2295% Confidence Interval[0.67, 2.25]P-value [1]0.5130.

[0743] Proportion = The number of subjects achieving a therapeutic glycemic response 3 at week n / the number of subjects with available data at week n in the efficacy analysis set * 100, n = 6, 12, 18, 24.[1] Testing for difference between DWP16001 and Dapagliflozin (Logistic regression model with treatment group as a factor and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0744] Note: Therapeutic glycemic response 3 = Change from Visit 2 [randomization] in HbA1c [HbA1c at Visit 2 - HbA1c at each assessment time point] > 1 % at each assessment time point or HbA1c < 7 %.

[0745] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0746]

[0747] 탐색적 평가변수

[0748] 1) Changes in fasting C-peptide at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0749] The results of the summary of changes in fasting C-peptide at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for PPS are presented in Table 49.

[0750] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double agents) or 3 or more agents in combination) within 24 weeks prior to the date of obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in fasting C-peptide at each time point after administration of the investigational drug compared to the baseline was -0.05 (0.02) ng / mL in the 6-week test group (inavogliflozin 0.3 mg), -0.04 (0.02) ng / mL in the control group (dapagliflozin 10 mg), -0.09 (0.02) ng / mL in the 12-week test group, -0.07 (0.02) ng / mL in the control group, and -0.07 (0.02) ng / mL in the 18-week test group. -0.08 (0.02) ng / mL in the control group, -0.06 (0.02) ng / mL in the 24-week trial group, -0.09 (0.02) ng / mL in the control group, -0.08 (0.02) ng / mL in the control group. The difference between the two groups (LS Mean Difference (95% CI)) was -0.01 (-0.06, 0.04) ng / mL at week 6, -0.02 (-0.06, 0.03) ng / mL at week 12, -0.02 (-0.07, 0.03) ng / mL at week 18, and -0.01 (-0.05, 0.03) ng / mL at week 24, indicating that there was no statistically significant difference between the two groups at any time point.

[0751] The change (SD) in fasting C-peptide by time point was -0.06 (0.21) ng / mL in the 6-week test group, -0.04 (0.15) ng / mL in the control group, -0.09 (0.20) ng / mL in the 12-week test group, -0.06 (0.19) ng / mL in the control group, -0.09 (0.22) ng / mL in the 18-week test group, -0.06 (0.18) ng / mL in the control group, and -0.09 (0.18) ng / mL in the 24-week test group, -0.07 (0.19) ng / mL in the control group. There was a statistically significant difference within the group in all time points and administration groups.

[0752] Change from baseline in fasting C-peptide at week 6, 12, 18 and 24 (Per-Protocol Set) 이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Baselinen119123Mean(SD)0.73(0.25)0.69(0.21)Median0.700.70Min, Max0.30, 1.460.20, 1.42Week 6n116122Mean(SD)0.67(0.29)0.65(0.21)Median0.630.63Min, Max0.23, 1.920.17, 1.36Change from baseline at week 6n116122Mean(SD)-0.06(0.21)-0.04(0.15)Median-0.07-0.03Min, Max-0.66, 0.79-0.56, 0.33P-value [1]<0.0001 (w)0.0045 (w)ANCOVA ResultLS Mean(SE)-0.05(0.02)-0.04(0.02)LS Mean Difference-0.0195% Confidence Interval for Difference[-0.06, 0.04]P-value [2]0.6602Week 12n117123Mean(SD)0.64(0.23)0.63(0.23)Median0.630.60Min, Max0.20, 1.220.20, 1.56Change from baseline at week 12n117123Mean(SD)-0.09(0.20)-0.06(0.19)Median-0.10-0.03Min, Max-0.83, 0.60-0.66, 0.70P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-0.09(0.02)-0.07(0.02)LS Mean Difference-0.0295% Confidence Interval for Difference[-0.06, 0.03]P-value [2]0.4519Week 18n117123Mean(SD)0.64(0.26)0.63(0.22)Median0.600.60Min, Max0.26, 1.920.13, 1.46Change from baseline at week 18n117123Mean(SD)-0.09(0.22)-0.06(0.18)Median-0.10-0.07Min, Max-0.89, 1.29-0.56, 0.60P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-0.08(0.02)-0.06(0.02)LS Mean Difference-0.0295% Confidence Interval for Difference[-0.07, 0.03]P-value [2]0.4398Week 24n119123Mean(SD)0.64(0.20)0.62(0.24)Median0.630.56Min, Max0.26, 1.260.13, 1.42Change from baseline at week 24n119123Mean(SD)-0.09(0.18)-0.07(0.19)Median-0.07-0.10Min, Max-0.73, 0.56-0.60, 0.40P-value [1]<0.0001 (w)<0.0001 (t)ANCOVA ResultLS Mean(SE)-0.09(0.02)-0.08(0.02)LS Mean Difference-0.0195% Confidence Interval for Difference[-0.05, 0.03]P-value [2]0.6760.

[0753] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0754] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0755] Note: Baseline is Visit 2 (randomization).

[0756] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0757]

[0758] 2) Changes in body weight at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (random assignment)

[0759] The results of the summary of the PPS regarding the change in body weight at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to the baseline are presented in Table 50.

[0760] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double) or 3 or more combined) within 24 weeks prior to the date of obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in body weight at each time point after administration of the investigational drug compared to the baseline was -1.92 (0.17) kg in the 6-week test group (inavogliflozin 0.3 mg), -1.80 (0.16) kg in the control group (dapagliflozin 10 mg), -2.72 (0.20) kg in the 12-week test group, -2.71 (0.19) kg in the control group, and -3.16 (0.24) kg in the 18-week test group, and the control group. -3.01 (0.23) kg in the 24-week experimental group, -3.15 (0.23) kg in the 24-week experimental group, and -3.01 (0.22) kg in the control group. The differences between the two groups (LS Mean Difference (95% CI)) were -0.13 (-0.55, 0.30) kg at 6 weeks, -0.01 (-0.51, 0.49) kg at 12 weeks, -0.15 (-0.76, 0.46) kg at 18 weeks, and -0.15 (-0.73, 0.44) kg at 24 weeks, indicating that there was no statistically significant difference between the two groups at any time point.

[0761] The change in body weight (SD) by time point was -1.87 (1.98) kg for the 6-week test group, -1.68 (1.41) kg for the control group, -2.65 (2.23) kg for the 12-week test group, -2.58 (1.79) kg for the control group, -3.10 (2.94) kg for the 18-week test group, -2.84 (1.94) kg for the control group, -3.09 (2.72) kg for the 24-week test group, -2.83 (2.02) kg for the control group, and there were statistically significant differences within the groups at all time points and administration groups.

[0762] Change from baseline in body weight at week 6, 12, 18 and 24 (Per-Protocol Set)이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Baselinen119123Mean(SD)69.28(12.11)67.22(11.40)Median67.9064.80Min, Max49.60, 107.3047.50, 109.20Week 6n116122Mean(SD)67.13(11.90)65.20(10.46)Median66.8063.90Min, Max46.40, 104.5046.00, 97.70Change from baseline at week 6n116122Mean(SD)-1.87(1.98)-1.68(1.41)Median-1.90-1.55Min, Max-8.10, 9.40-5.20, 1.20P-value [1]<0.0001 (w)<0.0001 (t)ANCOVA ResultLS Mean(SE)-1.92(0.17)-1.80(0.16)LS Mean Difference-0.1395% Confidence Interval for Difference[-0.55, 0.30]P-value [2]0.5627Week 12n117123Mean(SD)66.54(11.79)64.64(11.16)Median65.8063.20Min, Max44.00, 102.1045.00, 106.20Change from baseline at week 12n117123Mean(SD)-2.65(2.23)-2.58(1.79)Median-2.90-2.50Min, Max-11.10, 7.40-10.70, 1.00P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-2.72(0.20)-2.71(0.19)LS Mean Difference-0.0195% Confidence Interval for Difference[-0.51, 0.49]P-value [2]0.9748Week 18n117123Mean(SD)66.18(11.64)64.37(11.11)Median65.4062.30Min, Max44.50, 101.8045.00, 104.50Change from baseline at week 18n117123Mean(SD)-3.10(2.94)-2.84(1.94)Median-2.90-2.70Min, Max-14.90, 7.60-8.90, 5.30P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-3.16(0.24)-3.01(0.23)LS Mean Difference-0.1595% Confidence Interval for Difference[-0.76, 0.46]P-value [2]0.6226Week 24n119123Mean(SD)66.19(11.58)64.38(11.03)Median65.1062.90Min, Max46.50, 101.4044.00, 105.70Change from baseline at week 24n119123Mean(SD)-3.09(2.72)-2.83(2.02)Median-3.00-2.60Min, Max-16.00, 7.50-8.50, 1.40P-value [1]<0.0001 (w)<0.0001 (t)ANCOVA ResultLS Mean(SE)-3.15(0.23)-3.01(0.22)LS Mean Difference-0.1595% Confidence Interval for Difference[-0.73, 0.44]P-value [2]0.6226.

[0763] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0764] [2] Testing for difference between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0765] Note: Baseline is Visit 2 (randomization).

[0766] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0767]

[0768] 3) Visit 2(무작위배정) 대비 임상시험용의약품 투여 후 6주, 12주, 18주, 24주 각 시점의 공복 지질농도(Total cholesterol, LDL-C, HDL-C, Triglyceride) 변화량

[0769] ① Total cholesterol

[0770] The results of the summary of the change in total cholesterol at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to the baseline using mPPS1 (modified Per-Protocol Set 1) are presented in Table 51.

[0771] In mPPS1, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double agents) or 3 or more agents in combination) within 24 weeks prior to the date of obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in total cholesterol at each time point after administration of the investigational drug compared to the baseline was 5.07 (1.97) mg / dL in the 6-week test group (inavogliflozin 0.3 mg), 2.63 (1.93) mg / dL in the control group (dapagliflozin 10 mg), 6.80 (2.04) mg / dL in the 12-week test group, 5.40 (1.98) mg / dL in the control group, and 18-week test group. The mean values ​​for the 24-week trial group were 4.27 (1.94) mg / dL, the control group 3.66 (1.88) mg / dL, the 24-week trial group 4.48 (2.07) mg / dL, and the control group 5.57 (2.03) mg / dL. The differences between the two groups (LS Mean Difference (95% CI)) were 2.45 (-2.63, 7.53) mg / dL at week 6, 1.40 (-3.85, 6.64) mg / dL at week 12, 0.61 (-4.36, 5.58) mg / dL at week 18, and -1.09 (-6.43, 4.25) mg / dL at week 24, indicating that there was no statistically significant difference between the two groups at any time point.

[0772] The change (SD) in total cholesterol by time point was 4.65 (19.51) mg / dL in the 6-week test group, 1.55 (19.56) mg / dL in the control group, 7.79 (20.63) mg / dL in the 12-week test group, 4.61 (20.98) in the control group, 5.06 (19.64) mg / dL in the 18-week test group, 2.51 (20.37) mg / dL in the control group, 5.59 (17.04) mg / dL in the 24-week test group, 4.69 (25.08) mg / dL in the control group. There were statistically significant differences within groups in all time points and administration groups except for the 6-week and 18-week control groups.

[0773] Change from baseline in fasting lipid parameters at week 6, 12, 18 and 24 (modified Per-Protocol Set 1) [Total cholesterol] 이나보글리플로진 0.3 mg(N=118)다파글리플로진 10 mg(N=120)Baselinen118120Mean(SD)134.47(24.91)143.80(35.51)Median132.00138.00Min, Max90.00, 199.0077.00, 265.00Week 6n115119Mean(SD)138.43(30.14)145.04(38.88)Median134.00136.00Min, Max76.00, 230.0071.00, 279.00Change from baseline at week 6n115119Mean(SD)4.65(19.51)1.55(19.56)Median3.002.00Min, Max-37.00, 111.00-94.00, 41.00P-value [1]0.0174 (w)0.2378 (w)ANCOVA ResultLS Mean(SE)5.07(1.97)2.63(1.93)LS Mean Difference2.4595% Confidence Interval for Difference[-2.63, 7.53]P-value [2]0.3438Week 12n116120Mean(SD)142.09(27.82)148.41(36.32)Median136.00140.50Min, Max79.00, 228.0077.00, 278.00Change from baseline at week 12n116120Mean(SD)7.79(20.63)4.61(20.98)Median7.006.00Min, Max-35.00, 82.00-78.00, 66.00P-value [1]0.0001 (w)0.0177 (t)ANCOVA ResultLS Mean(SE)6.80(2.04)5.40(1.98)LS Mean Difference1.4095% Confidence Interval for Difference[-3.85, 6.64]P-value [2]0.5998Week 18n116120Mean(SD)139.38(29.27)146.31(32.64)Median134.00141.00Min, Max88.00, 237.0081.00, 247.00Change from baseline at week 18n116120Mean(SD)5.06(19.64)2.51(20.37)Median3.001.00Min, Max-46.00, 119.00-67.00, 51.00P-value [1]0.0086 (w)0.1377 (w)ANCOVA ResultLS Mean(SE)4.27(1.94)3.66(1.88)LS Mean Difference0.6195% Confidence Interval for Difference[-4.36, 5.58]P-value [2]0.8088Week 24n118120Mean(SD)140.06(26.82)148.49(36.41)Median134.00145.00Min, Max86.00, 217.0073.00, 265.00Change from baseline at week 24n118120Mean(SD)5.59(17.04)4.69(25.08)Median5.503.00Min, Max-42.00, 73.00-103.00, 113.00P-value [1]0.0002 (w)0.0440 (w)ANCOVA ResultLS Mean(SE)4.48(2.07)5.57(2.03)LS Mean Difference-1.0995% Confidence Interval for Difference[-6.43, 4.25]P-value [2]0.6885.

[0774] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0775] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0776] Note: Baseline is Visit 2 (randomization).

[0777] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0778]

[0779] ② LDL-C

[0780] The results summarizing the changes in LDL-C at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for mPPS1 are presented in Table 52.

[0781] In mPPS1, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous (before withdrawal of other hypoglycemic agents) hypoglycemic agent administration regimen (2 or fewer (single or double) or 3 or more combined) within 24 weeks prior to the date of obtaining written consent), and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in LDL-C at each time point after administration of the investigational drug compared to the baseline was 2.49 (1.81) mg / dL in the 6-week test group (inavogliflozin 0.3 mg), 1.91 (1.78) mg / dL in the control group (dapagliflozin 10 mg), 2.95 (1.79) mg / dL in the 12-week test group, and 2.71 (1.75) mg / dL in the control group, and 18 weeks. The test group was 0.29 (1.63) mg / dL, the control group was 1.38 (1.59) mg / dL, the 24-week test group was 0.85 (1.89) mg / dL, and the control group was 3.12 (1.85) mg / dL. The differences between the two groups (LS Mean Difference (95% CI)) were 0.57 (-4.10, 5.24) mg / dL at 6 weeks, 0.24 (-4.37, 4.85) mg / dL at 12 weeks, -1.10 (-5.28, 3.08) mg / dL at 18 weeks, and -2.27 (-7.13, 2.59) mg / dL at 24 weeks, and there was no statistically significant difference between the two groups at any time point.

[0782] The change (SD) in LDL-C by time point was 2.42 (16.77) mg / dL in the 6-week test group and 1.40 (19.16) mg / dL in the control group, 3.76 (15.91) mg / dL in the 12-week test group and 2.45 (20.28) mg / dL in the control group, 0.94 (14.64) mg / dL in the 18-week test group and 0.93 (18.49) mg / dL in the control group, and 1.75 (14.83) mg / dL in the 24-week test group and 2.72 (23.25) mg / dL in the control group. There was a statistically significant difference within the group only in the test group at the 12-week time point.

[0783] Change from baseline in fasting lipid parameters at week 6, 12, 18 and 24 (modified Per-Protocol Set 1) [LDL-C] 이나보글리플로진 0.3 mg(N=118)다파글리플로진 10 mg(N=120)Baselinen118120Mean(SD)71.41(22.84)77.41(29.44)Median68.0071.00Min, Max29.00, 129.0024.00, 177.00Week 6n115119Mean(SD)73.35(27.86)78.50(33.38)Median68.0070.00Min, Max23.00, 171.0029.00, 193.00Change from baseline at week 6n115119Mean(SD)2.42(16.77)1.40(19.16)Median-1.001.00Min, Max-28.00, 103.00-107.00, 80.00P-value [1]0.5573 (w)0.2588 (w)ANCOVA ResultLS Mean(SE)2.49(1.81)1.91(1.78)LS Mean Difference0.5795% Confidence Interval for Difference[-4.10, 5.24]P-value [2]0.8092Week 12n116120Mean(SD)75.11(25.25)79.86(31.47)Median72.0072.50Min, Max25.00, 160.0025.00, 191.00Change from baseline at week 12n116120Mean(SD)3.76(15.91)2.45(20.28)Median3.004.00Min, Max-24.00, 67.00-86.00, 78.00P-value [1]0.0353 (w)0.0542 (w)ANCOVA ResultLS Mean(SE)2.95(1.79)2.71(1.75)LS Mean Difference0.2495% Confidence Interval for Difference[-4.37, 4.85]P-value [2]0.9179Week 18n116120Mean(SD)72.10(26.14)78.33(28.02)Median68.0073.00Min, Max16.00, 165.0036.00, 167.00Change from baseline at week 18n116120Mean(SD)0.94(14.64)0.93(18.49)Median0.001.50Min, Max-29.00, 74.00-82.00, 44.00P-value [1]0.9464 (w)0.2481 (w)ANCOVA ResultLS Mean(SE)0.29(1.63)1.38(1.59)LS Mean Difference-1.1095% Confidence Interval for Difference[-5.28, 3.08]P-value [2]0.6056Week 24n118120Mean(SD)73.15(25.01)80.13(31.18)Median70.5071.50Min, Max25.00, 145.0028.00, 182.00Change from baseline at week 24n118120Mean(SD)1.75(14.83)2.72(23.25)Median0.501.50Min, Max-31.00, 71.00-114.00, 113.00P-value [1]0.5077 (w)0.1251 (w)ANCOVA ResultLS Mean(SE)0.85(1.89)3.12(1.85)LS Mean Difference-2.2795% Confidence Interval for Difference[-7.13, 2.59]P-value [2]0.3580.

[0784] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0785] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0786] Note: Baseline is Visit 2 (randomization).

[0787] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0788]

[0789] ③ HDL-C

[0790] The results of a summary of the changes in HDL-C at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline, targeting mPPS1, are presented in Table 53.

[0791] In mPPS1, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous (before withdrawal of other hypoglycemic agents) hypoglycemic agent administration regimen (2 or fewer (single or double) or 3 or more combined) within 24 weeks prior to the date of obtaining written consent), and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in HDL-C at each time point after administration of the investigational drug compared to the baseline was 1.96 (0.57) mg / dL in the 6-week test group (inavogliflozin 0.3 mg), 1.13 (0.56) mg / dL in the control group (dapagliflozin 10 mg), 3.18 (0.62) mg / dL in the 12-week test group, and 2.84 (0.60) mg / dL in the control group, and 18 weeks The experimental group was 3.82 (0.64) mg / dL, the control group was 3.42 (0.62) mg / dL, the 24-week experimental group was 4.32 (0.71) mg / dL, and the control group was 4.40 (0.69) mg / dL. The difference between the two groups (LS Mean Difference (95% CI)) was 0.83 (-0.63, 2.29) mg / dL at 6 weeks, 0.34 (-1.25, 1.92) mg / dL at 12 weeks, 0.40 (-1.23, 2.02) mg / dL at 18 weeks, and -0.08 (-1.90, 1.73) mg / dL at 24 weeks. There was no statistically significant difference between the two groups at any time point.

[0792] The changes in HDL-C by time point were 1.90 (5.34) mg / dL in the 6-week test group, 0.94 (6.05) mg / dL in the control group, 3.17 (6.08) mg / dL in the 12-week test group, 2.65 (6.41) mg / dL in the control group, 4.09 (6.15) mg / dL in the 18-week test group, 3.57 (6.53) mg / dL in the control group, 4.53 (6.90) mg / dL in the 24-week test group, and 4.44 (7.34) mg / dL in the control group. There were statistically significant differences within groups in all time points and administration groups except for the control group at the 6-week time point.

[0793] Change from baseline in fasting lipid parameters at week 6, 12, 18 and 24 (modified Per-Protocol Set 1) [HDL-C] 이나보글리플로진 0.3 mg(N=118)다파글리플로진 10 mg(N=120)Baselinen118120Mean(SD)46.06(9.88)47.43(10.83)Median43.0047.00Min, Max30.00, 69.0027.00, 86.00Week 6n115119Mean(SD)47.99(11.09)48.39(11.63)Median46.0048.00Min, Max26.00, 75.0028.00, 101.00Change from baseline at week 6n115119Mean(SD)1.90(5.34)0.94(6.05)Median2.001.00Min, Max-12.00, 16.00-15.00, 23.00P-value [1]0.0002 (t)0.0895 (w)ANCOVA ResultLS Mean(SE)1.96(0.57)1.13(0.56)LS Mean Difference0.8395% Confidence Interval for Difference[-0.63, 2.29]P-value [2]0.2652Week 12n116120Mean(SD)49.21(11.35)50.08(11.22)Median47.5049.00Min, Max31.00, 82.0030.00, 99.00Change from baseline at week 12n116120Mean(SD)3.17(6.08)2.65(6.41)Median3.002.00Min, Max-12.00, 21.00-10.00, 24.00P-value [1]<0.0001 (t)<0.0001 (w)ANCOVA ResultLS Mean(SE)3.18(0.62)2.84(0.60)LS Mean Difference0.3495% Confidence Interval for Difference[-1.25, 1.92]P-value [2]0.6765Week 18n116120Mean(SD)50.17(11.21)50.99(11.88)Median49.5051.00Min, Max29.00, 78.0028.00, 102.00Change from baseline at week 18n116120Mean(SD)4.09(6.15)3.57(6.53)Median3.003.00Min, Max-11.00, 22.00-12.00, 20.00P-value [1]<0.0001 (t)<0.0001 (t)ANCOVA ResultLS Mean(SE)3.82(0.64)3.42(0.62)LS Mean Difference0.4095% Confidence Interval for Difference[-1.23, 2.02]P-value [2]0.6317Week 24n118120Mean(SD)50.58(11.93)51.87(11.84)Median48.5050.50Min, Max28.00, 92.0029.00, 106.00Change from baseline at week 24n118120Mean(SD)4.53(6.90)4.44(7.34)Median4.004.00Min, Max-12.00, 29.00-15.00, 34.00P-value [1]<0.0001 (t)<0.0001 (w)ANCOVA ResultLS Mean(SE)4.32(0.71)4.40(0.69)LS Mean Difference-0.0895% Confidence Interval for Difference[-1.90, 1.73]P-value [2]0.9279.

[0794] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0795] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0796] Note: Baseline is Visit 2 (randomization).

[0797] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0798]

[0799] ④Triglyceride

[0800] The results summarizing the changes in triglyceride levels at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for mPPS1 are presented in Table 54.

[0801] In mPPS1, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double agents) or 3 or more agents in combination) within 24 weeks prior to the date of obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in triglyceride at each time point after administration of the investigational drug compared to the baseline was -6.85 (4.47) mg / dL in the 6-week test group (inavogliflozin 0.3 mg), -5.39 (4.38) mg / dL in the control group (dapagliflozin 10 mg), -3.23 (5.25) mg / dL in the 12-week test group, -12.02 (5.12) mg / dL in the control group, and -18. The experimental group was -11.64 (4.46) mg / dL, the control group was -12.39 (4.34) mg / dL, the 24-week experimental group was -8.22 (4.01) mg / dL, and the control group was -8.78 (3.94) mg / dL. The differences between the two groups (LS Mean Difference (95% CI)) were -1.46 (-12.95, 10.03) mg / dL at 6 weeks, 8.79 (-4.68, 22.27) mg / dL at 12 weeks, 0.75 (-10.66, 12.16) mg / dL at 18 weeks, and 0.56 (-9.75, 10.87) mg / dL at 24 weeks. There was no statistically significant difference between the two groups at any time point.

[0802] The change in triglyceride (SD) by time point was -4.37 (40.21) mg / dL in the 6-week test group, -10.00 (72.87) mg / dL in the control group, 0.59 (51.73) mg / dL in the 12-week test group, -16.03 (81.60) mg / dL in the control group, -9.60 (49.20) mg / dL in the 18-week test group, -17.31 (70.25) mg / dL in the control group, and -6.05 (42.91) mg / dL in the 24-week test group, -13.81 (71.91) mg / dL in the control group. There was a statistically significant difference within the groups only in the test and control groups at the 18-week time point.

[0803]

[0804] Change from baseline in fasting lipid parameters at week 6, 12, 18 and 24 (modified Per-Protocol Set 1) [Triglyceride]이나보글리플로진 0.3 mg(N=118)다파글리플로진 10 mg(N=120)Baselinen118120Mean(SD)119.06(58.44)132.49(94.92)Median106.00103.00Min, Max47.00, 385.0042.00, 754.00Week 6n115119Mean(SD)112.71(51.53)121.81(65.42)Median101.0098.00Min, Max44.00, 312.0046.00, 435.00Change from baseline at week 6n115119Mean(SD)-4.37(40.21)-10.00(72.87)Median-1.001.00Min, Max-112.00, 115.00-559.00, 147.00P-value [1]0.2178 (w)0.3894 (w)ANCOVA ResultLS Mean(SE)-6.85(4.47)-5.39(4.38)LS Mean Difference-1.4695% Confidence Interval for Difference[-12.95, 10.03]P-value [2]0.8024Week 12n116120Mean(SD)118.98(69.11)116.46(54.96)Median98.50104.50Min, Max45.00, 420.0046.00, 347.00Change from baseline at week 12n116120Mean(SD)0.59(51.73)-16.03(81.60)Median-3.00-6.00Min, Max-104.00, 233.00-574.00, 121.00P-value [1]0.6211 (w)0.1008 (w)ANCOVA ResultLS Mean(SE)-3.23(5.25)-12.02(5.12)LS Mean Difference8.7995% Confidence Interval for Difference[-4.68, 22.27]P-value [2]0.1997Week 18n116120Mean(SD)109.52(62.14)115.18(53.02)Median95.50103.00Min, Max42.00, 443.0037.00, 322.00Change from baseline at week 18n116120Mean(SD)-9.60(49.20)-17.31(70.25)Median-2.00-8.50Min, Max-152.00, 216.00-432.00, 122.00P-value [1]0.0318 (w)0.0238 (w)ANCOVA ResultLS Mean(SE)-11.64(4.46)-12.39(4.34)LS Mean Difference0.7595% Confidence Interval for Difference[-10.66, 12.16]P-value [2]0.8965Week 24n118120Mean(SD)113.01(50.84)118.68(55.61)Median101.00104.00Min, Max51.00, 322.0046.00, 352.00Change from baseline at week 24n118120Mean(SD)-6.05(42.91)-13.81(71.91)Median-1.00-6.00Min, Max-131.00, 112.00-402.00, 145.00P-value [1]0.1283 (t)0.1593 (w)ANCOVA ResultLS Mean(SE)-8.22(4.01)-8.78(3.94)LS Mean Difference0.5695% Confidence Interval for Difference[-9.75, 10.87]P-value [2]0.9148.

[0805] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0806] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0807] Note: Baseline is Visit 2 (randomization).

[0808] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0809]

[0810] 4) Changes in systolic and diastolic blood pressure at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0811] ①Systolic blood pressure (SBP)

[0812] The results of the summary of the change in systolic blood pressure at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to the baseline using mPPS2 (modified Per-Protocol Set 2) are presented in Table 55.

[0813] In mPPS2, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double) or 3 or more combined) within 24 weeks prior to obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in systolic blood pressure at each time point after administration of the investigational drug compared to the baseline was -2.76 (0.90) mmHg in the 6-week test group (inavogliflozin 0.3 mg), -3.49 (0.87) mmHg in the control group (dapagliflozin 10 mg), -6.43 (0.88) mmHg in the 12-week test group, -5.06 (0.85) mmHg in the control group, and -18-week test group. -6.82 (0.92) mmHg in the control group, -5.16 (0.88) mmHg in the 24-week trial group, -4.49 (0.96) mmHg in the control group, -4.27 (0.93) mmHg in the 24-week trial group. The differences between the two groups (LS Mean Difference (95% CI)) were 0.73 (-1.56, 3.02) mmHg at 6 weeks, -1.37 (-3.62, 0.88) mmHg at 12 weeks, -1.66 (-4.00, 0.68) mmHg at 18 weeks, and -0.22 (-2.67, 2.23) mmHg at 24 weeks, indicating that there was no statistically significant difference between the two groups at any time point.

[0814] The change in systolic blood pressure (SD) by time point was -3.67 (9.93) mmHg in the 6-week test group, -3.23 (8.88) mmHg in the control group, -7.10 (9.09) mmHg in the 12-week test group, -4.43 (9.82) mmHg in the control group, -7.37 (9.35) mmHg in the 18-week test group, -4.63 (10.16) mmHg in the control group, and -5.20 (9.81) mmHg in the 24-week test group, -3.74 (10.73) mmHg in the control group. There were statistically significant differences within the groups at all time points and administration groups.

[0815] Change from baseline in blood pressures at week 6, 12, 18 and 24 (modified Per-Protocol Set 2) [Systolic Blood Pressure] 이나보글리플로진 0.3 mg(N=114)다파글리플로진 10 mg(N=121)Baselinen114121Mean(SD)127.49(12.74)123.94(11.74)Median127.50123.00Min, Max91.00, 166.0097.00, 153.00Week 6n111120Mean(SD)124.04(13.24)120.64(11.35)Median123.00119.00Min, Max93.00, 152.0096.00, 153.00Change from baseline at week 6n111120Mean(SD)-3.67(9.93)-3.23(8.88)Median-3.00-3.50Min, Max-35.00, 20.00-30.00, 20.00P-value [1]0.0002 (t)0.0001 (t)ANCOVA ResultLS Mean(SE)-2.76(0.90)-3.49(0.87)LS Mean Difference0.7395% Confidence Interval for Difference[-1.56, 3.02]P-value [2]0.5318Week 12n112121Mean(SD)120.73(12.13)119.51(11.32)Median121.00120.00Min, Max92.00, 148.0091.00, 147.00Change from baseline at week 12n112121Mean(SD)-7.10(9.09)-4.43(9.82)Median-8.00-4.00Min, Max-31.00, 19.00-33.00, 22.00P-value [1]<0.0001 (t)<0.0001 (t)ANCOVA ResultLS Mean(SE)-6.43(0.88)-5.06(0.85)LS Mean Difference-1.3795% Confidence Interval for Difference[-3.62, 0.88]P-value [2]0.2306Week 18n112121Mean(SD)119.95(12.98)119.31(10.95)Median119.00118.00Min, Max82.00, 153.0091.00, 149.00Change from baseline at week 18n112121Mean(SD)-7.37(9.35)-4.63(10.16)Median-7.00-4.00Min, Max-33.00, 19.00-34.00, 22.00P-value [1]<0.0001 (t)<0.0001 (t)ANCOVA ResultLS Mean(SE)-6.82(0.92)-5.16(0.88)LS Mean Difference-1.6695% Confidence Interval for Difference[-4.00, 0.68]P-value [2]0.1634Week 24n114121Mean(SD)122.29(12.63)120.20(11.96)Median121.00119.00Min, Max89.00, 152.0093.00, 157.00Change from baseline at week 24n114121Mean(SD)-5.20(9.81)-3.74(10.73)Median-5.00-4.00Min, Max-34.00, 18.00-25.00, 53.00P-value [1]<0.0001 (t)<0.0001 (w)ANCOVA ResultLS Mean(SE)-4.49(0.96)-4.27(0.93)LS Mean Difference-0.2295% Confidence Interval for Difference[-2.67, 2.23]P-value [2]0.8568.

[0816] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0817] [2] Testing for diff erence between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0818] Note: Baseline is Visit 2 (randomization).

[0819] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0820]

[0821] ② Diastolic blood pressure (DBP)

[0822] The results of the summary of the change in diastolic blood pressure at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline, targeting mPPS2, are presented in Table 56.

[0823] In mPPS2, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double agents) or 3 or more agents in combination) within 24 weeks prior to the date of obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in diastolic blood pressure at each time point after administration of the investigational drug compared to the baseline was -2.04 (0.70) mmHg in the 6-week test group (inavogliflozin 0.3 mg), -1.88 (0.67) mmHg in the control group (dapagliflozin 10 mg), -4.30 (0.69) mmHg in the 12-week test group, -2.26 (0.66) mmHg in the control group, and -18-week test group. -3.41(0.71) mmHg in the control group, -2.42(0.68) mmHg in the 24-week trial group, -2.55(0.72) mmHg in the control group, -1.89(0.70) mmHg in the 24-week trial group. The difference (LS Mean Difference (95% CI)) between the two groups was -0.16(-1.94, 1.62) mmHg at 6 weeks, -2.04(-3.81, -0.28) mmHg at 12 weeks, -0.99(-2.80, 0.82) mmHg at 18 weeks, and -0.66(-2.50, 1.19) mmHg at 24 weeks, and there was a statistically significant difference between the two groups only at the 12-week point.

[0824] The diastolic blood pressure change (SD) by time point was -2.76 (8.36) mmHg for the 6-week test group, -1.57 (6.64) mmHg for the control group, -5.07 (7.87) mmHg for the 12-week test group, -1.88 (7.29) mmHg for the control group, -4.03 (7.86) mmHg for the 18-week test group, -2.12 (7.17) mmHg for the control group, and -3.19 (7.31) mmHg for the 24-week test group, -1.60 (7.95) mmHg for the control group. There were statistically significant differences within the groups at all time points and administration groups.

[0825] Change from baseline in blood pressures at week 6, 12, 18 and 24 (modified Per-Protocol Set 2) [Diastolic Blood Pressure] 이나보글리플로진 0.3 mg(N=114)다파글리플로진 10 mg(N=121)Baselinen114121Mean(SD)76.60(9.25)73.87(8.58)Median76.0074.00Min, Max53.00, 103.0051.00, 99.00Week 6n111120Mean(SD)73.72(9.48)72.20(8.45)Median74.0072.00Min, Max49.00, 93.0051.00, 93.00Change from baseline at week 6n111120Mean(SD)-2.76(8.36)-1.57(6.64)Median-3.00-2.00Min, Max-32.00, 23.00-21.00, 16.00P-value [1]0.0007 (t)0.0109 (t)ANCOVA ResultLS Mean(SE)-2.04(0.70)-1.88(0.67)LS Mean Difference-0.1695% Confidence Interval for Difference[-1.94, 1.62]P-value [2]0.8618Week 12n112121Mean(SD)71.61(8.54)71.99(8.70)Median72.0072.00Min, Max49.00, 91.0052.00, 92.00Change from baseline at week 12n112121Mean(SD)-5.07(7.87)-1.88(7.29)Median-5.00-1.00Min, Max-36.00, 24.00-26.00, 22.00P-value [1]<0.0001 (w)0.0055 (t)ANCOVA ResultLS Mean(SE)-4.30(0.69)-2.26(0.66)LS Mean Difference-2.0495% Confidence Interval for Difference[-3.81, -0.28]P-value [2]0.0234Week 18n112121Mean(SD)72.53(9.81)71.75(8.24)Median72.0071.00Min, Max50.00, 98.0052.00, 92.00Change from baseline at week 18n112121Mean(SD)-4.03(7.86)-2.12(7.17)Median-5.00-2.00Min, Max-29.00, 20.00-21.00, 19.00P-value [1]<0.0001 (t)0.0015 (t)ANCOVA ResultLS Mean(SE)-3.41(0.71)-2.42(0.68)LS Mean Difference-0.9995% Confidence Interval for Difference[-2.80, 0.82]P-value [2]0.2825Week 24n114121Mean(SD)73.40(9.39)72.27(9.11)Median73.5073.00Min, Max52.00, 97.0053.00, 107.00Change from baseline at week 24n114121Mean(SD)-3.19(7.31)-1.60(7.95)Median-3.00-2.00Min, Max-25.00, 14.00-21.00, 28.00P-value [1]<0.0001 (t)0.0293 (t)ANCOVA ResultLS Mean(SE)-2.55(0.72)-1.89(0.70)LS Mean Difference-0.6695% Confidence Interval for Difference[-2.50, 1.19]P-value [2]0.4842.

[0826] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0827] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0828] Note: Baseline is Visit 2 (randomization).

[0829] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0830]

[0831] 5) Changes in beta-cell function and insulin resistance measured by HOMA-beta and HOMA-IR at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0832] ① Beta cell function measured by HOMA-beta

[0833] The results of the summary of changes in HOMA-beta at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for PPS are presented in Table 57.

[0834] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double) or 3 or more combined) within 24 weeks prior to the date of obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in HOMA-beta at each time point after administration of the investigational drug compared to the baseline was 8.13 (3.08) in the 6-week test group (inavogliflozin 0.3 mg), 3.20 (3.04) in the control group (dapagliflozin 10 mg), 7.78 (1.94) in the 12-week test group, 5.23 (1.90) in the control group, 5.97 (2.27) in the 18-week test group, and 5.23 (1.90) in the control group. The mean values ​​for the 24-week trial group were 4.49 (2.22), the 24-week trial group 1.09 (4.79), and the control group 5.78 (4.72). The differences between the two groups (LS Mean Difference (95% CI)) were 4.93 (-2.95, 12.82) at 6 weeks, 2.55 (-2.42, 7.51) at 12 weeks, 1.48 (-4.31, 7.26) at 18 weeks, and -4.69 (-16.95, 7.56) at 24 weeks, indicating that there was no statistically significant difference between the two groups at any time point.

[0835] The change (SD) in HOMA-beta by time point was 8.74 (39.40) in the 6-week test group, 4.48 (21.23) in the control group, 6.71 (20.59) in the 12-week test group, 4.70 (20.22) in the control group, 6.09 (25.33) in the 18-week test group, 5.32 (21.88) in the control group, 2.57 (63.77) in the 24-week test group, and 7.95 (26.82) in the control group. There were statistically significant differences within the groups in all time points and administration groups.

[0836] Change from baseline in beta-cell function at week 6, 12, 18 and 24 (Per-Protocol Set) [HOMA-beta] 이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Baselinen119123Mean(SD)42.91(27.09)40.47(27.30)Median37.5033.30Min, Max6.10, 141.806.90, 204.90Week 6n116122Mean(SD)51.08(43.59)44.56(29.07)Median38.7036.75Min, Max7.80, 360.00-72.00, 164.00Change from baseline at week 6n116122Mean(SD)8.74(39.40)4.48(21.23)Median4.355.30Min, Max-87.50, 321.40-99.80, 75.60P-value [1]0.0097 (w)0.0024 (w)ANCOVA ResultLS Mean(SE)8.13(3.08)3.20(3.04)LS Mean Difference4.9395% Confidence Interval for Difference[-2.95, 12.82]P-value [2]0.2191Week 12n117123Mean(SD)49.46(30.06)45.17(27.17)Median41.5038.20Min, Max5.70, 180.009.90, 166.80Change from baseline at week 12n117123Mean(SD)6.71(20.59)4.70(20.22)Median4.803.50Min, Max-43.30, 82.40-80.40, 62.00P-value [1]0.0009 (w)0.0057 (w)ANCOVA ResultLS Mean(SE)7.78(1.94)5.23(1.90)LS Mean Difference2.5595% Confidence Interval for Difference[-2.42, 7.51]P-value [2]0.3136Week 18n117123Mean(SD)49.26(29.93)45.79(30.81)Median40.0036.80Min, Max9.70, 174.60-12.00, 226.70Change from baseline at week 18n117123Mean(SD)6.09(25.33)5.32(21.88)Median4.102.20Min, Max-88.40, 97.40-113.00, 65.80P-value [1]0.0040 (w)0.0067 (w)ANCOVA ResultLS Mean(SE)5.97(2.27)4.49(2.22)LS Mean Difference1.4895% Confidence Interval for Difference[-4.31, 7.26]P-value [2]0.6155Week 24n119123Mean(SD)45.48(67.01)48.41(31.90)Median41.4036.70Min, Max-576.00, 295.207.50, 159.20Change from baseline at week 24n119123Mean(SD)2.57(63.77)7.95(26.82)Median5.707.20Min, Max-607.10, 252.70-113.10, 93.40P-value [1]0.0002 (w)0.0003 (w)ANCOVA ResultLS Mean(SE)1.09(4.79)5.78(4.72)LS Mean Difference-4.6995% Confidence Interval for Difference[-16.95, 7.56]P-value [2]0.4513.

[0837] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0838] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0839] Note: Baseline is Visit 2 (randomization).

[0840] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0841]

[0842] ②Insulin resistance confirmed by HOMA-IR

[0843] The results of the summary of changes in HOMA-IR at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for PPS are presented in Table 58.

[0844] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double) or 3 or more combined) within 24 weeks prior to the date of obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in HOMA-IR at each time point after administration of the investigational drug compared to the baseline was -0.94 (0.15) in the 6-week test group (inavogliflozin 0.3 mg), -0.99 (0.14) in the control group (dapagliflozin 10 mg), -1.11 (0.10) in the 12-week test group, -1.05 (0.10) in the control group, -1.14 (0.11) in the 18-week test group, and -1.05 (0.10) in the control group. -1.01 (0.11), 24-week experimental group -1.09 (0.11), and control group -0.93 (0.11). The difference between the two groups (LS Mean Difference (95% CI)) was 0.05 (-0.32, 0.42) at 6 weeks, -0.06 (-0.33, 0.20) at 12 weeks, -0.13 (-0.41, 0.15) at 18 weeks, and -0.16 (-0.44, 0.13) at 24 weeks, indicating that there was no statistically significant difference between the two groups at any time point.

[0845] The change (SD) in HOMA-IR by time point was -0.90 (1.94) in the 6-week test group and -0.92 (1.49) in the control group, -1.16 (1.54) in the 12-week test group and -1.06 (1.70) in the control group, -1.16 (1.71) in the 18-week test group and -1.00 (1.58) in the control group, and -1.07 (1.52) in the 24-week test group and -0.88 (1.72) in the control group. There were statistically significant differences within the groups at all time points and administration groups.

[0846] Change from baseline in insulin resistance at week 6, 12, 18 and 24 (Per-Protocol Set) [HOMA-IR] 이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Baselinen119123Mean(SD)2.90(1.91)2.86(1.84)Median2.422.38Min, Max0.45, 9.400.21, 10.08Week 6n116122Mean(SD)2.00(2.26)1.90(1.05)Median1.541.66Min, Max0.27, 21.810.14, 5.47Change from baseline at week 6n116122Mean(SD)-0.90(1.94)-0.92(1.49)Median-0.68-0.72Min, Max-5.66, 13.12-7.71, 3.03P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-0.94(0.15)-0.99(0.14)LS Mean Difference0.0595% Confidence Interval for Difference[-0.32, 0.42]P-value [2]0.7912Week 12n117123Mean(SD)1.76(1.09)1.80(1.32)Median1.461.55Min, Max0.16, 5.170.22, 9.87Change from baseline at week 12n117123Mean(SD)-1.16(1.54)-1.06(1.70)Median-0.79-0.76Min, Max-6.94, 1.54-7.81, 4.83P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-1.11(0.10)-1.05(0.10)LS Mean Difference-0.0695% Confidence Interval for Difference[-0.33, 0.20]P-value [2]0.6426Week 18n117123Mean(SD)1.74(1.23)1.85(1.34)Median1.421.53Min, Max0.36, 8.840.06, 7.92Change from baseline at week 18n117123Mean(SD)-1.16(1.71)-1.00(1.58)Median-0.82-0.75Min, Max-7.20, 6.25-7.26, 2.88P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-1.14(0.11)-1.01(0.11)LS Mean Difference-0.1395% Confidence Interval for Difference[-0.41, 0.15]P-value [2]0.3553Week 24n119123Mean(SD)1.84(1.10)1.97(1.49)Median1.561.55Min, Max0.36, 5.350.11, 8.65Change from baseline at week 24n119123Mean(SD)-1.07(1.52)-0.88(1.72)Median-0.80-0.70Min, Max-7.03, 2.76-6.59, 3.94P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-1.09(0.11)-0.93(0.11)LS Mean Difference-0.1695% Confidence Interval for Difference[-0.44, 0.13]P-value [2]0.2767.

[0847] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0848] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥8 %]) as covariates).

[0849] Note: Baseline is Visit 2 (randomization).

[0850] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0851]

[0852] 6) Changes in renal function-related indicators (UACR, UGCR) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (randomization)

[0853] ①UACR

[0854] The results of a summary of the changes in UACR at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for the PPS are presented in Table 59.

[0855] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double agents) or 3 or more agents in combination) within 24 weeks prior to the date of obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in UACR at each time point after administration of the investigational drug compared to the baseline was -8.76 (3.43) g / kg in the 6-week test group (inavogliflozin 0.3 mg), -14.85 (3.36) g / kg in the control group (dapagliflozin 10 mg), -15.12 (4.60) g / kg in the 12-week test group, -11.76 (4.47) g / kg in the control group, and -18-week test group. -11.08(3.89) g / kg, control group -8.90(3.79) g / kg, 24-week test group -15.34(3.93) g / kg, control group -16.13(3.84) g / kg. The difference (LS Mean Difference (95% CI)) between the two groups was 6.09(-2.68, 14.87) g / kg at 6 weeks, -3.35(-15.10, 8.39) g / kg at 12 weeks, -2.18(-12.10, 7.73) g / kg at 18 weeks, and 0.79(-9.26, 10.84) g / kg at 24 weeks, and there was no statistically significant difference between the two groups at any time point.

[0856] The change in UACR (SD) by time point was -11.43 (89.49) g / kg for the 6-week test group and -7.25 (52.04) g / kg for the control group, -18.62 (103.10) g / kg for the 12-week test group and -7.42 (53.04) g / kg for the control group, -12.07 (46.16) g / kg for the 18-week test group and -8.84 (63.74) g / kg for the control group, and -19.52 (108.55) g / kg for the 24-week test group and -11.12 (70.82) g / kg for the control group. There was a statistically significant difference within the test groups at the 12-, 18-, and 24-week time points.

[0857] Change from baseline in renal function parameters at week 6, 12, 18 and 24 (Per-Protocol Set) [UACR] 이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Baselinen119123Mean(SD)47.15(129.16)34.70(97.22)Median12.3010.10Min, Max2.50, 1262.901.50, 816.40Week 6n116122Mean(SD)36.67(71.37)23.20(39.05)Median14.8011.20Min, Max1.80, 450.902.00, 328.70Change from baseline at week 6n116122Mean(SD)-11.43(89.49)-7.25(52.04)Median-0.50-0.40Min, Max-812.00, 309.10-487.70, 78.50P-value [1]0.3557 (w)0.6266 (w)ANCOVA ResultLS Mean(SE)-8.76(3.43)-14.85(3.36)LS Mean Difference6.0995% Confidence Interval for Difference[-2.68, 14.87]P-value [2]0.1726Week 12n116123Mean(SD)29.37(67.19)27.28(64.60)Median11.2011.80Min, Max1.20, 501.702.60, 567.10Change from baseline at week 12n116123Mean(SD)-18.62(103.10)-7.42(53.04)Median-1.050.20Min, Max-978.90, 360.80-536.90, 87.80P-value [1]0.0017 (w)0.7070 (w)ANCOVA ResultLS Mean(SE)-15.12(4.60)-11.76(4.47)LS Mean Difference-3.3595% Confidence Interval for Difference[-15.10, 8.39]P-value [2]0.5740Week 18n117123Mean(SD)25.02(50.17)25.86(63.91)Median11.3010.20Min, Max2.10, 460.702.70, 640.00Change from baseline at week 18n117123Mean(SD)-12.07(46.16)-8.84(63.74)Median-1.500.20Min, Max-248.10, 118.00-658.10, 87.50P-value [1]0.0062 (w)0.3524 (w)ANCOVA ResultLS Mean(SE)-11.08(3.89)-8.90(3.79)LS Mean Difference-2.1895% Confidence Interval for Difference[-12.10, 7.73]P-value [2]0.6651Week 24n118123Mean(SD)27.90(53.69)23.58(47.43)Median11.1010.20Min, Max2.00, 432.402.20, 416.80Change from baseline at week 24n118123Mean(SD)-19.52(108.55)-11.12(70.82)Median-1.55-0.70Min, Max-1116.40, 132.30-695.50, 168.30P-value [1]0.0008 (w)0.0538 (w)ANCOVA ResultLS Mean(SE)-15.34(3.93)-16.13(3.84)LS Mean Difference0.7995% Confidence Interval for Difference[-9.26, 10.84]P-value [2]0.8774.

[0858] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0859] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0860] Note: Baseline is Visit 2 (randomization).

[0861] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0862]

[0863] ②UGCR

[0864] The results of the summary of changes in UGCR at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline for PPS are presented in Table 60.

[0865] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double agents) or 3 or more agents in combination) within 24 weeks prior to the date of obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in UGCR at each time point after administration of the investigational drug compared to the baseline was 58.10 (2.18) mg / mg in the 6-week test group (inavogliflozin 0.3 mg), 45.75 (2.14) mg / mg in the control group (dapagliflozin 10 mg), 58.21 (2.07) mg / mg in the 12-week test group, 44.84 (2.02) mg / mg in the control group, and 18-week test group. The mean daily dose was 58.74 (2.33) mg / mg in the 24-week trial group, 45.40 (2.27) mg / mg in the control group, and 60.22 (2.31) mg / mg in the 24-week trial group and 43.51 (2.26) mg / mg in the control group. The difference between the two groups (LS Mean Difference (95% CI)) was 12.35 (6.76, 17.94) mg / mg at 6 weeks, 13.37 (8.06, 18.67) mg / mg at 12 weeks, 13.34 (7.40, 19.27) mg / mg at 18 weeks, and 16.71 (10.79, 22.63) mg / mg at 24 weeks, indicating a statistically significant difference between the two groups at all time points.

[0866] The change in UGCR by time point (SD) was 56.38 (24.08) mg / mg in the 6-week test group and 43.58 (21.16) mg / mg in the control group, 57.00 (22.19) mg / mg in the 12-week test group and 43.19 (20.18) mg / mg in the control group, 57.23 (24.63) mg / mg in the 18-week test group and 43.29 (23.42) mg / mg in the control group, and 59.39 (24.52) mg / mg in the 24-week test group and 42.31 (22.51) mg / mg in the control group. There were statistically significant differences within groups in all time points and administration groups.

[0867] Change from baseline in renal function parameters at week 6, 12, 18 and 24 (Per-Protocol Set) [UGCR] 이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Baselinen119123Mean(SD)0.72(3.49)1.53(7.42)Median0.120.12Min, Max0.00, 37.510.01, 75.38Week 6n116122Mean(SD)57.09(23.82)45.12(20.73)Median54.5743.37Min, Max0.06, 122.830.62, 137.45Change from baseline at week 6n116122Mean(SD)56.38(24.08)43.58(21.16)Median54.1042.62Min, Max-0.14, 122.64-20.53, 135.53P-value [1]<0.0001 (t)<0.0001 (w)ANCOVA ResultLS Mean(SE)58.10(2.18)45.75(2.14)LS Mean Difference12.3595% Confidence Interval for Difference[6.76, 17.94]P-value [2]<0.0001Week 12n116123Mean(SD)57.71(21.94)44.72(19.93)Median57.4341.80Min, Max6.96, 123.900.07, 129.39Change from baseline at week 12n116123Mean(SD)57.00(22.19)43.19(20.18)Median57.0541.69Min, Max6.84, 122.30-12.39, 124.69P-value [1]<0.0001 (t)<0.0001 (w)ANCOVA ResultLS Mean(SE)58.21(2.07)44.84(2.02)LS Mean Difference13.3795% Confidence Interval for Difference[8.06, 18.67]P-value [2]<0.0001Week 18n117123Mean(SD)57.96(24.33)44.82(22.53)Median54.7142.32Min, Max0.05, 120.360.11, 120.52Change from baseline at week 18n117123Mean(SD)57.23(24.63)43.29(23.42)Median54.5641.28Min, Max-0.08, 120.26-24.44, 120.27P-value [1]<0.0001 (t)<0.0001 (t)ANCOVA ResultLS Mean(SE)58.74(2.33)45.40(2.27)LS Mean Difference13.3495% Confidence Interval for Difference[7.40, 19.27]P-value [2]<0.0001Week 24n118123Mean(SD)60.12(24.59)43.84(22.15)Median57.9642.85Min, Max11.30, 124.740.07, 134.82Change from baseline at week 24n118123Mean(SD)59.39(24.52)42.31(22.51)Median55.9842.35Min, Max11.23, 124.33-13.64, 130.12P-value [1]<0.0001 (w)<0.0001 (t)ANCOVA ResultLS Mean(SE)60.22(2.31)43.51(2.26)LS Mean Difference16.7195% Confidence Interval for Difference[10.79, 22.63]P-value [2]<0.0001.

[0868] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0869] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0870] Note: Baseline is Visit 2 (randomization).

[0871] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0872]

[0873] 7) Changes in obesity-related indicators (adiponectin, leptin) at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to Visit 2 (random assignment)

[0874] ①Adiponectin

[0875] The results of a summary of the changes in adiponectin at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline, targeting PPS, are presented in Table 61.

[0876] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double agents) or 3 or more agents in combination) within 24 weeks prior to the date of obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in adiponectin at each time point after administration of the investigational drug compared to the baseline was -0.10 (0.34) ㎍ / mL in the 6-week test group (inavogliflozin 0.3 mg), 0.37 (0.33) ㎍ / mL in the control group (dapagliflozin 10 mg), 0.89 (0.34) ㎍ / mL in the 12-week test group, 0.70 (0.33) ㎍ / mL in the control group, and 18-week test group. The mean values ​​for the 24-week test group were 0.78 (0.33) ㎍ / mL, the control group 0.36 (0.32) ㎍ / mL, the 24-week test group 1.42 (0.35) ㎍ / mL, and the control group 0.92 (0.35) ㎍ / mL. The differences between the two groups (LS Mean Difference (95% CI)) were -0.47 (-1.33, 0.39) ㎍ / mL at 6 weeks, 0.19 (-0.68, 1.06) ㎍ / mL at 12 weeks, 0.42 (-0.41, 1.25) ㎍ / mL at 18 weeks, and 0.49 (-0.42, 1.40) ㎍ / mL at 24 weeks. There was no statistically significant difference between the two groups at any time point.

[0877] The change in adiponectin by time point (SD) was -0.08 (4.03) ㎍ / mL in the 6-week test group, 0.31 (4.15) ㎍ / mL in the control group, 0.88 (4.15) ㎍ / mL in the 12-week test group, 0.63 (3.45) ㎍ / mL in the control group, 0.80 (4.50) ㎍ / mL in the 18-week test group, 0.30 (3.21) ㎍ / mL in the control group, and 1.39 (4.63) ㎍ / mL in the 24-week test group, 0.84 (3.23) ㎍ / mL in the control group. There was a statistically significant difference within the group in all time points and administration groups except the 6-week time point.

[0878] Change from baseline in obesity parameters at week 6, 12, 18 and 24 (Per-Protocol Set) [Adiponectin] 이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Baselinen119123Mean(SD)6.22(4.07)6.34(3.42)Median5.015.61Min, Max1.00, 24.781.35, 23.79Week 6n116122Mean(SD)6.20(3.39)6.69(3.86)Median5.405.80Min, Max1.00, 17.271.58, 29.02Change from baseline at week 6n116122Mean(SD)-0.08(4.03)0.31(4.15)Median0.500.34Min, Max-21.27, 8.20-16.13, 23.71P-value [1]0.0976 (w)0.0862 (w)ANCOVA ResultLS Mean(SE)-0.10(0.34)0.37(0.33)LS Mean Difference-0.4795% Confidence Interval for Difference[-1.33, 0.39]P-value [2]0.2844Week 12n117123Mean(SD)7.13(4.38)6.97(3.60)Median6.246.27Min, Max1.00, 23.701.22, 23.79Change from baseline at week 12n117123Mean(SD)0.88(4.15)0.63(3.45)Median1.000.43Min, Max-21.16, 15.47-18.49, 9.53P-value [1]0.0008 (w)0.0062 (w)ANCOVA ResultLS Mean(SE)0.89(0.34)0.70(0.33)LS Mean Difference0.1995% Confidence Interval for Difference[-0.68, 1.06]P-value [2]0.6708Week 18n117122Mean(SD)7.03(4.24)6.65(2.95)Median6.266.21Min, Max1.00, 24.751.22, 14.77Change from baseline at week 18n117122Mean(SD)0.80(4.50)0.30(3.21)Median0.600.36Min, Max-21.28, 19.86-18.82, 7.34P-value [1]0.0019 (w)0.0147 (w)ANCOVA ResultLS Mean(SE)0.78(0.33)0.36(0.32)LS Mean Difference0.4295% Confidence Interval for Difference[-0.41, 1.25]P-value [2]0.3223Week 24n119123Mean(SD)7.62(4.55)7.18(3.53)Median6.496.39Min, Max1.00, 27.761.34, 17.81Change from baseline at week 24n119123Mean(SD)1.39(4.63)0.84(3.23)Median1.110.78Min, Max-20.88, 23.22-18.39, 9.90P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)1.42(0.35)0.92(0.35)LS Mean Difference0.4995% Confidence Interval for Difference[-0.42, 1.40]P-value [2]0.2868.

[0879] SD = standard deviation, Min = minimum, Max = maximum, ANCOVA = analysis of covariance, LS Mean = least squares mean, SE = standard error.[1] Testing for within-treatment group (paired t-test (t) or Wilcoxon signed rank test (w)).

[0880] [2] Testing for differences between DWP16001 and Dapagliflozin (ANCOVA with treatment group as a factor, baseline value and stratification factors (regimen ['Doublet and / or less combination' or 'Triplet and / or more combination'] and HbA1c level at visit 1 [screening][< 8 % or ≥ 8 %]) as covariates).

[0881] Note: Baseline is Visit 2 (randomization).

[0882] Data Source: Listing 16.2.3:1, Listing 16.2.6:1.

[0883]

[0884] ②Leptin

[0885] The results of a summary of the changes in leptin at 6, 12, 18, and 24 weeks after administration of the clinical trial drug compared to baseline, using the PPS, are presented in Table 62.

[0886] In the PPS, an analysis of covariance (ANCOVA) was performed with baseline and stratification factors (previous hypoglycemic agent administration regimen (2 or fewer (single or double) or 3 or more combined) within 24 weeks prior to the date of obtaining written consent, and HbA1c level (less than or equal to 8%) at Visit 1 (screening)) as covariates. As a result, the least squares mean (LS Mean (SE)) for the change in leptin at each time point after administration of the investigational drug compared to the baseline was -1.83 (0.45) ng / mL in the 6-week test group (inavogliflozin 0.3 mg), -2.03 (0.45) ng / mL in the control group (dapagliflozin 10 mg), -1.97 (0.48) ng / mL in the 12-week test group, -1.69 (0.47) ng / mL in the control group, and -18-week test group. -1.46(0.52) ng / mL, control group -1.06(0.51) ng / mL, 24-week trial group -1.46(0.52) ng / mL, control group -0.57(0.51) ng / mL. The difference between the two groups (LS Mean Difference (95% CI)) was 0.20(-0.96, 1.36) ng / mL at 6 weeks, -0.28(-1.51, 0.94) ng / mL at 12 weeks, -0.40(-1.74, 0.94) ng / mL at 18 weeks, and -0.89(-2.21, 0.43) ng / mL at 24 weeks, and there was no statistically significant difference between the two groups at any time point.

[0887] The change in leptin (SD) by time point was -1.75 (5.38) ng / mL in the 6-week test group, -2.04 (6.20) ng / mL in the control group, -1.96 (5.27) ng / mL in the 12-week test group, -1.82 (6.56) ng / mL in the control group, -1.63 (5.66) ng / mL in the 18-week test group, -1.36 (6.68) ng / mL in the control group, and -1.52 (4.96) ng / mL in the 24-week test group, -0.74 (6.26) ng / mL in the control group. There was a statistically significant difference within the group in all time points and administration groups except for the control group at the 24-week time point.

[0888] Change from baseline in obesity parameters at week 6, 12, 18 and 24 (Per-Protocol Set) [Leptin] 이나보글리플로진 0.3 mg(N=119)다파글리플로진 10 mg(N=123)Baselinen119123Mean(SD)10.48(10.49)10.85(9.19)Median6.588.52Min, Max0.68, 55.000.46, 55.99Week 6n116122Mean(SD)8.88(8.22)8.78(7.23)Median6.267.03Min, Max0.29, 36.830.25, 51.59Change from baseline at week 6n116122Mean(SD)-1.75(5.38)-2.04(6.20)Median-0.94-1.26Min, Max-29.17, 18.32-36.30, 23.71P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-1.83(0.45)-2.03(0.45)LS Mean Difference0.2095% Confidence Interval for Difference[-0.96, 1.36]P-value [2]0.7371Week 12n117123Mean(SD)8.56(8.44)9.03(7.42)Median5.747.69Min, Max0.20, 42.320.42, 56.24Change from baseline at week 12n117123Mean(SD)-1.96(5.27)-1.82(6.56)Median-1.28-0.96Min, Max-33.77, 10.57-40.67, 21.07P-value [1]<0.0001 (w)<0.0001 (w)ANCOVA ResultLS Mean(SE)-1.97(0.48)-1.69(0.47)LS Mean Difference-0.2895% Conf...

Claims

1. A pharmaceutical composition for preventing or treating renal dysfunction containing inabogliflozin.

2. A pharmaceutical composition according to claim 1, wherein the renal disorder includes a disease selected from diabetic nephropathy, renal failure, chronic kidney disease, glomerulonephritis, and proteinuria.

3. In the first paragraph, the pharmaceutical composition is a pharmaceutical composition for reducing the risk of a continuous decrease in the estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease, reaching end-stage renal disease, death due to cardiovascular disease, and death related to kidney disease.

4. A pharmaceutical composition according to claim 1, wherein the renal impairment is diabetic nephropathy.

5. A pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is administered to a patient with diabetes or a patient in the pre-diabetic stage.

6. A pharmaceutical composition according to any one of claims 1 to 5, wherein the pharmaceutical composition is for single administration.

7. A pharmaceutical composition according to any one of claims 1 to 5, wherein the pharmaceutical composition is for co-administration with metformin.

8. A pharmaceutical composition according to any one of claims 1 to 5, wherein the pharmaceutical composition is for co-administration with a DPP4 inhibitor.

9. A pharmaceutical composition according to claim 8, wherein the DPP4 inhibitor is gemigliptin.

10. A pharmaceutical composition according to any one of claims 1 to 5, wherein the pharmaceutical composition is for co-administration with metformin and a DPP4 inhibitor.

11. A pharmaceutical composition according to any one of claims 1 to 5, wherein the pharmaceutical composition is administered in combination with a sulfonylurea-based insulin secretagogue.

12. A pharmaceutical composition according to any one of claims 1 to 5, wherein the pharmaceutical composition is administered in combination with insulin.

13. A pharmaceutical composition for preventing or treating diabetes in patients with renal impairment, comprising inabogliflozin.

14. A pharmaceutical composition according to claim 13, wherein the renal disorder includes a disease selected from diabetic nephropathy, renal failure, chronic kidney disease, glomerulonephritis, and proteinuria.

15. A pharmaceutical composition according to claim 13, wherein the renal impairment is diabetic renal impairment.

16. A pharmaceutical composition according to any one of claims 13 to 15, wherein the pharmaceutical composition is for single administration.

17. A pharmaceutical composition according to any one of claims 13 to 15, wherein the pharmaceutical composition is for co-administration with metformin.

18. A pharmaceutical composition according to any one of claims 13 to 15, wherein the pharmaceutical composition is for co-administration with a DPP4 inhibitor.

19. A pharmaceutical composition according to claim 18, wherein the DPP4 inhibitor is gemigliptin.

20. A pharmaceutical composition according to any one of claims 13 to 15, wherein the pharmaceutical composition is for co-administration with metformin and a DPP4 inhibitor.

21. A pharmaceutical composition according to any one of claims 13 to 15, wherein the pharmaceutical composition is administered in combination with a sulfonylurea-based insulin secretagogue.

22. A pharmaceutical composition according to any one of claims 13 to 15, wherein the pharmaceutical composition is administered in combination with insulin.